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Chapter 1
General introduction
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Prostate cancer is the second most commonly diagnosed non-cutaneous malignancy 
and the fifth leading cause of cancer-related mortality in men worldwide.1 The prognosis 
depends on the extend of the disease, ranging from localized to metastatic disease. For 
each stage different therapeutic interventions are available. The vast majority of prostate 
cancer is diagnosed as localized disease, which can be monitored by active surveillance 
when low-risk, or treated with curative intend by radical prostatectomy or prostate 
radiotherapy. However, about 10-20% of the patients have loco-regional or distant 
metastatic disease at diagnosis.1 Metastatic prostate cancer can be roughly divided into 
metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant 
prostate cancer (mCRPC). The first setting is the hormone-sensitive disease phase, or 
equally referred to as castration-naïve, which is characterized by its sensitivity to androgen 
deprivation (e.g. castration).2 The effect of castration can suppress the disease for 
approximately 20 months,3-5 hereafter the disease becomes castration-resistant. For years, 
androgen-deprivation therapy (ADT) has been the cornerstone of treatment in metastatic 
prostate cancer.6 In the past decades the treatment options for metastatic prostate cancer 
have drastically expanded, changing clinical practice. Because prostate cancer cells remain 
dependent of the androgen receptor (AR) for survival and growth, treatment for metastatic 
prostate cancer mainly targets this receptor axis.7 Since 2004, large phase III trials have 
reported considerable survival benefit with taxane chemotherapy, androgen receptor 
targeted therapies (ART), and radio-active therapy in the castration-resistant phase.8-14 
Only recently, some of these treatment options have shifted from mCRPC to the mHSPC 
setting, allowing for more aggressive therapy in an earlier phase of the disease, resulting 
in an even larger survival benefit.2-4 Figure 1 shows the treatment options, as included in 
the current European (ESMO, EAU, NCCN) guidelines, and upcoming treatment options in 
different disease stages of metastatic prostate cancer. The constant development of new 
therapy options and the introduction in an earlier disease phase have brought challenges 
for clinicians to individualize treatment selection. Thereby, the treatment of metastatic 
prostate cancer patients is and will continue to be a multidisciplinary team effort.
Unmet needs in the treatment selection process for metastatic prostate cancer patients 
include understanding prognosis to determine when intervention is needed (prognostic 
factors), indicators to reduce toxicity of systemic treatments, identification of factors 
predictive of treatment response to select an effective treatment for a patient (predictive 
factors), and early response markers to ascertain a treatment is working. In this thesis 
we aim to increase our insight on several of these factors. Moreover, we intent to widen 
the understanding on pharmacological effects of anti-cancer medication to improve and 
maintain its safe administration.
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PERSPECTIVE ON PHARMACOLOGY
In addition to the shift of available treatment options to an earlier disease phase, the 
development of new therapies is ongoing and combinations of available treatment 
options are subject of promising ongoing investigations.15 The rationale for combining 
these therapies lies in the different working mechanisms and in previous (pre-)clinical 
work showing that the activity of taxanes and ART is strongly affected by hormonal 
manipulations.16-18 Currently, phase I-II studies investigate the clinical effect of combination 
therapies in humans.15,19 Studies combining treatment options, though, warrant thorough 
pharmacokinetic investigation to test for clinical relevant drug-drug interactions. 
Taxanes, i.e. docetaxel and cabazitaxel, have an extensive hepatic metabolism and biliary 
excretion.20 Their metabolism is mainly mediated by CYP3A iso-enzymes in the liver 
(80-90%), and for a small part by CYP2C8.21 Therefore, liver (dys-)function is a major factor 
in taxane dose adaptations.22 Moreover, the use of co-medication and herbal supplements, 
especially (strong) inducers/inhibitors of the CYP3A-system, influence pharmacokinetics 
of all taxanes.23-26 Therefore, in Chapter 2 and 3 we investigate the effects of enzalutamide 
and prednisone, as strong to moderate CYP3A4 inducers, on the pharmacokinetics of 
cabazitaxel and docetaxel, respectively.
14 
 
docetaxel/abiraterone/prostate radiotherapy to ADT in the hormone-sensitive phase has been 
demonstrated to improve OS.3,4,56-58 It remains to be determined which patient may benefit most 
from either early concomitant docetaxel, abiraterone, or prostate radiotherapy since molecular 
biomarkers for early therapy response and risk stratification are currently lacking, similar to the 
castration-resistant setting. Based on the available trial data it has been suggested that the extent of 
metastatic disease may become one of the most important factors to determine treatment choice. 
Most physicians contemplate chemo-hormonal therapy (ADT + docetaxel) only in patients who are 
considered ‘high-volume’ metastatic by clinical parameters and conventional imaging. Abiraterone 
has been proven to be effective in high- and low-volume patients. And low-volume patients might 
also benefit from additional prostate radiotherapy. Most recently the addition of apalutamide and 
enzalutamide to ADT in hormone-sensitive setting has shown positive results. In Chapter 9 we 
comprehensively review the available treatment options for mHSPC patients, and more importantly 
define tools to guide treatment selection by summarizing available trial data.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Treatment options in metastatic prostate cancer Figure 1. Treatment options in metastatic prostate cancer
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One of the newly developed therapies for non-metastatic CRPC and potentially mHSPC 
is apalutamide.27,28 Apalutamide is a new ART, binding to the ligand-binding domain of 
the AR, inhibiting AR nuclear translocation and impeding AR mediated transcription.29 
Before introduction in clinical practice it is important to have complete knowledge on 
pharmacodynamic effects of the agent. The most important and extensively investigated 
pharmacodynamic effects involve cardiac impairment. Medication has the ability to 
extent the ventricular repolarization of the heart, which could potentially result in cardiac 
arrhythmias and cardiac arrest. These side effects should be listed in the leaflet of the 
medication. Caution is needed with combinations of medication known to have an 
significant effect on ventricular repolarization, as an additive effect cannot be excluded. 
Therefore, in Chapter 4, the effect of apalutamide on ventricular repolarization is 
investigated in a thorough, international, multicenter trial involving 45 CRPC patients.
PERSPECTIVE ON TREATMENT SELECTION
Treatment options for metastatic prostate cancer, both castration-resistant and hormone-
sensitive, have notably evolved in the past few years. However, the optimal individual 
treatment selection in mCRPC or mHSPC patients remains to be elucidated, which 
makes treatment decisions extremely challenging.30,31 Prognostic factors, to estimate 
the probability of a specific clinical outcome such as survival, may help to make a risk 
assessment at that moment and to identify the best timing of treatment start. Predictive 
factors are biomarkers to foresee treatment response to a specific therapy. Additionally, 
treatment response markers are needed to determine the effect of the treatment on the 
tumor preferably as soon as possible after treatment start. In the absence of clinically 
available predictive biomarkers in the current practice, treatment choice is mainly based 
on clinical symptoms, metastatic burden, comorbidities, patients’ preference, physicians’ 
experience and toxicity.
mCRPC – prognostic factors
The identification of prognostic factors is usually based on cohort studies, along with 
data of post-hoc analysis of large phase III trials in which patients are treated with the 
same therapy. Trials with a long follow-up and extensive baseline parameters can most 
accurately identify factors which predict overall survival or toxicity. Previously, in mCRPC 
patients receiving first-line chemotherapy (docetaxel) prognostic models and nomograms 
have been developed based on the TAX327 trial,7 which identified parameters such as 
performance status, time since diagnosis, metastatic extent, the presence of pain, duration 
of ADT, and laboratory results to predict for survival.32-34 For second-line chemotherapy 
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(cabazitaxel), similar prognostic factors have been identified based on the TROPIC trial.8,35 In 
Chapter 5 we aim to confirm some of these findings and identify new factors in a different 
cohort of mCRPC patients treated with cabazitaxel. We used the large prospectively 
collected dataset of the CABARESC trial, which originally investigated the influence of 
budesonide on cabazitaxel-induced diarrhea in 246 mCRPC patients.36 The CABARESC trial 
originated from 2011, which ensures sufficient follow-up period for this post-hoc analysis 
performed in 2016.
Prognostic factors can indicate overall survival, but can also predict for the occurrence of 
adverse events. In prostate cancer patients treatment with taxanes is often accompanied 
by considerable toxicity. Neutropenia has been the primary dose limiting toxicity of the 
performed phase I trials in patients with solid tumors treated with cabazitaxel.37,38 This 
adverse event occurs frequently in cabazitaxel treated patients (80%) and can result in the 
life-threatening complication of febrile neutropenia (8%).8 Other frequent adverse events 
were diarrhea, leukopenia, thrombocytopenia, and anemia. Pharmacogenetics study the 
differences in patients genetics, resulting in differences in proteins involved in metabolism 
or transportation of medication. Genetic differences could result in lower or higher levels 
of medication in the circulation of a patient, consequently affecting toxicity and survival. 
For instance, treatment with fluoropyrimidines can result in severe, even life-threatening, 
toxicity. This toxicity seems to be strongly affected by activity of Dihydropyrimidine 
Dehydrogenase (DPD), which is the main metabolizing enzyme of fluoropyrimidines. 
Therefore, nowadays the individual DPD activity is measured by genetic profiling of the 
patient before treatment is started.39 Patient-related factors that possibly identify patients 
with increased risk of toxicity, or decreased risk of survival are useful to personalize 
treatment. Therefore, in Chapter 6 we investigate the influence of genetic differences on 
cabazitaxel pharmacokinetics and treatment outcomes in 128 mCRPC patients. Single-
nucleotide polymorphisms (SNPs) are the most prevalent genetic variants in humans and 
are defined as one single nucleotide difference in a human gene, which occurs in at least 
1% of the population. SNPs in the genes encoding for transporters and enzymes involved in 
cabazitaxel metabolism and working mechanism are most likely to affect clinical outcomes. 
Transmembrane transporters P-glycoprotein (P-gp; ABCB1), organic anion transporters 
(OATP1B1; SLCO1B1 and OATP1B3; SLCO1B3) and cytochrome P450 iso-enzymes (CYP3A4 
and CYP3A5) are important in taxane metabolism.40-43 Moreover, the binding site of taxanes 
in the cell nucleus on the microtubules, β-tubulin isoform (TUBB), may play a role in taxane 
resistance, and possibly survival.42,44 Therefore, we assessed the association of SNPs in the 
following genes, SLCO1B1 (OATP1B1), SLCO1B3 (OATP1B3), CYP3A4, CYP3A5, ABCB1 and 
TUBB1, with survival, toxicity, and pharmacokinetics in cabazitaxel treated mCRPC patients. 
Better understanding of mechanisms underlying inter-patient variability can help to 
personalize treatment options in these patients.
Chapter 1 – 15
1
mCRPC – predictive markers
The field of metastatic prostate cancer would benefit from identification of predictive 
tumor biomarkers to individualize treatment. Up to now no predictive biomarkers are 
clinically available; however, liquid biopsies quickly gain ground as potential predictive 
biomarker. Liquid biopsies are simple blood collections in which valuable tumor- and 
patient-related information is hidden. Liquid biopsies include for instance identification 
and characterization of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-
free DNA (cfDNA) and exosomes. Molecular characterization of the CTCs has been shown to 
provide disease information. The question remains how to interpret this information, and 
which clinical consequences it has. Currently, the most extensively investigated factor in 
patients with mCRPC is the androgen-receptor splice variant 7 (AR-V7) expression in CTCs. 
This mRNA splice variant of the AR lacks the ligand binding domain of the AR, resulting 
in a constitutively active receptor.45 Therapies specifically targeting the AR, by ligand 
binding competition (enzalutamide) or reduced production of ligands (abiraterone), have 
been associated with decreased treatment response in AR-V7 positive patients.45,46 Based 
on a different working mechanism taxanes have been shown to still be effective in AR-V7 
positive patients.47,48 In an ongoing trial (CABA-V7), AR-V7 expression in CTCs is being 
further explored as a potential predictive biomarker, as it is prospectively investigated 
whether AR-V7 positive patients will respond to cabazitaxel therapy (NCT03050866). 
Meanwhile, AR-V7 positivity has also been related to unfavorable baseline characteristics 
and may therefore merely reflect a higher tumor burden.49,50 To improve our understanding 
of the clinical value of AR-V7, we investigated the association of AR-V7 to CTC count and 
OS (Chapter 7). In a post-hoc analysis of three prospectively performed clinical trials, 127 
patient samples were evaluated for CTC enumeration and AR-V7 expression to determine 
their associations and relate it to OS.
mCRPC – treatment response markers
Prostate-specific antigen (PSA) is the most widely used biomarker to detect and monitor 
treatment of men with prostate cancer. However, PSA production is androgen-dependent 
and as some drugs modulate androgen concentrations, PSA levels may decrease without 
clinical or radiological responses.51 In combination with its low specificity, PSA is a 
debatable response biomarker. Usually, radiologic responses are defined by conventional 
imaging modalities, like PET CT/bone scan. Despite their limitations, these scans are 
standard in the current patient care and clinical trials to determine treatment response. 
Although, new, more sensitive imaging modalities are upcoming, the introduction 
and embedding of these modalities in clinical care awaits sufficient results of clinical 
trials showing their benefit over conventional imaging. Nowadays, liquid biopsies are 
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increasingly investigated also as potential treatment response marker. Since 2004 it 
is known that the enumeration of CTCs has prognostic significance in several tumor 
types.52 A baseline CTC count ≥5 CTCs/7.5mL blood has a worse prognosis compared to 
patients with a CTC count of less than 5 CTC/7.5mL blood.53 Therefore, a CTC count of >5 
CTC/7.5mL blood is referred to as ‘unfavorable’ and <5 CTCs/ 7.5mL blood as ‘favorable’ 
in several tumor types.52 Moreover, CTC conversion from unfavorable to favorable during 
treatment has been shown to be a stronger prognostic factor than a >50% decline in PSA 
and is suggested as surrogate marker for OS in clinical trials.53,54 However, it needs further 
investigation before individual treatment decisions can be made based on CTC conversion 
or percentage change in CTC count.55 To improve our knowledge on the clinical value of 
CTC responses, we performed an (unpublished) interim-analysis of the first twenty patients 
of the CABA-V7 trial. Herein, we evaluated the response rates in AR-V7 positive mCRPC 
patients during treatment with cabazitaxel (Chapter 8). The final results are expected in 
the complete analysis of the CABA-V7 trial.
mHSPC
The field of mHSPC is rapidly evolving, with treatment options shifting from the castration-
resistant setting to the hormone-sensitive setting of prostate cancer. Since 2015, the 
addition of docetaxel/abiraterone/prostate radiotherapy to ADT in the hormone-sensitive 
phase has been demonstrated to improve OS.3,4,56-58 It remains to be determined which 
patient may benefit most from either early concomitant docetaxel, abiraterone, or prostate 
radiotherapy since molecular biomarkers for early therapy response and risk stratification 
are currently lacking, similar to the castration-resistant setting. Based on the available 
trial data it has been suggested that the extent of metastatic disease may become one of 
the most important factors to determine treatment choice. Most physicians contemplate 
chemo-hormonal therapy (ADT + docetaxel) only in patients who are considered ‘high-
volume’ metastatic by clinical parameters and conventional imaging. Abiraterone has 
been proven to be effective in high- and low-volume patients. And low-volume patients 
might also benefit from additional prostate radiotherapy. Most recently the addition of 
apalutamide and enzalutamide to ADT in hormone-sensitive setting has shown positive 
results. In Chapter 9 we comprehensively review the available treatment options for 
mHSPC patients, and more importantly define tools to guide treatment selection by 
summarizing available trial data.
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ABSTRACT
Purpose: In ongoing clinical research on metastatic castration-resistant prostate cancer 
(mCRPC) treatment, the potential enhanced efficacy of the combination of taxanes with 
AR-targeted agents, i.e. enzalutamide and abiraterone, is currently being explored. Since 
enzalutamide induces the CYP3A4 enzyme and taxanes are metabolized by this enzyme, a 
potential drug-drug interaction needs to be investigated.
Design: Therefore, we performed a pharmacokinetic cross-over study in mCRPC patients 
who were scheduled for treatment with cabazitaxel Q3W (25 mg/m2). Patients were studied 
for three consecutive cabazitaxel cycles. Enzalutamide (160 mg QD) was administered 
concomitantly after the first cabazitaxel cycle, during 6 weeks. Primary endpoint was the 
difference in mean area under the curve (AUC) between the first (cabazitaxel monotherapy) 
and third cabazitaxel cycle, when enzalutamide was added.
Results: A potential clinically relevant 22% (95%CI: 9–34%, p=0.005) reduction in 
cabazitaxel exposure was found with concomitant enzalutamide use. The geometric mean 
AUC0-24h of cabazitaxel was 181 ng*h/mL (95%CI 150-219 ng*h/mL) in cycle 3 and 234 
ng*h/mL (95%CI 209-261 ng*h/mL) in cycle 1. This combination did not result in excessive 
toxicity, while PSA response was promising.
Conclusions: We found a significant decrease in cabazitaxel exposure when combined 
with enzalutamide. In an era of clinical trials on combination strategies for mCRPC, it is 
important to be aware of clinically relevant drug-drug interactions. Since recent study 
results support the use of a lower standard cabazitaxel dose of 20 mg/m2, the clinical 
relevance of this interaction may be substantial, since the addition of enzalutamide may 
result in sub-therapeutic cabazitaxel exposure.
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TRANSLATIONAL RELEVANCE
Preclinical data suggest enhanced efficacy of cabazitaxel when combined with hormonal 
therapies for metastatic castration-resistant prostate cancer (mCRPC). Clinical studies 
on combining taxanes, i.e. docetaxel and cabazitaxel, and AR-targeted agents, i.e. 
enzalutamide and abiraterone, are ongoing. It is important to be aware of potential 
drug-drug interactions between these agents, especially since enzalutamide is known to 
be a strong CYP3A4 inducer and taxanes are metabolized by this enzyme. We performed 
a pharmacokinetic study to identify the influence of enzalutamide on cabazitaxel 
concentrations in mCRPC patients. We found a potential clinically relevant reduction in 
cabazitaxel concentration (>20%) when combined with enzalutamide. Nonetheless, the 
combination was safe and well-tolerated. Moreover, PSA response levels were higher than 
expected in this heavily pretreated patient population. Studies with this drug combination 
are warranted, but investigators need to be aware of the current findings.
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INTRODUCTION
The current treatment paradigm in mCRPC comprises monotherapy options with 
chemotherapy, i.e. docetaxel or cabazitaxel, or with novel hormonal therapies, including 
enzalutamide and abiraterone.1 Clinical studies with various combinations of therapies, e.g. 
taxanes with novel hormonal therapies, with various designs and aims, are in progress.2-5 
A summary of ongoing clinical trials on these combinations was recently reviewed by 
Sternberg, and showed the rationale for combination therapies.6 In addition, preclinical 
in vivo work has shown that the activity of cabazitaxel is strongly affected by hormonal 
manipulations, e.g. either by castration or testosterone supplementation.7 Clinical studies 
with combined treatments, though, warrant thorough pharmacokinetic investigation to 
test for clinical relevant drug-drug interactions.
Taxanes, i.e. docetaxel and cabazitaxel, have an extensive hepatic metabolism (63-77%) 
and biliary excretion.8 Their metabolism is mediated by CYP3A iso-enzymes in the liver, 
and for a small part by CYP2C8. Therefore, liver (dys-)function is a major factor in taxane 
dose adaptations.9 Pharmacokinetics of docetaxel show a considerable interpatient 
variability (30-50%), depending on patient characteristics, like gender and age. The 
interpatient variability of cabazitaxel is moderate (~24%) and cabazitaxel pharmacokinetics 
are less susceptible for patient characteristics.10 However, the use of co-medication 
and herbal supplements, especially (strong) inducers/inhibitors of the CYP3A-system 
influence the pharmacokinetics of all taxanes.11-13 The influence of CYP3A-inducers on the 
pharmacokinetics of cabazitaxel have been extensively investigated by Sarantopoulos et 
al., showing that cabazitaxel is susceptible for CYP3A induction or inhibition. Repeated 
administration of a strong CYP3A inducer, rifampin, resulted in an 21% increase in 
cabazitaxel clearance and a 17% decrease in cabazitaxel concentration.14 Additionally, 
the pharmacokinetics of taxanes can potentially be influenced by changes in drug-
transporters, like ABCB1 (P-glycoprotein).11,15 Although cabazitaxel has less propensity 
for ABCB1 mediated drug resistance, the upregulation of the efflux pump can potentially 
impact the pharmacokinetics of cabazitaxel.16
Enzalutamide is known to be a moderate inducer of CYP2C9 and CYP2C19 and a strong 
inducer of CYP3A4. Maximal CYP3A4 induction by enzalutamide may not appear until one 
month after treatment start, when steady state levels of enzalutamide are reached.17 Since 
enzalutamide induces CYP3A4, and since taxanes are predominantly metabolized via that 
enzyme, a drug-drug interaction between these agents is expected.12,15
Recently, Morris et al. published a pharmacokinetic study in patients on the combination 
of enzalutamide and docetaxel.18 They found a 12% decrease in docetaxel concentrations 
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during concomitant enzalutamide use compared with docetaxel alone, which they 
regarded as clinically irrelevant. However, given the short combination period of only 3 
weeks, during which steady state exposure of enzalutamide may not have been reached 
yet, the true drug-drug interaction might be larger than reported. The half-life and steady 
state level of orally administrated enzalutamide (160 mg once daily) are relatively long: 6 
days and 4 weeks, respectively. So, to identify the true inductive effects of enzalutamide 
on cabazitaxel exposure, we aimed to study the combination for at least the time-period 
that steady state of enzalutamide (i.e. after 4 weeks) is reached.17 Therefore, we studied 3 
consecutive cabazitaxel cycles in our trial, where enzalutamide is used for 6 weeks by men 
with mCRPC.
PATIENTS AND METHODS
Between April 2015 and August 2016 this prospective, non-randomized, non-blinded, 
cross-over, pharmacokinetic trial was undertaken in the Erasmus University Medical 
Center in Rotterdam, the Netherlands. The Ethical board of the Erasmus University Medical 
Center approved the study protocol and written informed consent was obtained from 
all participants. The study was conducted in accordance with the ethical guidelines of 
the Declaration of Helsinki. The study was registered at the Dutch Trial Register (www.
trialregister.nl) by number NL51749.078.14.
Study population
Patients enrolled in this study had histologically proven adenocarcinoma of the prostate 
with documented progression after docetaxel treatment and were eligible to receive 
second line chemotherapy, i.e. cabazitaxel. As the pharmacokinetic interaction was 
our primary endpoint, prior cabazitaxel treatment was allowed and prior enzalutamide 
treatment had to be ceased at least 6 weeks before start of the study. Eligible patients were 
aged at least 18 years, with an Eastern Cooperative Oncology Group (ECOG) performance 
status of 0 or 1 and adequate liver function, defined by total bilirubin ≤ 1.5 x the upper 
limit of normal (ULN; except for documented Gilbert’s disease), ASAT and ALAT ≤ 2.5 x ULN 
(or ≤ 5 x ULN if liver metastases are present). Patients with a medical history of seizures or 
predisposition to seizures were excluded. Medication or herbal supplements which may 
interact with either cabazitaxel or enzalutamide, e.g. by induction or inhibition of CYP3A4, 
CYP2C8, CYP2C9 or CYP2C19, were prohibited during this trial.
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Study design
Patients received three consecutive cycles of cabazitaxel as a 1-hour infusion of 25 mg/m2 
once every three weeks. Dose modifications of cabazitaxel were allowed to a minimal dose 
of 12.5 mg/m2 (50% of the registered dose). Premedication consisted of intravenously given 
dexamethasone (10 mg), followed by granisetron 1 mg. Oral prednisone, at a dose of 5 mg 
twice daily, was taken for as long as cabazitaxel treatment continued. At day 7 after the first 
cabazitaxel cycle within the study, a daily dose of 160 mg enzalutamide (4 capsules of 40 
mg, orally) was added until eight (plus/minus one) days after the third cabazitaxel cycle. So, 
enzalutamide was co-treated for a total of six weeks. Enzalutamide administration was at 
10.00 AM, without permission of dose interruptions or modifications. Patient compliance 
was assessed through a patient diary. Using this cross-over design all patients were their 
own control, making enzalutamide co-medication the only structural varying factor. See 
Figure 1 for a simplified scheme of the study design.
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Figure 1. Study Design 
The study included three consecutive courses of cabazitaxel, and one week after the first cabazitaxel cycle 
enzalutamide was added for a period of six weeks.Abbreviations: PK=pharmacokinetics, Q3W=3-weekly. 
 
PK-assessments 
Plasma samples for cabazitaxel pharmacokinetic (PK) assessments were obtained at cycle 1 (before 
initiation of enzalutamide dosing), cycle 2 and at cycle 3, when steady state levels of enzalutamide 
have been reached. Blood samples (4mL) were withdrawn on the first day of each cabazitaxel cycle, 
at different time-points (pre-infusion and at 0.5, 0.92, 1.08, 1.25, 1.5, 2, 3, 5, 7, 11-13, 24, and 192 
hours after the start of cabazitaxel). Measurement of plasma concentrations of cabazitaxel was 
performed using a validated liquid chromatography with tandem mass spectrometry methods (UP-
MS/MS).19 We used non-compartmental analysis (Phoenix version 6.1; Pharsight) and estimated the 
residual AUC by a linear PK curve from the latest measurable PK-point. The last PK-sample was taken 
at 192h, which corresponds with the regular control at the outpatient clinic at 1 week after 
cabazitaxel infusion. PK parameters determined included cabazitaxel exposure (expressed as dose-
corrected area under the plasma concentration time curves from time zero to infinity (AUC0-inf)). 
When cabazitaxel concentrations were below the limit of detection at this point, we used the 24 
hour sampling point as latest PK-sample, and therefore the dose corrected AUC0-24h as primary 
outcome measurement. Other PK parameters included were the maximum drug concentration 
(Cmax), and its half-life (t1/2).  
 
En
d 
of
 st
ud
y 
Enzalutamide 160mg/day 
Start at day 7, stop at day 49 
Cycle 1 Cycle 2 Cycle 3
Figure 1. Study Design
The study included three consecutive courses of cabazitaxel, and one week after the first cabazitaxel cycle 
enzalutamide was added for a period of six weeks.Abbreviations: PK=pharmacokinetics
PK-assessments
Plasma samples for cabazitaxel pharmacokinetic (PK) assessments were obtained at 
cycle 1 (before initiation of enzalutamide dosing), cycle 2 and at cycle 3, when steady 
state levels of enzalutamide have been reached. Blood samples (4 mL) were withdrawn 
on the first day of each cabazitaxel cycle, at different time-points (pre-infusion and at 
0.5, 0.92, 1.08, 1.25, 1.5, 2, 3, 5, 7, 11-13, 24, and 192 hours after the start of cabazitaxel). 
Measurement of plasma concentrations of cabazitaxel was performed using a validated 
liquid chromatography with tandem mass spectrometry methods (UP-MS/MS).19 We used 
non-compartmental analysis (Phoenix version 6.1; Pharsight) and estimated the residual 
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AUC by a linear PK curve from the latest measurable PK-point. The last PK-sample was taken 
at 192h, which corresponds with the regular control at the outpatient clinic at 1 week after 
cabazitaxel infusion. PK parameters determined included cabazitaxel exposure (expressed 
as dose-corrected area under the plasma concentration time curves from time zero to 
infinity (AUC0-inf)). When cabazitaxel concentrations were below the limit of detection at 
this point, we used the 24 hour sampling point as latest PK-sample, and therefore the dose 
corrected AUC0-24h as primary outcome measurement. Other PK parameters included were 
the maximum drug concentration (Cmax), and its half-life (t1/2).
PSA-assessments
Although not specified per protocol, serum PSA levels were determined at study baseline 
and before start of each cycle. Exploratory analyses were performed to identify proportion 
of patients with ≥ 50% decline of PSA from study start compared to the end of the 
treatment period.
Statistical Analysis
In order to take into account dose-reduced cabazitaxel cycles, all measured concentrations 
were dose-corrected to a dose of 25 mg/m2 by the formula AUC*(25/dose given in that 
cycle). Before analyzing the dose-corrected areas under the curve (AUC) and maximum 
cabazitaxel concentrations (Cmax), a natural log-transformation of these data was performed 
in order to take into account possible deviations from normality. The (log) dose-corrected 
area under the curve (AUC) of cabazitaxel without enzalutamide (AUC Cycle 1) was 
compared to the (log) dose-corrected AUC of cabazitaxel with enzalutamide (AUC Cycle 
3), using a paired t-test. In addition, as a secondary endpoint, the same test was used to 
compare (log) dose-corrected AUC of cycle 1 to cycle 2, the (log) maximum cabazitaxel 
concentration (Cmax) in cycle 1 to cycle 3, and the same for the half-life (t1/2) of cabazitaxel. 
The mean differences and 95% CIs for the differences were exponentiated to provide 
point estimates of the ratio of geometric means and 95% CIs for these ratios, which can be 
interpreted as relative differences in percentages. The study required an estimated sample 
size of 14 evaluable patients to detect a clinical relevant difference in AUC with 80% power 
and a two-sided significance level of 0.05. IBM SPSS Statistics 21 was used for all analyses.
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RESULTS
Patient characteristics & Pharmacokinetic parameters
Baseline characteristics are available for all 14 patients and are shown in Table 1. All 
patients were chemically castrated and used androgen-deprivation therapy throughout 
the whole study period. Cabazitaxel pharmacokinetic parameters are shown in Table 2. 
We aimed to identify the AUC0-inf of cabazitaxel by collecting PK samples up to 192 hours. 
However, in most cases the concentration of cabazitaxel was below the detection limit 
(LLQ) in the 192 hour-PK samples. As a result the residual AUC was >20% of the total AUC, 
which is not acceptable according to the general PK-assumptions. Therefore we had to 
decide to limit our AUC calculation up to the 24 hour sample (AUC0-24h).
The geometric mean exposure was 22% (95% CI 9 – 34%, p=0.005) lower in the third 
cycle (cabazitaxel combined with enzalutamide: AUC0-24h of 181 ng*h/mL, 95%CI 150-219 
ng*h/mL) compared to the fi rst cycle (cabazitaxel monotherapy: AUC0-24h of 234 ng*h/
mL, 95%CI 209-261 ng*h/mL). Interestingly, this decrease was already observed during 
Table 1. Patient Characteristics
Characteristic Value No. (%)
Evaluable patients (n) 14 (100)
Age (years) , mean ± SD 67.7 ± 6.1
WHO performance status
- 0 4 (29)
- 1 10 (71)
Liver function baseline, mean ± SD
- Bilirubine (µmol/L) 5.4 ± 2.1
- ASAT (U/L) 24.6 ± 9.9
- ALAT (U/L) 19.1 ± 8.5
Prior therapy
- Docetaxel 14 (100)
- Abiraterone 6 (43)
- Enzalutamide 3 (21) 
- Radiotherapy 3 (21)
- Experimental* 5 (36)
- Cabazitaxel 2 (14)
Type of castration
- Chemical 14 (100)
Abbreviations: n= number, SD= standard deviation; WHO=World Health Organization.*Experimental included 
participation in phase I and II clinical trial with a variety of agents: TAS-119, ARN-509, Dendritic cell therapy
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cycle 2 (AUC0-24h of 182 ng*h/ml, 95%CI 157-211 ng*h/mL; relative diff erence = -22%, 
95% CI -13 – -31%, p<0.001) despite the shorter period of the drug-drug combination 
during that cycle. In addition, the variation in pharmacokinetic eff ects, as expressed by 
the coeffi  cient of variation (CV%), was higher in the third cycle than in cycle 1 and cycle 2 
in the study, respectively 34%, 19% and 26%, see Figure 2. As secondary endpoints other 
pharmacokinetic endpoints; maximum concentration (Cmax) of cabazitaxel and half-life (t1/2) 
of cabazitaxel were measured, and compared between cycle 1 and cycle 3. The maximum 
concentration of cabazitaxel in the fi rst cycle (Cmax 138 ng/mL, 95% CI 111-171 ng/mL) was 
signifi cantly higher than in the third cycle (Cmax 96 ng/mL, 95% CI 86-108 ng/mL; relative 
diff erence = -30%, 95% CI -42 – -16%, p=0.001). There was no diff erence in half-life of 
cabazitaxel between both cycles (cycle 1: t1/2 22h, 95% CI 14-33h vs. cycle 3: t1/2 18h, 95% CI 
12-27h; relative diff erence = -18%, 95% CI -59 – 64%, p=0.552).
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Table 2. Cabazitaxel pharmacokinetics
Abbreviations: PK = pharmacokinetics; C1/2/3 = cycle 1/2/3, caba = cabazitaxel; enza = enzalutamide; CI = Confindence Interval; AUC0-24h= Area under the curve for 24 hours, 
expressed as geomean; Cmax= max concentration, expressed as geomean; t1/2= half-life, expressed as geomean; CV% = coefficient of variation . * = comparison between cycle 
1 and cycle 3.
Figure 2. Individual dose-corrected cabazitaxel AUC0-24h. 
Each line refers to one patient. The dose-corrected AUC0-24h of cabazitaxel (Y-axis) is measured per cycle (X-axis), and AUC-values for individual patients are connected 
between the cycles.
Cabazitaxel PK parameters C1 (caba) C2 (caba+enza) C3 (caba + enza) Difference C3/C1 % (95% CI) P-value*
AUC0-24h ng*h/mL (CV%) 234 (19) 182 (26) 181 (34) -22 (-9 till -34) 0.005
Cmax ng/mL (CV%) 138 (39) 96 (49) 96 (20) -30 (-42 till - 6) 0.001
t1/2 h (CV%) 22 (87) 14 (41) 18 (79) -18 (-59 till 64) 0.552
Figure 2. Individual dose-corrected cabazitaxel AUC0-24h.
Each line refers to one patient. The dose-corrected AUC0-24h of cabazitaxel (Y-axis) is measured per cycle (X-axis), and 
AUC-values for individual patients are connected between the cycles.
Table 2. Cabazitaxel pharmacokinetics
Cabazitaxel PK parameters C1 (caba)
C2 
(caba+enza)
C3 (caba + 
enza)
Diff erence C3/C1 % 
(95% CI) P-value*
AUC0-24h ng*h/mL (CV%) 234 (19) 182 (26) 181 (34) -22 (-9 till -34) 0.005
Cmax ng/mL (CV%) 138 (39) 96 (49) 96 (20) -30 (-42 till -16) 0.001
t1/2 h (CV%) 22 (87) 14 (41) 18 (79) -18 (-59 till 64) 0.552
Abbreviations: PK = pharmacokinetics; C1/2/3 = cycle 1/2/3, caba = cabazitaxel; enza = enzalutamide; CI = 
Confi ndence Interval; AUC0-24h= Area under the curve for 24 hours, expressed as geomean; Cmax= max concentration, 
expressed as geomean; t1/2= half-life, expressed as geomean; CV% = coeffi  cient of variation . * = comparison 
between cycle 1 and cycle 3.
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Toxicity & PSA response
There were no unexpected serious adverse events (SAEs) during combined treatment 
with these drugs. A total of four SAEs were generally related to cabazitaxel treatment 
(monotherapy), including neutropenic fever (2 times), deep venous thrombosis, and 
hypertension. Hypertension (grade 3) occurred during the third cycle, although this patient 
was already known with hypertension. The deterioration of the blood pressure may be 
attributed to enzalutamide use as well. Four out of six (67%) grade 3-4 adverse events 
occurred during cabazitaxel monotherapy, while the other two adverse events happened 
during the combination therapy of cabazitaxel and enzalutamide, indicating an overall 
well-tolerated combination strategy.
Since PSA response was not specified per protocol, we analyzed response rates in an 
explorative way. Since baseline PSA was missing for one patient, PSA analyses were 
performed in 13 of 14 patients. PSA responses of 50% or more were observed in eight 
(62%) of the 13 patients at completion of the three consecutive cycles of cabazitaxel in the 
study, which we regarded as high given the extensive prior treatment in this typical patient 
cohort (Figure 3). Five of the PSA responders had prior treatment with an AR-agent, and 
both cabazitaxel pre-treated patients had a >50% PSA decline.
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DISCUSSION
In this pharmacokinetic cross-over study in patients with mCRPC treated with cabazitaxel, 
we evaluated the difference in exposure (AUC0-24h) of cabazitaxel when administered with or 
without enzalutamide. Our study showed a significant and potentially clinically important 
reduction (22%) in cabazitaxel exposure by simultaneous treatment with enzalutamide.
As mentioned, enzalutamide is classified as a strong inducer of CYP3A4 enzyme,17 and 
all taxanes, including cabazitaxel, are metabolized primarily by this enzyme. Therefore, a 
drug-drug interaction was expected a priori, although the magnitude of that interaction 
was uncertain. In this study, the inductive effects of enzalutamide on cabazitaxel exposure 
is relatively high and results in a clinically relevant interaction between these agents. 
In contrast, Morris et al.18 found a moderate 12% reduction of docetaxel concentration 
(AUCinf) with concomitant enzalutamide use. The substantial difference between the 
identified percentages of enzalutamide related drug-induction in the study of Morris et 
al.18 and our cohort may be due to the different taxanes that were used. Although our 
primary endpoint was to compare cabazitaxel study cycle 1 to cabazitaxel study cycle 3, 
we already saw comparable geomean cabazitaxel AUC0-24h decreases during cabazitaxel 
study cycle 2, following 14 days of treatment with enzalutamide. Although the steady 
state levels of enzalutamide are reached after 4 weeks, the inducing effect on CYP3A4 is 
probably complete after two weeks. This observation is consistent with prior observations 
that induction of CYP enzymes is complete within 9-14 days after start of treatment with 
strong CYP inducers.20 Nonetheless, study cycle 3 was not similar to study cycle 2: the 
interpatient variability was substantially higher in the third cycle, as several patients had 
higher cabazitaxel concentrations in that cycle than in cycle 2. Contrarily, other patients 
had a further decrease in cabazitaxel exposure in the third cycle (see Figure 2). The 
interpatient variability of cabazitaxel is moderate with 24%.10 In this study, it appears that 
interpatient variability (%CV) increases when cabazitaxel is combined with enzalutamide 
and even further in consecutive cycles. We cannot provide a clear explanation for this 
phenomenon. This increased variation was not dependent on occurrence of hepatotoxicity, 
co-medication, or number of cabazitaxel cycles preceding the start of this study. Also 
patient compliance to daily take oral enzalutamide did not differ during the cycles, based 
on notes in patient diaries. Moreover, medication or herbal supplements that could interact 
with enzalutamide were prohibited per protocol, so the risk of interpatient variation 
in pharmacokinetics of enzalutamide, with potential impact on pharmacokinetics of 
cabazitaxel, is brought back to the minimum. However, enzalutamide concentrations were 
not measured, which is a limitation of our study.
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Recently, the results of the ‘PROSELICA’ study have become available. PROSELICA was 
a post-marketing study, mandated by the Food and Drug Administration (FDA), to 
investigate if a 20 mg/m2 three-weekly dose of cabazitaxel is non-inferior to the standard 
dose of 25 mg/m2.21 The PROSELICA study showed a non-inferior overall survival outcome 
with the 20 mg/m2 dose. As expected the lower dose was also associated with a notably 
favorable adverse event profile. Although to date the dose in the label has not been 
changed, in clinical practice the use of the 20 mg/m2 dose is being adopted widely, both 
in the US and in Europe. If indeed such a lower dose of cabazitaxel is applied, an additional 
reduction of 22% in cabazitaxel exposure by enzalutamide may result in sub-therapeutical 
cabazitaxel concentrations.
Interestingly, the PSA response, which was studied exploratively, was higher in this study 
than the response rate reported in the TROPIC trial, which was the registration trial for 
cabazitaxel treatment (62% versus 39%).22,23 The higher PSA response is encouraging, since 
most of our patients had received prior AR-targeted therapy, several had previously been 
treated with cabazitaxel, and several had been on clinical phase I and II studies with a 
variety of drugs, rendering the 4th or even 5th line treatment. Moreover, in our cohort the 
cabazitaxel concentration was reduced with a mean of 22% for 2 cycles due to the drug-
drug interaction with enzalutamide. This implies that the additive effect of the drug-drug 
combination on PSA response is promising, despite the inductive effects of enzalutamide 
on cabazitaxel pharmacokinetics. Still, our response rates should be interpreted with 
caution due to the exploratory design of the analysis, the small sample size, and the limited 
study period.
Furthermore, the combination treatment was very well tolerated considering the 
low incidence and severity of adverse events, although our results should be seen in 
perspective given the short treatment period and the prior cabazitaxel cycles that 
were allowed. In a recent study by Massard et al. on the combination of cabazitaxel and 
abiraterone, also a lower incidence of grade ≥ 3 neutropenia was reported than in the 
TROPIC trial (56%). This lower incidence of neutropenia did not result in less (marker) 
efficacy, as PSA levels dropped in 46% patients.4
In conclusion, our study shows a significant and clinically relevant reduction in cabazitaxel 
exposure when combined with enzalutamide, most probably due to CYP3A4 induction by 
enzalutamide. Prospective clinical studies with this promising combination are warranted, 
but investigators need to be aware of the observed drug-drug interaction.
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ABSTRACT
Aim: Docetaxel has been approved for the treatment of metastatic prostate cancer in 
combination with prednisone. Since prednisone is known to induce the cytochrome 
P450 iso-enzyme CYP3A4, which is the main metabolizing enzyme of docetaxel in the 
liver, a potential drug-drug interaction (DDI) may occur. In this prospective randomized 
pharmacokinetic cross-over study we investigated docetaxel exposure with concomitant 
prednisone, compared to docetaxel monotherapy in men with metastatic prostate cancer.
Methods: Patients scheduled to receive at least 6 cycles of docetaxel (75 mg/m2) and who 
lent written informed consent, were randomized to receive either the first 3 cycles, or the 
last 3 consecutive cycles with prednisone (BID 5mg). Pharmacokinetic blood sampling 
was performed during cycle 3 and cycle 6. Primary endpoint was difference in docetaxel 
exposure, calculated as area under the curve (AUC0-inf) and analyzed by means of a linear 
mixed model. Given the cross-over design the study was powered on eighteen patients to 
answer the primary, pharmacokinetic, endpoint.
Results: Eighteen evaluable patients were included in the trial. Docetaxel concentration 
with concomitant prednisone (AUC0-inf 2784 ng*h/mL, 95% CI 2436-3183 ng*h/mL) was 
similar to the concentration of docetaxel monotherapy (AUC0-inf 2647 ng*h/mL, 95%CI 
2377-2949 ng*h/mL). Exploratory analysis showed no toxicity differences between 
docetaxel monotherapy and docetaxel cycles with prednisone.
Conclusion: No significant difference in docetaxel concentrations was observed. In 
addition, we found similar toxicity profiles in absence and presence of prednisone. 
Therefore, from a pharmacokinetic point of view, docetaxel may be administrated with or 
without prednisone.
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I N T R O D U C T I O N
Docetaxel, a taxane chemotherapeutic agent, was approved by the Food and Drug 
Administration (FDA) and European Medicines Agency (EMA) in 2004 as first-line 
chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) as a result 
of survival benefit obtained in TAX327.1,2 In that study, mitoxantrone plus prednisone 
treatment was compared to a 3-weekly docetaxel (75 mg/m2) regimen in mCRPC patients. 
Prednisone (5 mg bi-daily BID) was added to docetaxel to equally compare both treatment 
arms, although the preceding phase 2 trials with docetaxel (36 mg/m2, weekly) in 
mCRPC had been conducted without prednisone.3,4 In the final analysis, treatment with 
docetaxel plus prednisone improved overall survival (OS) with 2.9 months compared 
to the mitoxantrone group. Subsequently, docetaxel and prednisone became first-line 
chemotherapy for mCRPC .
After the registration of docetaxel plus prednisone, the role of corticosteroids in the 
treatment of mCRPC remained controversial. In patients with symptomatic bone 
metastases corticosteroids may have a favorable palliative effect, and a reduction in 
docetaxel-induced toxicity has been suggested.5-7 However, the effect of prednisone on OS 
in mCRPC patients remains unclear.6,8 Of note, prolonged use of corticosteroids may lead to 
the development of multiple severe toxicities including osteoporosis, adrenal insufficiency, 
immune suppression, and may exacerbate comorbidities like diabetes.9 These side-effects 
of long-term corticosteroid are a justifiable reason to reconsider the addition of prednisone 
to the docetaxel regimen.
Recently, two large clinical trials, CHAARTED and STAMPEDE, assessed the survival benefit 
of docetaxel combined with androgen-deprivation therapy (ADT) in metastatic hormone-
sensitive prostate cancer (mHSPC).10,11 In order to avoid long term exposure to steroids, the 
investigators of the CHAARTED trial decided to administer docetaxel without prednisone, 
whereas docetaxel was administered with prednisone in the STAMPEDE study. At the time 
of the initiation of our study, only the results of CHAARTED were available, showing a 
robust survival benefit of 13.6 months compared to androgen deprivation therapy alone. 
Toxicity rates were similar to previously published work on docetaxel plus prednisone 
in mCRPC patients , except for a higher febrile neutropenia rate in CHAARTED without 
prednisone, as compared to TAX327 where docetaxel was administered with prednisone.1,12 
Likewise, a retrospective trial by Kongsted et al. showed that the toxicity rates of febrile 
neutropenia and edema were significantly higher in the docetaxel monotherapy group 
compared to the docetaxel plus prednisone-group (for an overview of toxicity rates 
previously reported on docetaxel with or without prednisone, see Table 1).5
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As a underlying mechanism, prednisone could influence docetaxel pharmacokinetics via 
the CYP3A4 iso-enzyme. Glucocorticoids are known as CYP3A inducers, and docetaxel 
is mainly metabolized in the liver by the cytochrome P450 iso-enzymes CYP3A4 and 
CYP3A5.13 Consequently, this potential drug-drug interaction could lead to higher 
clearance of docetaxel and therefore diminished docetaxel exposure. In this study, we 
therefore investigated the effects of prednisone on docetaxel pharmacokinetics in patients 
with metastatic prostate cancer.
METHODS
This prospective, randomized, cross-over pharmacokinetic trial was carried out between 
September 2016 and February 2018 at the Erasmus MC Cancer Institute in Rotterdam, the 
Netherlands. The study protocol was approved by the Ethical board of the Erasmus MC, and 
the study was conducted according to the ethical guidelines of the Declaration of Helsinki. 
All participants signed informed consent before start of the study. The study was registered 
at the European Clinical Trials Database (EudraCT 2016-001269-10) and the Dutch Trial 
Register (‘www.trailregister.nl’ by NTR-number NTR6037 or acronym Doc-Pred).
Patients
We included patients with histologically confirmed metastatic prostate cancer, both 
hormone-sensitive or castration-resistant, who were scheduled to receive a minimum 
of 6 cycles of docetaxel chemotherapy. Eligible patients were 18 years and older, with 
an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Adequate 
organ function was required, defined by creatinine clearance >60mL/min, bilirubin levels 
<1x ULN, ALAT/ASAT <2.5x ULN, alkaline phosphatase (AF) < 5x ULN, absolute neutrophil 
count >1,5x10^9/L and platelets >100x10^9/L. Patients had to be castrated either by 
Table 1. Literature review of docetaxel toxicities with and without prednisone
Trials Prednisone Neutropenia (Gr3-4) Febrile neutropenia
TAX-327 Yes 32% 3%
Venice Yes 7% <1%
Mainsail Yes 16% 5%
GETUG-AFU15 No 32% 8%
CHAARTED No 12% 6%
STAMPEDE Yes 12% 15%
Kongsted et al. No - 25%
Yes - 10%
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continued androgen deprivation therapy (ADT) with gonadotropin releasing hormone 
(GnRH) analogues or by surgical orchiectomy. It was preferred ADT started four weeks 
prior to chemotherapy, to reach castration-levels of testosterone before treatment start. 
Prior hormonal treatment, like enzalutamide and abiraterone, was allowed. However, these 
therapies, including prednisone, had to be stopped at least 6 weeks before the start of this 
study. Medication or herbal supplements known to induce or inhibit CYP3A pathway were 
prohibited.
Study Design
Patients received 6 consecutive cycles of 3-weekly docetaxel (75 mg/m2) and were 
digitally randomized to receive either the first 3 docetaxel cycles or the last 3 cycles with 
prednisone (cross-over). Prednisone 5 mg BID was administered during three consecutive 
cycles. Prednisone started at day 1 of cycle 1 or cycle 4 and was stopped after the last day 
of cycle 3 or cycle 6 (depending on randomization arm, A or B respectively). Prednisone 
dose-modifications were not allowed during the last week before pharmacokinetic 
sampling (cycle 3 day 1 and cycle 6 day 1) and patient compliance was assessed 
through a patient diary. Docetaxel dose-modifications because of hematological or 
non-hematological toxicities were allowed, and schedule modifications were allowed up 
to one week. Dexamethasone is a strong CYP3A4 inducer, its use, as premedication, was 
restricted to 12 and 3 hours before docetaxel-infusion to reduce its influence on docetaxel 
pharmacokinetics.
Pharmacokinetic sampling
To have maximum inducible effects of prednisone on the CYP-enzymes and to ensure 
a sufficient wash-out period after prednisone, we decided to undertake PK-samples 
during cycle 3 and cycle 6. Hospital admission during the first day of the 3rd and the 
6th docetaxel cycle was required to obtain 24-hour pharmacokinetic-blood samples. 
Blood/plasma samples for determination of docetaxel pharmacokinetics were taken at 
predefined time points (pre-infusion and at 0.5, 0.92, 1.25, 1.5, 2, 3, 4, 6, 8 and 24 hours 
after the start of docetaxel). Plasma concentrations of docetaxel were measured using 
a validated liquid chromatography with tandem mass spectrometry method (UP-LCMS/
MS).14 Pharmacokinetic parameters were docetaxel concentration, expressed as dose-
corrected area under the curve from pre-infusion time-point to infinity (AUC0-inf), maximum 
drug concentration (Cmax), docetaxel half-life (t1/2) and docetaxel clearance. AUC0-inf was 
calculated using a linear pharmacokinetic curve to estimate the residual AUC from the 
latest measurable pharmacokinetic point (24h time-point).
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Toxicity
Secondary endpoint was describing toxicity rates during docetaxel monotherapy cycles 
and docetaxel with prednisone cycles. Standard laboratory control was performed prior 
to each docetaxel cycle and when indicated according to the physician. Toxicities were 
scored using the CTCAE (v.4.0) grading. If relevant differences in toxicity rates between the 
treatment arms occurred, these were analyzed by means of McNemar test.
Statistical analysis
A difference in systemic exposure to docetaxel of 25% was determined to be clinically 
relevant and it was assumed that the within-patient standard deviation in docetaxel 
pharmacokinetics was 25%. Given a power of 80% and a two-sided alpha of 5%, 18 patients 
were required to detect a difference.15 Since docetaxel dose-modifications were allowed, 
a dose-correction was applied for all docetaxel concentrations to the standard dose of 
75 mg/m2. All docetaxel cycles with prednisone were compared to all docetaxel cycles 
without prednisone, regardless of the randomization arm. Analyses of the AUC0-inf and 
Cmax were performed on log-transformed values, since these parameters were assumed to 
follow a lognormal distribution.16 Estimates for the mean differences in (log) AUC0-inf, Cmax 
and clearance were obtained using a linear mixed effect model with treatment, sequence, 
and period as fixed effects and subject within sequence as a random effect.17 Variance 
components were estimated based on restricted maximum likelihood (REML) methods and 
the Kenward-Roger method of computing the denominator degrees of freedom was used. 
The mean differences and their 95% CIs were exponentiated to provide point estimates 
of the ratio of geometric means and 95% CIs for these ratios, which can be interpreted as 
relative differences in percentages. T1/2 was analysed by means of the Wilcoxon signed rank 
test and described with medians and interquartile ranges.
RESULTS
Patients
Twenty-nine patients were screened, of whom four were screen failures which were 
excluded from study participation (Figure 1). We randomized 25 patients to receive either 
cycles 1-3 with concomitant prednisone, and cycles 4-6 without prednisone (arm A, N=12), 
or vice versa (arm B, N=13). During treatment one patient withdrew consent in arm A, and 
six patients stopped treatment in arm B due to radiologic confirmed progression (N=3) or 
withdrawal of consent (N=3).
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Baseline patient and disease characteristics are shown in Table 2. All patients, except three 
mHSPC patients, received the first cycle of docetaxel 4 weeks after initiation of ADT, to 
reach castration levels of testosterone. However, all patients received ADT for more than a 
month before PK samples during cycle 3 were withdrawn.
Pharmacokinetic parameters
The geometric mean exposure of docetaxel was not significantly different (1.9%, 95% CI 
-9.9% till 15.2%, P=0.75) during docetaxel with concomitant prednisone treatment (AUC0-inf 
of 2784 ng*h/mL, 95% CI 2436-3183 ng*h/mL) compared to docetaxel monotherapy 
(AUC0-inf of 2647 ng*h/mL, 95% CI 2377-2949 ng*h/mL). The pharmacokinetic variation, 
as expressed by coefficient of variation, was slightly higher in the docetaxel with 
prednisone arm as compared to docetaxel monotherapy (27% and 22% respectively). All 
pharmacokinetic parameters are shown in Table 3 and were not significantly different for 
docetaxel with or without prednisone. Additionally, we graphically showed differences 
in exposure of docetaxel in mCRPC patients (blue line) and mHSPC patients (red line), 
separately in arm A and arm B; see Figure 2. We performed a t-test on the complete 
patient group (arm A and arm B combined) and found no significant (P=0.2) difference 
38 
 
difference.15 Since docetaxel dose-modifications were allowed, a dose-correction was applied for all 
docetaxel concentrations to the standard dose of 75 mg/m2. All docetaxel cycles with prednisone 
were compared to all docetaxel cycles without prednisone, regardless of the randomization arm. 
Analyses of the AUC0-inf and Cmax were performed on log-transformed values, since these parameters 
were assumed to follow a lognormal distribution.16 Estimates for the mean differences in (log) AUC0-
inf, Cmax and clearance were obtained using a linear mixed effect model with treatment, sequence, 
and period as fixed effects and subject within sequence as a random effect.17 Variance components 
were estimated based on restricted maximum likelihood (REML) methods and the Kenward-Roger 
method of computing the denominator degrees of freedom was used. The mean differences and 
their 95% CIs were exponentiated to provide point estimates of the ratio of geometric means and 
95% CIs for these ratios, which can be interpreted as relative differences in percentages. T1/2 was 
analysed by means of the Wilcoxon signed rank test and described with medians and interquartile 
ranges. 
 
RESULTS 
Patients 
Twenty-nine patients were screened, of whom four were screen failures which were excluded from 
study participation (Figure 1). We randomized 25 patients to receive either cycles 1-3 with 
concomitant prednisone, and cycles 4-6 without prednisone (arm A, N=11), or vice versa (arm B, 
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Figure 1. Flowchart 
a. due to inadequate laboratory 
values 
b. Arm A: Three cycles of docetaxel  
plusprednisone followed by three  
cycles of docetaxel alone 
c. Arm B: Three cycles of docetaxel  
alone followed by three cycles of  
docetaxel plus prednisone  
Figure 1. Flowchart
a. due to inadequate laboratory values
b. Arm A: Three cycles of docetaxel plusprednisone followed by three cycles of docetaxel alone
c. Arm B: Three cycles of docetaxel alone followed by three cycles of docetaxel plus prednisone
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Table 2. Patient and disease characteristics
Characteristic N (%)
Patients 18 (100)
Age (Median, IQR) 70 (62-73)
BMI (Median, IQR) 25.8(24.6-28.7)
WHO Performance Status
- 0 8 (44)
- 1 10 (56)
Hormone Status
- Hormone sensitive 11 (61)
- Castration resistant 7 (39)
Metastatic stage at screening
- M0 5 (28)
- M1a 4 (22)
- M1b 8 (44)
- M1c 1 (6)
Gleason score at diagnosis
- ≤ 7 4 (22)
- > 7 14 (77)
Type of castration
- Bilateral orchidectomy 1 (6)
- LHRH analogues 17 (94)
Previous therapy
- Radicale prostatectomy 1 (6)
- RTx prostate 3 (16)
- Hormone therapy
  Bicalutamide 6 (33)
  Enzalutamide 2 (11)
- Radium-223 1 (6)
- Experimental therapy 1 (6)
Lab results at baseline Median (IQR)
- PSA, µg/L 20 (3-87)
- Hb, mmol/L 8 (7-10)
- LDH, U/L 196 (178-216)
- AP, U/L 103 (70-160)
- Albumin, g/L 44 (43-46)
Abbreviations: IQR = Inter Quartile Range, BMI = Body Mass Index, WHO = World Health Organizations, LHRH = 
luteinizing hormone releasing hormone, RTx = radiotherapy, PSA = prostate specific antigen, Hb = hemoglobin, LDH 
= lactate dehydrogenase, AP = alkaline phosphatase
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between the exposure in mCRPC patients and mHSPC patients. Of note, we found a 13.4% 
(95% CI 2.1%-23.4%, P=0.025) lower exposure of docetaxel over time, independent from 
randomization or disease setting. This, so called, period-effect shows lower measured 
concentrations of docetaxel in cycle 6 compared to the concentrations in cycle 3, 
regardless of the addition of prednisone (Figure 2).
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Figure 2. Docetaxel concentration by disease setting 
Each line represents a patient for whom the measured docetaxel concentration (geomean AUC0-inf) at cycle 3 
and cycle 6 were connected with a line to visualize the concentration differences between the cycles. In the 
majority of the patients the measured concentration in cycle 6 is lower than in cycle 3, reflecting the period-
effect observed in this study. The red lines represent patients in the hormone-sensitive disease setting and the 
blue lines represent the castration-resistant patients, subdivided by randomization arm. 
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Figure 2. Docetaxel concentration by disease setting
Each line represents a patient for whom the measured docetaxel concentration (geomean AUC0-inf) at cycle 3 and 
cycle 6 were connected with a line to visualize the concentration differences between the cycles. In the majority of 
the patients the measured concentration in cycle 6 is lower than in cycle 3, reflecting the p riod-eff ct observed i  
this study. The red lines represent patients in the hormone-sensitive disease setting and the blue lines represent the 
castration-resistant patients, subdivided by randomization arm.
Table 3. Docetaxel pharmacokinetics
Docetaxel PK 
parameters
Docetaxel 
(N=18)
Docetaxel+Prednisone 
(N=18)
Relative difference 
(95% CI) P-value
AUC0-inf a
geomean ng*h/mL (CV%)
2647 (22) 2784 (27) 1.9% (-9.9 till 15.2) 0.75
Cmaxa
geomean ng/mL (CV%)
2454 (26) 2505 (25) -1.4% (-15.3 till 14.8) 0.85
CLa
geomean, L/h (CV%)
55 (26) 53 (26) -2.3% (-9.5 till 5-6) 0.53
T1/2b
median, h (IQR)
12.6 (10.6-14.5) 13.7 (11.3-16.3) 0.31
Abbreviations: AUC0-inf = Area under curve timepoint zero until infinity, Cmax = maximum concentration, CL = 
clearance, T1/2 = half-life, geomean = geometric mean, CV% = coefficient of variation, CI = confidence interval, a= 
analyzed by means of a linear effect model, b= analyzed by means of Wilcoxon signed rank test.
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Toxicity
Toxicity rates were similar between the cycles with and without prednisone, Table 4, 
except for neutropenia. A non-significant trend towards a higher rate of all grade (gr 1-4) 
neutropenia (N=12) was observed in patients treated without prednisone as compared 
to with prednisone (44 vs 22%, P=0.22). Seven patients (39%) experienced an episode of 
grade 3 – 4 neutropenia. Three febrile neutropenia hospitalizations were observed, two 
of which happened during co-administration of prednisone. There was no difference in 
the disease setting; toxicity was equally distributed in castration-resistant and hormone-
sensitive setting (data not shown).
Table 4. Toxicity with or without prednisone
Toxicity
All grades
With prednisone N (%) Without prednisone N (%)
Nausea 3 (17) 5 (28)
Mucositis 9 (50) 8 (44)
Diarrhea 5 (28) 2 (11)
Sens PNP 6 (33) 6 (33)
Fatigue 12 (67) 13 (72)
Neutropenia 4 (22) 8 (44)
Febrile neutropenia 1 (6) 2 (11)
Nail toxicity 5 (28) 6 (33)
Edema 0 (0) 1 (6)
Dysgeusia 1 (6) 1 (6)
Abbreviations: Sens PNP = sensory polyneuropathy
DISCUSSION
In this randomized study, the effects of prednisone on the pharmacokinetics of docetaxel 
were evaluated. No significant difference in docetaxel exposure with or without the 
administration of prednisone was observed. This is the first randomized pharmacokinetic 
study investigating the effects of prednisone on the pharmacokinetics of docetaxel. From a 
pharmacological perspective, we conclude that prednisone did not affect the exposure of 
the docetaxel regimen.
Glucocorticoids are classified as inducers of the CYP3A enzyme,18 and docetaxel is 
metabolized primarily by this iso-enzyme. Previously, an interaction study of docetaxel 
and prednisone has been published in the Clinical Study Report (CSR) of docetaxel and no 
relevant drug-drug interaction was reported.19 However, that PK-study was not randomized 
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and included only two docetaxel cycles; one with prednisone and one without, possibly 
not providing enough time for optimal CYP-induction by prednisone. Moreover, that study 
was limited by sparse PK-sampling (only 6 samples during each cycle) and by limited 
pharmacokinetic endpoints of docetaxel (clearance only). Therefore, in our study, we used 
a randomized cross-over design including 6 cycles of docetaxel (3 cycles in absence and 
3 cycles in presence of prednisone), an enriched sampling scheme with more relevant 
pharmacokinetic endpoints.
Although we corrected for dose-reductions due to toxicity over time, we unexpectedly 
did find a significant period-effect in this study. This means that a decrease in docetaxel 
exposure occurred in the consecutive cycles independent of randomization or treatment. 
This might be an explanation for the trend towards an overall higher incidence of 
(febrile) neutropenia seen at the start of chemotherapy cycles. There are a few potential 
explanations for this phenomenon. First, a time-dependent induction of CYP3A4 by 
upregulation of Pregnane X receptor (PXR) due to repetitive docetaxel exposure could 
occur.20-23 This phenomenon is called ‘auto-induction’ and is previously described with 
several other agents, e.g. dabrafenib.24 A second possible explanation is an upregulation of 
ABCB1 (P-glycoprotein) by docetaxel. P-glycoprotein is an active drug-efflux transporter at 
the cell membrane of hepatocytes, kidney cells and intestine cells. Its upregulation leads 
to an increased efflux of docetaxel out of the circulation, resulting in decreased plasma 
concentrations.25 This phenomenon could even lead to pharmacokinetic resistance to the 
drug.26,27 This period effect is unlikely to be caused by castration-levels of the patients, since 
the maximum induction effect of ADT is reached after approximately 4 weeks , whereas in 
our study patients had received at least nine weeks of ADT at the time of PK sampling.
Interestingly, we observed no difference in docetaxel-induced toxicities in the absence or 
presence of prednisone, except for a non-significant difference in neutropenia. Because our 
study was not powered or designed for toxicity related questions, we can only conclude 
from a pharmacokinetic point of view that prednisone could be safely omitted from the 
docetaxel regimen.
The major benefit of administering docetaxel without prednisone could be a reduced 
treatment-period of prednisone for patients with metastatic prostate cancer. Long-term 
corticosteroid use, albeit in low dosage, may contribute to the development of severe 
toxicities, as mentioned before.9 By excluding prednisone from the initial docetaxel 
chemotherapy regimen patients will no longer be unnecessarily exposed to these side-
effects. Especially for those patients in the hormone-sensitive phase, who usually have a 
long life expectancy, excluding prednisone will be of relevance to avoid long-term toxicity 
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with unclear antitumor activity. In this light, Ghatalia et al. found no positive effect on 
survival nor on cabazitaxel-induced toxicity in patients with mCRPC.28
Limitations of our study include the administration of the standard pre-medication 
dexamethasone, which is another CYP3A inducer. We aimed to minimize the 
pharmacokinetic effect of dexamethasone on docetaxel by excluding the latest gift of 
dexamethasone before docetaxel infusion. Strengths of our study are the randomized 
design with extensive PK sampling at multiple time points.
In conclusion, we found no influence of prednisone on docetaxel pharmacokinetics. 
Docetaxel is registered with concomitant prednisone in the mCRPC setting. In metastatic 
hormone-sensitive disease, the use of prednisone should be supported by other 
arguments balancing the benefit of prednisone versus the potential long-term side effects 
of corticosteroid use.
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ABSTRACT
Purpose: Phase Ib study evaluating the effect of apalutamide, at therapeutic exposure, 
on ventricular repolarization by applying time-matched pharmacokinetics and 
electrocardiography (ECG) in patients with castration-resistant prostate cancer. Safety of 
daily apalutamide was also assessed.
Methods: Patients received 240 mg oral apalutamide daily. Time-matched ECGs were 
collected via continuous 12-lead Holter recording before apalutamide (Day –1) and on Days 
1 and 57 (Cycle 3 Day 1). Pharmacokinetics of apalutamide were assessed on Days 1 and 
57 at matched time points of ECG collection. QT interval was corrected for heart rate using 
Fridericia correction (QTcF). The primary endpoint was the maximum mean change in QTcF 
(ΔQTcF) from baseline to Cycle 3 Day 1 (steady state). Secondary endpoints were the effect 
of apalutamide on other ECG parameters, pharmacokinetics of apalutamide and its active 
metabolite, relationship between plasma concentrations of apalutamide and QTcF, and 
safety.
Results: Forty-five men were enrolled; 82% received treatment for ≥3 months. At steady 
state, the maximum ΔQTcF was 12.4 ms and the upper bound of its associated 90% CI 
was 16.0 ms. No clinically meaningful effects of apalutamide were reported for heart rate 
or other ECG parameters. A concentration-dependent increase in QTcF was observed for 
apalutamide. Most adverse events (AEs) (73%) were grade 1–2 in severity. No patients 
discontinued due to QTc prolongation or AEs.
Conclusion: The effect of apalutamide on QTc prolongation was modest and does not 
produce a clinically meaningful effect on ventricular repolarization. The AE profile was 
consistent with other studies of apalutamide.
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INTRODUCTION
Prostate cancer is the second most common cancer in men worldwide, accounting for 15% 
of cancers diagnosed in men.1 Metastatic castration-resistant prostate cancer (mCRPC) 
is associated with progressive morbidities, including skeletal-related events.2 Because 
prostate cancer cells depend on the androgen receptor (AR) for survival and growth, 
treatment for recurrent or primary metastatic prostate cancer targets this receptor axis.3 
Despite initial therapies that target the AR, many patients progress to CRPC.3 Apalutamide 
is an orally administered next-generation AR inhibitor currently approved in the United 
States for patients with nonmetastatic CRPC (nmCRPC).4 It directly binds the ligand-binding 
domain of the AR, inhibits AR nuclear translocation and DNA binding, and impedes 
AR-mediated transcription.5
The efficacy and safety of apalutamide were demonstrated in patients with prostate cancer 
in the SPARTAN study, a randomized, double-blind, placebo-controlled, multicenter trial 
that evaluated apalutamide treatment in 1207 patients with high-risk nmCRPC.6 This 
study was the first to demonstrate a significant longer median metastasis-free survival 
(MFS; 2 years over placebo) in apalutamide-treated patients compared with placebo-
treated patients, with consistent benefit for apalutamide across all secondary endpoints, 
including time to symptomatic progression.6 Minimal cardiac adverse events (AEs) were 
observed; atrial fibrillation was cited as the primary cardiac-associated AE reason for dose 
interruption and occurred in 0.7% and 0.5% of patients in the apalutamide and placebo 
arms, respectively. Based on these data, apalutamide was approved in February 2018 by 
the US Food and Drug Administration (FDA) for the treatment of men with nmCRPC.4
Apalutamide pharmacokinetics (PK) have been well characterized in clinical studies. 
Apalutamide is rapidly absorbed, with a median time to maximum observed plasma 
concentration (Cmax) of 2–3 h after oral administration.7 Additionally, PK were approximately 
proportional across dose levels, with a mean effective half-life of approximately 3 days 
after multiple doses (Data on file, Janssen). Steady-state exposure was achieved following 
4 weeks of continuous, daily apalutamide administration.4,7 For N-desmethyl apalutamide, 
a minimal peak to trough fluctuation ratio in plasma at steady state (≈1.3) was observed. 
Time to reach Cmax (tmax) for N-desmethyl apalutamide at steady state was variable and 
typically occurred at around 1 or 24 h post dose (Data on file, Janssen).
The preclinical cardiovascular safety of apalutamide and its active metabolite N-desmethyl 
apalutamide has been assessed in in vitro and in vivo studies (Data on file, Janssen). Both 
apalutamide and N-desmethyl apalutamide inhibited human ether-à-go-go-related (hERG) 
gene current, with half maximal inhibitory concentration (IC50) values of 6.17 μM and 4.56 
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μM, respectively, representing a safety margin of at least 7 relative to the anticipated Cmax 
for unbound apalutamide and N-desmethyl apalutamide in patients at the clinical dose 
of 240 mg/day (Data on file, Janssen). No relevant effect was produced (no prolongation 
in action potential duration; no effect on resting membrane potential) in isolated canine 
Purkinje fibers with up to 30 μM of apalutamide or N-desmethyl apalutamide (Data on 
file, Janssen). Preclinical in vitro receptor binding assay testing did not reveal an effect of 
apalutamide on Na+ or Ca2+ channels (Data on file, Janssen). No in vivo treatment-related 
cardiovascular effects (blood pressure, heart rate, body temperature, ECG lead II intervals, 
PR, QRS, QT, QTc, or ECG waveform morphology) were noted in a single-dose telemetry 
study in conscious dogs up to 40 mg/kg or after repeated dosing in good laboratory 
practice toxicology studies in dogs up to 10 mg/kg/day with exposures in the range of the 
clinical exposure for apalutamide and its metabolite N-desmethyl apalutamide (Data on 
file, Janssen). Overall preclinical cardiovascular safety assessment of apalutamide was not 
indicative of an increased risk for QTc prolongation in clinical use (Data on file, Janssen).
The effect of apalutamide on ventricular repolarization was previously evaluated as part 
of a phase I/II study7 that included time-matched triplicate 12-lead electrocardiograms 
(ECGs) collected at baseline and at steady state in 12 patients with CRPC. The data showed 
no significant effect from apalutamide on ECG parameters, and there was no conclusive 
evidence for an increase in Fridericia corrected QT interval (QTcF) (Data on file, Janssen).
Androgen deprivation therapy (ADT) can increase cardiovascular risk because of its 
adverse effect on risk factors for cardiovascular disease.8,9 Combination treatment with 
bicalutamide plus LHRH agonist therapy and 150-mg bicalutamide monotherapy may lead 
to QTc prolongation.10-12 In AFFIRM, a randomized phase III study, the effect of enzalutamide 
(160 mg/day) on QTcF was assessed at steady state in 800 patients with CRPC.13 No clinically 
meaningful changes were observed between the mean QTcF interval change from baseline 
in patients treated with enzalutamide versus those treated with placebo.13 A recent post 
hoc analysis of the TERRAIN study suggests a higher risk for atrial fibrillation in patients 
with mCRPC taking enzalutamide (160 mg/day) versus bicalutamide (50 mg/day).14
Because drug-induced QT interval prolongation has been one of the most common causes 
of drug withdrawals or restrictions of already marketed drugs,15,16 a thorough premarketing 
assessment of a drug’s potential to cause ECG change or generate life-threatening 
arrhythmias is a regulatory requirement detailed in the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use – Harmonised Tripartite Guideline E14 (ICH E14).17 Therefore, the current 
study evaluated the effect of therapeutic doses of apalutamide (240 mg) and its active 
metabolite, N-desmethyl apalutamide, on ventricular repolarization in patients with CRPC.
Chapter 4 – 59
4
In accordance with the ICH E14 guideline, a thorough QT (TQT) study ideally has a four-way 
crossover design, including a therapeutic dose, a supratherapeutic dose, a placebo, and 
a positive control. In light of the absence of a preclinical QT signal and no conclusive 
evidence for QTc prolongation in a previous phase I/II study, combined with the need for 
≥ 8 weeks of dosing with apalutamide to reach steady-state conditions, providing 8 weeks 
of placebo treatment in a cancer population would be unethical. The implementation 
of a positive control would have required the standalone administration of a positive 
control (e.g., moxifloxacin) and adequate washout prior to starting apalutamide treatment, 
to avoid any carry-over effect on the predose (Day –1) and Cycle 1 Day 1 (C1D1]) ECG 
assessments. Moreover, there is limited safety experience with apalutamide at a dose of 
>240 mg from previous clinical studies. Thus, an alternative multiple dose–dedicated 
QTc study design was chosen and customized for the oncological setting and for the PK 
characteristics of apalutamide.
MATERIAL AND METHODS
Patients
Enrolled patients were diagnosed with adenocarcinoma of the prostate and with either 
high-risk nmCRPC (prostate-specific antigen [PSA] doubling time ≤10 months) or mCRPC. 
Other inclusion factors were surgical or medical castration with testosterone levels <50 ng/
dL, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, adequate bone 
marrow and organ function, QTcF ≤470 ms, and left ventricular ejection fraction of >45%. 
Key exclusion criteria included known brain metastases, prior treatment with enzalutamide 
or apalutamide, grade ≥2 electrolyte abnormalities (hypokalemia, hypocalcemia, 
hypomagnesemia), uncontrolled hypertension, significant cardiac function abnormalities 
on screening ECG, and history or evidence of certain cardiac conditions. Patients 
requiring concurrent therapy with medications known to be associated with QTc interval 
prolongation and an increased risk of torsades de pointes were excluded from the study. 
Per protocol, strong CYP3A4 inducers, strong CYP2C8 inducers (e.g., rifampin), and strong 
CYP2C8 inhibitors (e.g., gemfibrozil) were prohibited in order to not influence apalutamide 
exposure levels.
Study design
This was an open-label, multicenter, phase Ib study to investigate the effect of daily 
apalutamide (240 mg, orally) on ventricular repolarization (QTc). Approximately 42 patients 
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with high-risk nmCRPC (defined as having a PSA doubling time of ≤10 months) or mCRPC 
were planned to be enrolled, to ensure that at least 38 patients completed the study.
The study consisted of screening, treatment, and follow-up phases. After providing 
informed consent, the patients entered a 28-day screening phase for determination of 
eligibility. If eligible, patients began the open-label treatment phase and were monitored 
for PK, pharmacodynamics ([PD] ECGs), and safety (including cardiac safety). Apalutamide 
was administered in continuous 28-day treatment cycles. The duration of the treatment 
phase for PD (ECG) and PK data collection was from baseline on C1D–1 until C3D1 (Day 
57). Patients were allowed to continue apalutamide treatment after C3D1 until disease 
progression, withdrawal of consent, loss to follow-up, the occurrence of unacceptable 
toxicity, or loss of clinical benefit (investigator opinion). The follow-up phase for AEs lasted 
from discontinuation of apalutamide until 30 days after the last dose. Upon discontinuation 
of study drug, patients returned once for an end-of-treatment (EoT) visit ≤30 days after 
their last dose.
Pharmacodynamic (ECG) evaluations
Patients were admitted to the study center on C1D–1 (baseline), C1D1, and C1D3 for PK/PD 
evaluation. Study drug intake was planned at 9:00 am on C1D1 and C1D3 after overnight 
fasting. Continuous 12-lead ECGs were collected by a Holter monitor on C1D–1, C1D1, 
and C3D1 from 8:00 am to 3:00 pm. Triplicate 12-lead ECGs were obtained during a 10-min 
time interval at the following time points: at pre-dose (–0.5 h) and at 1, 2, 3, 4, and 5 h 
after apalutamide administration. This 10-min timeframe began 5 min before and ended 
5 min after each scheduled time point. Holter recordings were sent to a blinded, third-
party, central ECG contract laboratory for 12-lead ECG selection/extraction, ECG interval 
measurements, and ECG interpretation.
ECG parameters measured included QRS (the onset of ventricular depolarization), PR 
(the period extending from the beginning of the onset of atrial depolarization until the 
beginning of the QRS complex), RR (with R being the point corresponding to the peak of 
the QRS complex of the ECG wave, and RR being the interval between successive Rs), and 
QT (electrical depolarization and repolarization of the ventricles).
Pharmacokinetic evaluations
After apalutamide administration on C1D1 and C3D1, time-matched PK blood samples 
were collected ≤5 min after completion of the 10-min timeframe for planned ECG collection 
at pre-dose (–0.5 h) and at 1, 2, 3, 4, and 5 h post dose. To calculate an area under the 
curve (AUC) value over 24 h after the first dose (C1D1), a 24-h PK sample was also collected 
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during C1D2. Plasma concentrations of apalutamide and N-desmethyl apalutamide were 
determined using validated liquid chromatography/tandem mass spectrometry methods. 
The assay consisted of protein precipitation followed by liquid chromatography with 
tandem mass spectrometric detection. Stable isotope labeled internal standards were used 
for quantification. Chromatography was performed with a Waters Xbridge C18 column 
(50 × 2.1 mm, 3.5 µm) using a gradient with 0.1% formic acid and acetonitrile. An API5000 
mass spectrometer in the negative ion mode with a Turbo-Ionspray Interface (AB SCIEX, 
MA, USA) was used. Multiple reaction monitoring (MRM) transitions were from m/z 476.1 to 
419.1 and from 479.1 to 419.1 for apalutamide and the internal standard, respectively. For 
N-desmethyl apalutamide and the internal standard, respectively, MRM transitions were 
from m/z 464.1 to 235.0 and from 469.2 to 240.1. The quantification range was 0.0250-25.0 
µg/mL for both analytes, and the assay performance was monitored using quality control 
samples. The recorded values all met the acceptance criteria.
PK parameters calculated for apalutamide and N-desmethyl apalutamide using 
noncompartmental analysis included Cmax, tmax, AUC from time 0 to 24 h after dosing 
(AUC24h), and the minimum observed plasma concentration (Cmin). Additionally, the 
accumulation index (AI), metabolite:parent drug ratio, corrected for molecular weight 
(MPR; for N-desmethyl apalutamide only), and peak/trough ratio at steady state (PTR) were 
also calculated.
The PK/PD data collection sought to determine the potential relationship between 
change from baseline in QTc (ΔQTc) and the plasma concentrations of apalutamide and 
N-desmethyl apalutamide. The measured QT data were corrected for HR using Fridericia 
(QTcF),18 Bazett (QTcB), and a study-specific correction Power (QTcP) correction method. 
The correlation between QTcF and RR was not significant, with a slope of 0.031 and a 90% 
CI (–0.01 to 0.07) that included zero. A similar analysis with the QTcP method also showed 
no statistically significant relationship between QTc and RR, whereas with the QTcB method 
a statistically significant relationship between QTc and RR was observed. Overall, these 
analyses support the use of the QTcF method as the primary correction method; thus, only 
QTcF data are reported herein. Baseline was defined as the mean QTc values of the triplicate 
ECG measurements taken at baseline. These baseline QTc values were time-matched 
with those on C1D1 and C3D1. The ΔQTc was calculated at each time point. The primary 
endpoint was the maximum mean change in QTc (ΔQTc) on C3D1, which was estimated by 
the mean ΔQTc at around tmax (i.e., steady-state). The duration of PD and PK assessments 
during the treatment phase was from baseline until C3D1.
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Safety evaluations
Patients were monitored for safety during the screening, treatment, and follow-up phases 
until 30 days after the last dose of study drug. The safety evaluations included AE reporting, 
clinical laboratory safety evaluations, ECGs, multigated acquisition scan, or echocardiogram 
(screening only for determination of LVEF), ECOG performance status scores, vital signs, and 
physical examination. For patients who remained in the study after 3 cycles of apalutamide 
treatment, collection of AEs was limited to serious AEs (SAEs) and grade ≥3 AEs. Patients were 
followed for disease progression as clinically indicated per institutional guidelines, which 
could include PSA monitoring or imaging collected at the discretion of the investigator. The 
safety population included all patients who received at least one dose of apalutamide.
Statistical analysis
The clinical cutoff for the statistical analysis of the study was defined when the last patient 
enrolled had completed the C3D1 (Day 57) assessments. For the statistical analysis based 
on the primary correction method (QTcF), the mean changes from baseline (ΔQTcF) at 
each time point were summarized (mean, standard deviation [SD], median and range, 
two-sided 90% confidence interval [CI]). The primary endpoint analysis focused on the 
maximum mean ΔQTcF at C3D1, which was estimated by the mean QTcF change at around 
tmax, the time when Cmax was reached. The mean ΔQTcF (± SD) over time was plotted. For 
each treatment and time point of measurement, HR, QRS, PR, and RR intervals, as well as 
the change from baseline in HR, QRS, PR, and RR (ΔHR, ΔQRS, ΔPR, ΔRR), were summarized 
using descriptive statistics (mean, SD, median, range, and 90% CI).
Individual plasma concentrations for apalutamide and its active metabolite N-desmethyl 
apalutamide were tabulated with descriptive statistics (including arithmetic mean, SD, 
coefficient of variation, median, minimum, and maximum) at each sampling time point for 
each visit. Individual and mean plasma concentration-time profiles were plotted.
A linear mixed-effects model was fitted to the ΔQTc data from C1D1 and C3D1 with either 
parent or metabolite concentration as a predictor and patient as a random effect. On the 
basis of these relationships, the predicted population average ΔQTc and its corresponding 
upper 90% two-sided CI bound were computed at the mean Cmax of apalutamide and 
N-desmethyl apalutamide, or other concentrations of interest.
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RESULTS
Patient and disease characteristics
At the time of clinical cutoff, 45 men enrolled at five study centers received at least one 
dose of apalutamide and were included in the safety analysis set. At study entry the 
majority (97.8%) of patients had mCRPC. One patient had high-risk nmCRPC. Forty-three 
of the 45 patients were considered study completers (defined as having completed C3D1 
ECG collection and PK sampling procedures in the presence of adequate compliance 
with intake of the study drug during Cycles 1 and 2) and were included in the primary 
analysis set. Median age at study entry was 67 years (range, 52–86 years) (Table 1). All 
patients had received therapy for prostate cancer prior to study entry in addition to ADT 
or surgical castration; the most commonly prescribed prior therapies were bicalutamide 
(89%), abiraterone acetate (42%), and docetaxel (38%) (Table 1). Overall, study participants 
were largely compliant with avoidance of prohibited medications that could influence 
apalutamide or N-desmethyl apalutamide PK.
Table 1. Patient and disease characteristics
Baseline characteristic Total (N = 45)
Median age, y (range) 67 (52–86)
Race, n (%)
- White 42 (93)
- Black or African American 3 (7)
Median weight, kg (range) 80 (50–135)
Median time from initial diagnosis, mo (range) 68.2 (3.9–280.3)
Extent of disease, n (%)
- Bone 40 (91)
- Soft tissue or node 14 (32)
- Liver 2 (4)
- Lung 1 (2)
- Other 3 (7)
- None 1 (2)
ECOG PS, n (%)
- 0 27 (60)
- 1 18 (40)
Median testosterone, nM (range) 0.85 (0.07–1.63)
Prior therapy, n (%) 45 (100)
- Bicalutamide 40 (89)
- Abiraterone acetate 19 (42)
- Docetaxel 17 (38)
- Cabazitaxel 11 (24)
Abbreviations: ECOG PS=Eastern Cooperative Oncology Group performance status.
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Patient disposition
At the time of clinical cutoff, the median treatment duration was 5 months (range, 2–8 
months); 82% of patients had received treatment for ≥3 months. Furthermore, 13 of 45 
patients had discontinued treatment. Treatment was discontinued due to progressive 
disease in 12 patients, and one patient withdrew consent.
Primary endpoint
A total of 831 evaluable ECGs were reviewed in this study, out of 855 expected ECG 
extractions. For each QTc correction method, the relation between QTc and RR at baseline 
was evaluated graphically by plotting the logarithm of baseline QTc values against the 
logarithm of corresponding RR intervals. This analysis supported the QTcF method being 
used as the primary correction method. The primary endpoint was maximum mean ΔQTcF 
on C3D1. There was no notable difference in QTcF intervals between baseline (Day –1) and 
after the first dosing (C1D1). For all corresponding time points on C3D1, there were mean 
increases from baseline in QTcF, but no obvious time-related trends over the course of the 
Table 2. Mean ΔQTcF over time after single dose and steady state
Absolute QTcF interval,a ms ΔQTcF (LS mean) interval,b ms
N Mean (SD) 95% CI N Mean (SE) 90% CI
C1D1
Predose 43 428.7 (13.5) (424.5–432.9) 43 –0.7 (1.59) –3.4 to 1.9
1 h 42 430.1 (14.5) (425.6–434.6) 41 –0.4 (1.62) –3.1 to 2.3
2 h 43 432.4 (15.2) (427.7–437.0) 42 1.9 (1.61) –0.8 to 4.5
3 h 43 424.7 (13.9) (420.4–429.0) 42 –3.1 (1.61) –5.8 to –0.4
4 h 43 425.7 (14.5) (421.3– 430.2) 42 –2.1 (1.61) –4.8 to 0.6
5 h 43 422.4 (15.9) (417.5–427.3) 41 –5.5 (1.62) –8.2 to –2.8
C3D1
Predose 42 441.6 (16.8) (436.3–446.8) 42 12.0 (2.14) 8.4–15.5
1 h 42 442.7 (18.6) (436.9–448.5) 41 12.3 (2.16) 8.7–15.9
2 h 43 442.9 (16.4) (437.8–447.9) 42 12.4 (2.15) 8.8–16.0
3 h 42 439.3 (15.7) (434.4–444.2) 41 10.9 (2.15) 7.3–14.5
4 h 42 436.5 (14.2) (432.0–440.9) 41 8.2 (2.15) 4.6–11.8
5 h 42 436.0 (16.3) (430.9–441.1) 40 8.0 (2.16) 4.4–11.6
aThe time-matched baseline is defined as the mean values of the triplicate electrocardiographic measurements 
taken on C1D–1, at the time points matching with those on C1D1 and C3D1. bA repeated-measures mixed model 
was used with time point, and baseline value of QTc as fixed effect, and patient as a random effect. Abbreviations: CI 
confidence interval, LS least squares, SD standard deviation, SE standard error, C1D–1=Cycle 1 Day –1, C1D1=Cycle 1 
Day 1, C3D1=Cycle 3 Day 1.
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day. The least squares mean increases from baseline on C3D1 ranged from 8.0 to 12.4 ms 
(Table 2). The least squares mean (standard error) QTcF change at tmax on C1D1 and on 
C3D1 was +1.9 (1.6) ms and +12.4 (2.1) ms, respectively. The upper limit of the 90% CI of the 
least squares mean baseline corrected QTcF change at each postdose time point was below 
10 ms for C1D1 (maximum of upper limits = 4.5 ms) and above 10 ms, for C3D1 (maximum 
of upper limits= 16.0 ms).
Patients with QTcF intervals exceeding the threshold values of 450, 480, and 500 ms are 
summarized in Table 3. Twelve patients had QTcF value >450 ms and ≤480 ms at baseline 
while the number increased to 20 patients on C3D1. One patient had a QTcF interval >480 
and ≤500 ms at 1 h post dose on C3D1; this same patient also had a predose (C1D1, at –1 
h) QTcF value of 469.3 ms. No QTcF intervals >500 ms were recorded. Numbers of patients 
with a QTcF interval change from baseline exceeding the threshold values of 30 or 60 ms 
are also summarized in Table 3. Two patients on C1D1 and nine patients on C3D1 had 
a QTcF interval change from baseline of >30 but ≤60 ms. Among the patients with QTcF 
interval changes from baseline of >30 ms but ≤60 ms, no association was observed with 
presence of underlying electrolyte abnormalities or significant cardiac medical history. 
One patient had a QTcF interval change from baseline of 60.4 ms at 1 h post dose on C3D1 
(455.7 ms). The two patients with QTcF >480 ms or with QTcF increase of >60 ms from 
baseline did not have a significant cardiac medical history and did not use any concomitant 
medications with a liability for QTc prolongation. The patient with QTcF >480 ms on C3D1 
showed grade 1 hypocalcemia at baseline and C3D1, but potassium and magnesium levels 
were normal.
Table 3. Categorical analysis of QTcF at baseline and post apalutamide treatment
Baseline
(N = 43)
C1D1
(N = 43)
C3D1
(N = 43)
Total
(C1D1 + C3D1)
(N = 43)
Pre- or post-apalutamide QTcF > 450 ms, n (%)a
> 450 to ≤ 480 ms 12 (28) 6 (14) 20 (47) 20 (47)
> 480 to ≤ 500 ms 0 0 1 (2) 1 (2)
> 500 ms 0 0 0 0
QTcF increase from baseline > 30 ms, n (%)b
> 30 to ≤ 60 ms - 2 (5) 9 (21) 9 (21)
> 60 ms - 0 1 (2) 1 (2)
aPercentages are calculated with the number of patients in primary analysis as denominators and only the worst 
value for a patient is presented; the C1D1 predose measurement and C1D–1 measurement are considered as 
baseline. bPercentages are calculated with the number of patients in primary analysis as denominators; time-
matched baseline is defined as the mean values of the triplicate electrocardiographic measurements taken on 
C1D–1 (including pre-dose), at the time points matching with those on C1D1 (including pre-dose) and C3D1 
(including pre-dose). Abbreviations: C1D–1=Cycle 1 Day –1, C1D1=Cycle 1 Day 1, C3D1=Cycle 3 Day 1.
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Secondary endpoints
For all time points on C1D1, mean HR was increased from baseline (Table 4), without 
obvious time-related trends over the course of the day. The mean increases from baseline 
on C1D1 ranged from 0.1 to 2.5 bpm. For all time points on C3D1, there were mean 
decreases from baseline in HR, but with no obvious time-related trends over the course 
of the day. The mean decreases from baseline on C3D1 ranged from –0.4 to –3.5 bpm. 
The number of patients with any HR (>100 bpm [n = 3] or <50 bpm [n = 2]) was similar at 
baseline and on C1D1 and C3D1 (data not shown). Apalutamide did not have a clinically 
significant effect on HR.
For all time points on C1D1, there were mean decreases from baseline in RR interval but with 
no obvious time-related trends over the course of the day (Table 4). The decreases from 
baseline on C1D1 ranged from –6.4 to –21.5 ms. For all time points on C3D1, there were 
mean increases from baseline in RR interval, also with no obvious time-related trends over 
the course of the day. The increases from baseline on C3D1 ranged from 6.3 to 41.0 ms. The 
observations on the RR interval are inversely correlated with the observations on HR interval.
For mean PR interval over time compared with baseline, no obvious time-related 
trends were noted over the course of C1D1 or C3D1 (Table 4). The incidence count and 
percentage of patients with any PR interval >200 ms by study day and by time point was 
similar at baseline and on C1D1 or C3D1 (data not shown). No effect of apalutamide on 
the length of the PR interval was apparent. For all time points on C1D1 and C3D1, mean 
Table 4. Change from baseline in heart rate, RR interval, PR interval, and QRS interval at C1D1, C3D1
N Mean ± SD 90% CI
Heart rate, bpm
C1D1 Predose 43 0.6 ± 5.83 –0.9 to 2.1
1 h 41 0.7 ± 5.96 –0.9 to 2.3
2 h 42 2.4 ± 13.11 –1.0 to 5.8
3 h 42 2.5 ± 11.97 –0.6 to 5.7
4 h 42 0.1 ± 13.26 –3.4 to 3.5
5 h 41 2.2 ± 6.01 0.6–3.8
C3D1 Predose 42 –2.5 ± 6.09 –4.0 to –0.9
1 h 41 –1.7 ± 5.93 –3.2 to –0.1
2 h 42 –3.4 ± 6.60 –5.1 to –1.7
3 h 41 –1.3 ± 13.69 –4.9 to 2.3
4 h 41 –3.5 ± 14.82 –7.4 to 0.4
5 h 40 –0.4 ± 7.17 –2.3 to 1.5
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Table 4. Change from baseline in heart rate, RR interval, PR interval, and QRS interval at C1D1, C3D1 (continued)
N Mean ± SD 90% CI
RR interval, ms
C1D1 Predose 43 –7.5 ± 89.97 –30.6 to 15.5
1 h 41 –13.3 ± 92.29 –37.6 to 11.0
2 h 42 –16.1 ± 92.55 –40.1 to 8.0
3 h 42 –16.0 ± 83.55 –37.7 to 5.7
4 h 42 –6.4 ± 86.57 –28.9 to 16.1
5 h 41 –21.5 ± 63.13 –38.1 to 4.9
C3D1 Predose 42 39.0 ± 89.10 15.8–62.1
1 h 41 27.5 ± 84.93 5.2–49.9
2 h 42 41.0 ± 77.88 20.8–61.2
3 h 41 33.2 ± 143.13 –4.5 to 70.8
4 h 41 36.4 ± 141.19 –0.7 to 73.5
5 h 40 6.3 ± 79.87 –15.0 to 27.6
PR interval, ms
C1D1 Predose 43 2.6 ± 12.34 –0.5 to 5.8
1 h 41 1.9 ± 13.01 –1.6 to 5.3
2 h 41 –0.7 ± 10.12 –3.4 to 2.0
3 h 41 –1.1 ± 9.78 –3.7 to 1.5
4 h 41 –1.8 ± 9.51 –4.3 to 0.7
5 h 41 –0.3 ± 6.31 –2.0 to 1.4
C3D1 Predose 42 2.2 ± 13.70 –1.3 to 5.8
1 h 41 0.1 ± 17.29 –4.4 to 4.7
2 h 42 1.6 ± 11.38 –1.4 to 4.5
3 h 40 –0.9 ± 15.72 –5.1 to 3.3
4 h 40 –2.7 ± 14.82 –6.6 to 1.3
5 h 40 0.6 ± 8.54 –1.7 to 2.8
QRS interval, ms
C1D1 Predose 43 0.5 ± 3.36 –0.4 to 1.4
1 h 41 0.9 ± 3.35 0.0–1.8
2 h 42 0.5 ± 3.97 –0.5 to 1.6
3 h 42 0.8 ± 3.58 –0.2 to 1.7
4 h 42 0.9 ± 3.00 0.1–1.6
5 h 41 0.5 ± 3.53 –0.4 to 1.5
C3D1 Predose 42 2.4 ± 4.53 1.2–3.6
1 h 41 1.6 ± 5.05 0.3–2.9
2 h 42 1.9 ± 4.91 0.7–3.2
3 h 41 2.2 ± 4.88 0.9–3.4
4 h 41 1.6 ± 5.07 0.3–3.0
5 h 40 2.3 ± 4.71 1.1–3.6
Abbreviations: SD=standard deviation, CI=confidence interval, C1D–1=Cycle 1 Day –1, C1D1=Cycle 1 Day 1, 
C3D1=Cycle 3 Day 1
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increases were observed from baseline in the QRS interval (Table 4). The mean increases 
from baseline on C1D1 ranged from 0.5 to 0.9 ms and on C3D1 from 1.6 to 2.4 ms. No 
patients had a QRS interval >110 ms at baseline or on C1D1. QRS intervals >110 ms but 
≤115 ms on C3D1 were recorded in three patients. The largest mean change (increase) in 
QRS duration from baseline was 2.4 ms on C3D1 at pre-dose. Overall, no clinically relevant 
effects of apalutamide on the QRS interval were observed.
T-wave morphology was monitored, and the number of patients with flat, inverted, or 
biphasic T-waves was similar on pretreatment and post-treatment days. For most patients 
with T-wave abnormalities observed during the treatment phase, these observations 
were also noted on predose ECG before apalutamide administration. De novo T-wave 
abnormalities were observed in three patients (7%), which were absent at baseline, and no 
QTcF prolongation ≥480 ms was observed in these three patients. Apalutamide treatment 
did not have an apparent association with the appearance or worsening of T-wave 
abnormalities, and no U-waves were observed in any patient.
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Figure 1. Plasma concentration of apalutamide and N-desmethyl apalutamide and their association with QTcF: 
a. mean plasma concentration–time profiles of apalutamide after administration of 240 mg apalutamide on 
C1D1 and C3D1; b. mean plasma concentration–time profiles of N-desmethyl apalutamide after administration 
of 240 mg apalutamide on C1D1 and C3D1; c. scatter plot of the relationship between ΔQTcF and plasma 
concentration of apalutamide; d. scatter plot of the relationship between ΔQTcF and plasma concentration of 
N-desmethyl apalutamide 
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Mean plasma concentrations over time for apalutamide and N-desmethyl apalutamide are 
shown in Figure 1a and 1b. Repeated once-daily administration of 240-mg apalutamide 
under fasted conditions resulted in a three- and five-fold increase of Cmax and AUC24h, 
respectively, when comparing apalutamid e systemic exposure between C1D1 and C3D1 
(Table 5). Median tmax was reached at approximately 2 h post dose on C1D1 and C3D1. At 
steady-state (C3D1), the active metabolite N-desmethyl apalutamide exhibited a flat PK 
profile with a mean PTR of 127%. The MPRs for Cmax and AUC24h were 105 ± 21% and 133 ± 
28%, respectively (Table 5). A significant correlation was observed between the change 
in QTcF from baseline and the concentration of apalutamide (slope estimate, 2.89; 90% 
CI, 2.11–3.67; p < 0.0001) (Figure 1c). The predicted ΔQTcF (90% CI) at a mean Cmax of 5.95 
μg/mL was 13.8 ms (9.77-17.85). Likewise, a significant correlation was observed between 
the change in QTcF from baseline and the concentration of N-desmethyl apalutamide 
(slope estimate, 2.28; 90% CI, 1.70-2.85; p < 0.0001) (Figure 1d). For instance, on C3D1 
the predicted ΔQTcF (90% CI) at a mean steady-state Cmax of 5.84 μg/mL was 12.0 ms 
(8.58–15.38).
Table 5. Pharmacokinetics of apalutamide and N-desmethyl apalutamide
Parametera
Apalutamide N-desmethyl apalutamide
C1D1 (N = 45) C3D1 (N = 43) C1D1 (N = 45) C3D1 (N = 43)
Cmax, μg/mL 2.06 (0.58) 5.95 (1.66) 0.092 (0.057) 5.85 (1.04)
tmax, h 2.12 (1.08–5.10) 2.10 (1.00–4.17) 24.00 (4.10–24.58) 1.10 (0.00–4.17)
AUC24h, μg·h/mL 21.1 (4.93) 100 (31.6) 1.41 (0.79) 124 (23.0)
Cmin, μg/mL – 3.72 (1.19) – 4.66 (0.90)
PTR, % – 163 (24.7) – 127 (13.3)
AI(Cmax) – 3.09 (1.26) – 82.1 (50.5)
AI(AUC24h) - 4.95 (1.69) - 122 (108)
MPR Cmax, % (SD) - - - 105 (20.8)
MPR AUC24h, % (SD) - - - 133 (28.0)
aAll values are presented as the mean (SD) except for tmax, which is presented as the median (range), or as otherwise 
noted. Abbreviations: C1D1=Cycle 1 Day 1, C3D1=Cycle 3 Day 1, Cmax=maximum observed plasma concentration, 
tmax=time to Cmax, AUC24h=AUC from time 0 to 24h after dosing, Cmin=minimum observed plasma concentration, 
PTR=peak/trough ratio at steady state, AI=accumulation index, MPR=metabolite:parent drug ratio corrected for 
molecular weight.
Safety
Dose modifications were allowed for toxicity attributed to apalutamide, and re-escalation 
was permitted if first discussed with and approved by the sponsor. The majority of patients 
had neither dose reduction (42 patients, 93%) nor dose interruption (38 patients, 84%).
There were no dose re-escalations after initial dose reduction. Drug-related toxicities 
70 – Chapter 4
4
leading to temporary dose interruption included grade 3 diarrhea and aspartate 
transaminase/alanine transaminase increase and grade 2 fatigue. Two patients required a 
dose reduction due to fatigue. Thirteen (29%) patients discontinued treatment, with 12 of 
those discontinuing due to progressive disease and one due to withdrawal of consent (no 
discontinuations were due to AEs).
Thirty-seven (82%) patients experienced at least one treatment-emergent AE (TEAE), most 
of which were grades 1–2. The most commonly reported TEAEs (≥10% of patients) were 
fatigue (40%), decreased appetite (24%), back pain (16%), diarrhea and dyspnea (13% 
each), rash/erythema (13%), and constipation and nausea (11% each). No treatment-
emergent seizures were reported. The AEs recorded in this study were consistent with 
those observed in other published apalutamide studies.6,7,19,20 Grade 3 TEAEs were reported 
in eight (18%) patients and grade 4 AEs in two (4%) patients. Grade 3 TEAEs reported in >1 
patient were anemia (3 patients, 7%) and back pain (2 patients, 4%); these grade 3 TEAEs 
were not considered related to apalutamide treatment. Three patients reported grade 
3 toxicities considered possibly or probably related to apalutamide, including fatigue, 
diarrhea, and aspartate transaminase/alanine transaminase increase. In one patient, 
grade 3 cardiac failure was reported on study Day 45 and was not considered related to 
apalutamide treatment. Grade 3 nervous system disorder and spinal cord compression 
were reported in two patients, were not considered related to apalutamide treatment, 
and occurred in an overall context of worsening vertebral metastatic disease. One patient 
experienced grade 4 thrombocytopenia, which was not considered related to apalutamide 
treatment and occurred in the context of progressive disease. Another patient had grade 
4 neutropenia not considered related to apalutamide treatment that occurred while the 
patient took sulfamethoxazole plus trimethoprim for a bladder infection.
Five patients experienced ≥1 SAE, but none were considered related to apalutamide 
treatment; SAEs were grades 1–3, except for a grade 4 SAE of general health deterioration 
in one patient, who subsequently died from progressive disease. One patient experienced 
a grade 3 SAE of medullary compression, which was considered not related to apalutamide 
treatment and likely related to underlying metastatic disease in the vertebra. Another 
patient with bone metastases experienced a grade 3 SAE of progressive lower back pain, 
which was attributed to the magnetic resonance imaging–verified metastatic disease in the 
pelvis. One patient experienced multiple SAEs: grade 2 hypercalcemia, grade 3 jaw necrosis, 
grade 3 pain left hip, and grade 3 neurologic deficit due to spinal cord compression 
resulting from bone metastases; none were considered related to apalutamide treatment. 
The final patient, a 70-year-old man with a history of hypertension, mitral valve prolapse, 
and type 2 diabetes, experienced multiple SAEs, including grade 3 lower back pain, grade 
2 infection, and grade 2 delirium, none of which were considered related to apalutamide 
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treatment. This patient also experienced a grade 3 SAE of heart failure caused by de novo 
atrial fibrillation that was not considered related to apalutamide treatment.
Laboratory values were collected over time (data not shown). Most patients had occasional 
changes in serum chemistry and some hematologic abnormalities, the majority of which 
were grade 0–2 in severity. Elevated thyroid-stimulating hormone (TSH) levels above 
the upper limit of normal during the study were observed in 13 patients (29%), were 
usually limited in magnitude and, in the majority of cases, thyroid hormone levels stayed 
within normal limits. In two patients (4%), significant TSH elevations were observed in 
combination with a decrease in thyroid hormone levels. One of these two patients had a 
medical history of hypothyroidism and required an increase in thyroid supplementation 
therapy in the course of the study.
DISCUSSION
These data from an open-label, multicenter, phase Ib dedicated QT/QTc study that 
investigated the effect of apalutamide on ventricular repolarization and other ECG 
parameters confirm the absence of major effects from apalutamide on the QTc interval 
in men with CRPC. This modified QTc study, tailored to the oncologic setting and taking 
into account the PK characteristics of apalutamide, was rigorously executed with time-
matched ECG and PK sample collection and central blinded ECG interval measurement 
and interpretation. Across all time points at steady state, the baseline-adjusted QTc 
intervals and the upper bounds of their associated 90% CIs were ≤20 ms following 240-mg 
once-daily doses of apalutamide. Consistent with the primary endpoint results, categorical 
analysis of absolute QTcF values revealed a slightly higher incidence of QTcF readings >450 
but ≤480 ms on C3D1 compared with baseline and C1D1. These results indicate that the 
QTc increases observed with apalutamide become apparent at steady state (after minimally 
4 weeks) but not after the first dose, likely because of an accumulation of apalutamide with 
repeat dosing.
There were two outliers with a larger QTc prolongation. One patient with a QTcF interval 
>480 and ≤500 ms also had a higher predose QTcF value (469.3 ms) and had a concurrent 
C3D1 observation of grade 1 hypocalcemia. A second patient had a large absolute ΔQTcF 
(60.4 ms) at 1 h post dose on C3D1 (QTcF 455.7 ms), which may have been related to 
exposure to apalutamide (6.84 μg/mL) or N-desmethyl apalutamide (8.21 μg/mL). However, 
the QTcF value was lower at 2 h post dose despite higher drug concentrations (QTcF of 446 
ms [change of 58.3 ms]), with exposure of apalutamide and N-desmethyl apalutamide of 
8.77 and 8.87 μ/mL, respectively, suggesting that the increase of more than 60.4 ms was 
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not consistent at similar exposure within the same individual. No patients discontinued 
treatment due to QTc prolongation, and no evidence of development of ventricular 
arrhythmias was observed that could be attributed to underlying QTc prolongation.
According to Sarapa et al., the magnitude of changes in QTcF interval (as observed in 
the present study) may be considered a mild to moderate QTc-prolonging effect for an 
anticancer agent, and these same authors have suggested that a dedicated QTc study 
for anticancer agents that excludes ∆QTc of <20 ms can be concluded as a negative 
study,21 consistent with the present data showing no new clinical concerns.4 Our data are 
supported by a small and voluntary QTc substudy of the SPARTAN trial,6 which also revealed 
no patients in the apalutamide arm with a QTcF interval >480 ms. In the placebo arm of the 
SPARTAN study, two of six patients had at least one postdose QTcF interval >450 and ≤480 
ms; one of these two patients had a baseline QTcF interval >450 ms.
De novo T-wave abnormalities were observed in three patients (7%) and were absent at 
baseline, and no QTcF prolongation ≥480 ms was observed in these three patients. No 
evidence for an apalutamide treatment effect was noted on the length of the PR interval 
in our study. The observed mean increases in QRS duration as observed on C3D1 were 
minimal (<2.5 ms) and are considered not clinically meaningful.
Overall, exposures of apalutamide and its extent of accumulation observed in this study 
are consistent with those previously reported.7 To explore the relationship between 
apalutamide concentration at steady state and QTcF, PK (plasma concentration) and PD 
(change from baseline in QTcF) data were analyzed using a linear mixed-effects model. 
The analysis revealed an association between plasma concentration of apalutamide 
and QTcF and predicted a prolongation of 13.81 ms at Cmax at steady state (C3D1), with 
an upper bound of two-sided 90% CI of 17.85 ms. Because of the correlation between 
apalutamide and N-desmethyl apalutamide exposures, a similar association between 
plasma concentration of N-desmethyl apalutamide and QTcF was detected. Based on 
the flat PK profile of N-desmethyl apalutamide at steady state, the apparent association 
between N-desmethyl apalutamide concentration and QTcF at steady state is considered 
less clinically meaningful compared with the parent drug. Overall, results of the PK/PD 
analysis indicated that a large effect on ∆QTcF is not expected at steady state following 240 
mg daily dose of apalutamide.
These data from a Phase Ib QT/QTc study that investigated the effect of apalutamide on 
QTc intervals revealed no new safety signals associated with apalutamide treatment in 
men with CRPC. For the primary endpoint, no significant safety findings related to QT 
prolongation were documented and there were no observed arrhythmias related to 
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apalutamide. Overall, the safety profile observed in this study was as expected based on 
the known safety profile of apalutamide and results from other studies.6,7,19,20
Overall, these data demonstrate that apalutamide does not produce clinically meaningful 
changes in QTc interval or produce a concerning effect on ventricular repolarization in 
patients with CRPC.
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ABSTRACT
Background: Treatment selection for men with metastatic castration-resistant prostate 
cancer (mCRPC) has become increasingly challenging with the introduction of novel 
therapies at earlier disease stages. The purpose of this study was to identify prognostic 
factors for overall survival (OS) and PSA response in patients with mCRPC treated with 
cabazitaxel.
Methods: We performed a post-hoc analysis of a randomized phase II trial of mCRPC 
patients treated with cabazitaxel. Cox and logistic regression models were used to 
investigate the influence of clinical and biochemical variables on OS and PSA response. 
Nomograms were developed to estimate the chance of PSA response and OS.
Results: 224 mCRPC patients were included in the current analysis. In multivariable 
analysis, WHO performance status, baseline hemoglobin, alkaline phosphatase and 
albumin were all significantly associated with OS. Hemoglobin and alkaline phosphatase 
were significantly associated with PSA response.
Conclusion: This study identified prognostic factors for OS and PSA response of men with 
mCRPC treated with cabazitaxel. In an increasingly complicated treatment landscape with 
several treatment options available our findings might serve to estimate the chance of 
survival of men qualifying for treatment with second-line chemotherapy in daily practice. 
Furthermore, these data can be used to risk-stratify patients in clinical trials.
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INTRODUCTION
With the introduction of novel agents, treatment options for metastatic castration-resistant 
prostate cancer (mCRPC) have notably evolved in the past few years. Since level one 
evidence supporting an optimal treatment sequence in mCRPC is lacking, the choice of 
treatment by the clinician has become increasingly challenging. Treatment decisions are 
generally made on the basis of clinical symptoms, comorbidities, expected side-effects 
and preferences by the patient and the treating physician. Risk classification and prognosis 
assessment remain critical before the start of a new therapy. Therefore, it is important 
to identify biomarkers, predictive and prognostic factors for clinical outcome, in order 
to simplify treatment choice and timing. Such factors may serve to predict individual 
prognosis at the start of therapy and to classify patients in different risk-groups, which can 
also be used for stratification in clinical trials.
Prognostic models and nomograms for mCRPC patients receiving first-line chemotherapy 
have been developed based on large phase III trials,1-3 including parameters such as 
performance status, time since last docetaxel use, the presence of measurable disease, 
the presence of visceral disease, the presence of pain, duration of hormonal treatment, 
hemoglobin (Hb), prostate specific antigen (PSA) and alkaline phosphatase (AP). For 
second-line chemotherapy with cabazitaxel, prognostic factors were identified based on 
the TROPIC trial.4,5 However, these findings have not been investigated in other datasets 
of men treated with cabazitaxel. In the current study, we aimed to identify prognostic 
factors for men with mCRPC receiving cabazitaxel. For this purpose, we used data from a 
multicenter randomized phase II trial.6
PATIENTS AND METHODS
Patients
We performed a post-hoc analysis of a randomized phase II trial (CABARESC, NTR2991). 
The CABARESC trial was designed to investigate the influence of budesonide (9mg 
daily) on cabazitaxel pharmacokinetics and cabazitaxel-induced diarrhea and was 
reported elsewhere.6 Between December 2011 and October 2015, a total of 246 mCRPC 
patients were included in the study. The study was conducted in 22 Dutch hospitals and 
was approved by the ethics committee of the Erasmus MC (MEC 11-324) and all local 
institutional review boards. Written informed consent was obtained from all participants.
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Full study details are described in the original paper.6 Briefly, patients were eligible if they 
had metastatic castration-resistant adenocarcinoma of the prostate with disease progression 
during or after docetaxel therapy, defined as two consecutive rises in PSA (taken ≥ 1 week 
apart) or according to RECIST criteria. Full inclusion criteria are shown in Supplementary 
1: material and methods. In this study, no significant impact of budesonide on the 
pharmacokinetics of cabazitaxel and cabazitaxel-induced diarrhea was found. We have 
previously shown that there was no influence of prior treatment with abiraterone acetate or 
enzalutamide on OS and PSA response of men treated with cabazitaxel.13 Patients who were 
deemed inevaluable in the original CABARESC trial (N=19) (Supplementary Table 2) and 
patients with missing or inadequate PSA values were considered ineligible for the current 
analysis (N=3), leaving 224 patients evaluable for the current analysis.
Biomarker panel
From all evaluable patients, laboratory and clinical factors collected at baseline and during 
treatment were available. The biochemical parameters were collected at baseline included: 
PSA, lactate dehydrogenase (LDH), AP, albumin (Alb), Hb, derived neutrophil-lymphocyte 
ratio (dNLR), WHO performance status (0 vs 1), age, type of castration (GnRH analogues vs. 
surgical castration) and time since last chemotherapy cycle (>6 months vs ≤6 months). The 
dNLR was computed by the absolute neutrophil count (ANC) divided by the absolute white 
blood cell count (WBC) minus the ANC, (ANC/ (WBC-ANC)). The occurrence of ≥ grade 3 
neutropenia during treatment was collected. Log transformation was applied to variables 
with a non-normal distribution.
Primary objective and definitions
The objective of the current analysis was to identify prognostic factors associated with 
OS and PSA response in mCRPC patients treated with cabazitaxel. OS was defined by time 
from randomization to death from any cause. Patients still alive at the end of the study 
were censored. Prostate Cancer Working Group 2 (PCWG2) criteria were used to define PSA 
response as a ≥ 50% decline from baseline measured twice 3 to 4 weeks apart.14
Statistical analysis
Descriptive statistics were used to summarize patients’ characteristics. Univariable and 
multivariable Cox regression analyses were used to investigate the influence of laboratory 
and clinical parameters on OS. Univariable and multivariable logistic regression analysis were 
used with PSA response (≥50%) as the dependent variable and baseline parameters were 
included as covariates. Factors with a p<0.10 in univariable analysis were entered into the 
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multivariable analysis. The multivariable model was constructed using backward selection 
at the 5% level. Data were analyzed using STATA® version 14 (Stata-Corp LP TX, USA). Based 
on the multivariable model for OS and PSA response we have generated a nomogram for OS 
and PSA response. Software program ‘R’ was used to generate both nomograms.
RESULTS
Patient Characteristics
Baseline characteristics were available for 224 patients and are shown in Table 1. The 
characteristics were similar to other studies of men treated with second-line chemotherapy.5
Table 1. Baseline characteristics
Characteristic Value No. (%)
All 224 (100)
Age, mean ± SD 68.8 ± 7.2
WHO
- 0 92 (41)
- 1 130 (58)
- Missing 2 (1)
Type castration
- Surgical 30 (13) 
- LHRH-analogue 194 (87) 
No. prior therapies
- 1 204 (91)
- ≥ 2 20 (9)
Months since last chemotherapy
- ≤6 months 102 (46)
- > 6 months 122 (54)
Baseline lab results Median (IQR)
- Hb (mmol/L) 7.7 (6.8-8.2)
- Albumin (g/L) 39.0 (36.0-43.0)
- AP (U/L) 130.0 (86.0-262.0)
- LDH (U/L) 271.0 (210.0-392.0)
- ANC (109/L) 5.9 (4.4-7.6)
- PSA (µg/L) 154.1 (59.0-388.3)
- dNLR 2.7 (1.8-3.9)
Abbreviations: WHO= world health organization, Hb = hemoglobin, AP = Alkaline Phosphatase, LDH = lactate 
dehydrogenase, ANC= absolute neutrophil count, PSA= prostate specific antigen, dNLR= derived Neutrophil-
Lymphocyte ratio
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Overall survival
Median OS of patients in this dataset was 13.3 months (IQR 7.0 – 22.3). Results of the 
univariable and multivariable analyses for OS are shown in Table 2. Time since last 
chemotherapy, neutropenia grade 3/4, PSA and LDH were significantly associated with 
OS in univariable analysis, but not in multivariable analysis. In multivariable analysis, four 
parameters remained significantly associated with OS; WHO performance status (HR 1.49, 
95% CI 1.04-2.13, p=0.028), Hb (HR 0.73, 95% CI 0.61-0.87, p=0.001), AP (HR 1.50, 95%CI 
1.18-1.91, p=0.001) and Alb (HR 0.92, 95% CI 0.89-0.95, p<0.001). Of note, dNLR (p=0.45) 
was not associated with OS in univariable analysis. Figure 1 presents a nomogram that 
is based on the multivariable model for OS. This nomogram can be used to predict 
the individual survival probability at 12 and 24 months. For example, a patient with a 
performance score of 1, an Hb level of 7.0 mmol/L, albumin level of 40 g/L and AP of 90 U/L 
(log_AP=4,5) has a 12-month survival probability of approximately 60% and a 24-month 
survival probability of approximately 20%.
Table 2. Univariable and multivariable model for OS
Variable Univariable HR (95%CI) P-value Multivariable HR (95%CI) P-value
WHO PS (1 vs 0) 1.57 (1.16-2.13) 0.004 1.49 (1.04-2.13) 0.028
Time since last therapy (>6 months) 0.59 (0.44-0.79) <0.001
Neutropenia (Gr. 3/4) 0.67 (0.50-0.90) 0.007
Hb (mmol/L) 0.057 (0.49-0.67) <0.001 0.73 (0.61-0.87) 0.001
PSA (log, µg/L) 1.12 (1.01-1.26) 0.040
AP (log, U/L) 1.83 (1.49-2.25) <0.001 1.50 (1.18-1.91) 0.001
LDH (log, U/L) 2.37 (1.73-3.25) <0.001
Albumin (g/L) 0.91 (0.89-0.94) <0.001 0.92 (0.89-0.95) <0.001
Univariable N=206-224 (because of missing values the number of included patients can differ per variable) 
Multivariable N=200. Abbreviations: WHO PS=world health organization performance status, Hb=hemoglobin, 
PSA=prostate specific antigen, AP=alkaline phosphatase, LDH=lactate dehydrogenase, log=log transformed 
variables when data were not normally distributed.
PSA response
Univariable analysis showed significant associations between PSA response and WHO 
performance status, Hb, AP and LDH. In the multivariable model Hb and AP remained 
significantly associated with PSA response and were taken into the final model (Table 3). 
Higher hemoglobin level before treatment (OR 1.48, 95%CI 1.05-2.07, p=0.024), and a lower 
AP level at the start of treatment (OR 0.61, 95%CI 0.39-0.96, p=0.034) resulted in a higher 
chance of PSA response. Figure 2 displays a nomogram to calculate the chance of PSA 
response for an individual patient treated with cabazitaxel based on our multivariable model.
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Table 3. Univariable and multivariable model for PSA response
Variable Univariable OR (95%CI) P-value Multivariable OR (95%CI) P-value
WHO PS (1 vs 0) 0.48 (0.27-0.84) 0.011
Hb (mmol/L) 1.67 (1.22-2.29) 0.002 1.48 (1.05-2.07) 0.024
AP (log, U/L) 0.50 (0.33-0.77) 0.002 0.61 (0.39-0.96) 0.034
LDH (log, U/L) 0.49 (0.27-0.88) 0.016
Univariable N= 217-224 (because of missing values the number of included patients can differ per variable)
Multivariable N=215 Abbreviations: WHO PS=world health organization performance status, Hb=hemoglobin, 
AP=alkaline phosphatase, LDH=lactate dehydrogenase, log=log transformed variables when data were not 
normally distributed.
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Figure 1. Nomogram for overall survival 
Prognostic nomogram predicting overall survival probability. For each variable, starting with WHO 
performance score on the second axis, draw a vertical line up to the ‘Points’ axis (top line) to identify the 
number of prognostic points the patient receives for the value of this variable. Calculate the ‘Total Points’ by 
adding up the prognostic points for each variable. Determine the 12-month or 24-month overall survival by 
drawing a vertical line from the ‘Total Points’ axis down to the axis indicating the survival probabilty. WHO PS= 
world health organization performance status, Hb = hemoglobin, AP = alkaline phosphatase, log = log 
transformed variables when data were not normally distributed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Nomogra  for overall survival
Prognostic nomogram predicting overall survival probability. For each variable, starting with WHO performance 
score on the second axis, draw a vertical line up to the ‘Points’ axis (top line) to identify the number of prognostic 
points the patient receives for the value of this variable. Calculate the ‘Total Points’ by adding up the prognostic 
points for each variable. Determine the 12-month or 24-month overall survival by drawing a vertical line from 
the ‘Total Points’ axis down to the axis indicating the survival proba ilty. WHO PS= world he lth organization 
perform ce status, Hb = hemoglobin, AP = alkaline phosphatase, log = log transformed variables when data were 
not normally distributed.
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Figure 2. Nomogram for PSA response  
Prognostic nomogram predicting PSA response. For both variables, Hb and AP_log, draw a vertical line from the 
absolute value of this variable up to the ‘Points’ axis (top line) to identify the number of prognostic points the 
patient receives for these variables. Calculate the ‘Total Points’ by adding up the prognostic points for both 
variables. Determine the probability of PSA response by drawing a vertival line form the ‘Total Points’ axis 
down to the axis of the probability of PSA response. Hb = hemoglobin, AP = alkaline phosphatase, log = log 
transformed variables when data were not normally distributed. 
  
Figure 2. Nomogram for PSA respon e
Prognostic nomogram predicting PSA response. For both variables, Hb and AP_log, draw a vertical line from the 
absolute value of this variable up to the ‘Points’ axis (top line) to identify the number of prognostic points the patient 
receives for these variables. Calculate the ‘Total Points’ by adding up the prognostic points for both variables. 
Determine the probability of PSA response by drawing a vertival line form the ‘Total Points’ axis down to the axis of 
the probability of PSA response. Hb = hemoglobin, AP = alkaline phosphatase, log = log transformed variables when 
data were not normally distributed.
DISCUSSION
In this post-hoc analysis of a large phase II trial of patients with mCRPC treated with 
cabazitaxel, we found that WHO performance status, baseline Hb, AP and albumin were 
all significantly associated with OS. In addition, Hb and AP were identified as parameters 
to predict the probability of PSA response in mCRPC patients receiving second-line 
chemotherapy. To our knowledge, we are the first to report prognostic factors and a 
nomogram for OS and PSA response in men with mCRPC treated with cabazitaxel outside 
of the TROPIC registration trial.5 Treatment selection of men with metastatic prostate 
cancer has become increasingly challenging with the introduction of novel therapies at 
earlier disease stages. In this changing treatment paradigm, predictors and prognostic 
factors of treatment response and outcome are still lacking. The current study shows that 
readily available, cheap and easy to use clinical parameters are of prognostic value for 
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estimating the chance of PSA response and OS using the presented nomograms (Figure 1 
and 2). These individual probabilities of survival and response might help the physician 
to decide when to initiate treatment in daily clinical practice. As an illustration, if the 
identified prognostic factors follow a trend towards an unfavourable condition, it may help 
the physician to avoid missing the window of opportunity for cabazitaxel treatment and 
initiate therapy before the patients’ condition is declining.
Several distinct predictors of OS and PSA response (e.g. albumin) were identified as 
compared to the models constructed from the TROPIC dataset.5,7 The difference between 
the identified variables in the final model from Halabi et al. and our cohort may be due to 
a different population, different primary trial design and different model assumptions. The 
strength of our model is that it is based only on men treated with cabazitaxel. In contrast, 
the Halabi nomogram has been constructed based on the TROPIC trial and validated on 
the SPARC trial, including also men treated with mitoxantrone and satraplatin which are 
not used in the current treatment armamentarium.5 Therefore, our study might represent 
a more contemporary real-world patient population. This study is limited by its post-hoc 
design. As a result, radiographic variables such as the presence of visceral disease were not 
collected in the primary trial.
dNLR, a parameter to determine the inflammatory response rate of the host, has been 
reported and validated as a prognostic factor for OS and response in mCRPC patients 
treated with docetaxel, cabazitaxel and abiraterone.7-10 In addition, a high dNLR was 
associated with poor OS in other tumor types.11 However, in our analyses no significant 
association between dNLR and OS, nor between dNLR and PSA response was found. 
Furthermore, in a post-hoc analysis of the TROPIC trial neutropenia during treatment with 
cabazitaxel has shown a significant relation with OS of men with mCRPC.12 Although we 
had comparable treatment groups, no association between the occurrence of grade 3-4 
neutropenia and OS or PSA response was found.
In conclusion, this study identified clinical and biochemical variables associated with OS 
and PSA response of patients with mCRPC treated with cabazitaxel. In an increasingly 
complicated treatment landscape with several treatment options available including 
chemotherapy and novel AR-targeted agents, our findings have prognostic value for 
treatment response and survival of men qualifying for treatment with second-line 
chemotherapy in daily practice. Furthermore, these data can be used to risk-stratify 
patients in future clinical trials.
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SUPPLEMENTARY
Supplementary 1: materials and methods
Inclusion and exclusion criteria CABARESC study:
Inclusion criteria:
- Metastatic castrate resistant prostate cancer (mCRPC) patients with documented 
disease progression, defined as: documented rising PSA levels (at least 2 consecutive 
rises in PSA over a reference value taken at least 1 week apart, or a PSA rise of ≥ 2.0 
µg/l), appearance of new lesions or documented disease progression based on CT scan 
or bone scan.
- Previous treatment with a docetaxel-containing regimen
- Age ≥ 18 years;
- WHO performance status ≤ 1
- Adequate renal function (within 21 days before randomization) defined as serum 
creatinin ≤ 1.5 x ULN and/or calculated creatinin clearance ≥ 50ml/min, according to 
MDRD formula.
- Adequate hepatic functions (within 21 days before randomization) defined as: total 
bilirubin ≤ 1.0 x ULN; alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) ≤2.5x ULN, in case of liver metastasis < 5 ULN; alkaline phosphatase (AP) < 5x 
ULN) In case of bone metastasis, AP < 10x ULN is accepted.
- Adequate hematological blood counts (within 21 days before randomization) defined 
as (absolute neutrophil count (ANC) ≥1.5 x 109/L and platelets ≥ 100 x 109/L);
- Castration, either surgically or by continued LHRH agonist therapy
- Written informed consent according to ICH-GCP
Exclusion criteria:
- Impossibility or unwillingness to take oral drugs;
- Serious illness or medical unstable condition requiring treatment, brain metastases 
or history of psychiatric disorder that would prohibit the understanding and giving of 
informed consent.
- Use of medications or dietary supplements known to induce or inhibit CYP3A
- Known hypersensitivity to corticosteroids
- Any active systemic or local bacterial, viral, fungal - or yeast infection.
- Ulcerative colitis, Crohn’s disease or celiac disease (active or in medical history)
- Ostomy
- Planned/active simultaneous yellow fever vaccine
- Geographical, psychological or other non-medical conditions interfering with follow-up
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Supplementary Table 2. Ineligible patient of the CABARESC trial
Reason for exclusion Group CABA Group BUD Post-hoc Total
No cabazitaxel (in study context)a 3 7 0 10
Initial cabazitaxel dose <25mg/m2 5 1 0 6
Treatment started before randomization 1 0 0 1
Death before start therapy 1 0 0 1
Long treatment delay after randomizationb 1 0 0 1
Missing laboratory values 0 0 3 3
Total 11 8 3 22
adue to disease progression and worsening of patient conditions: patient did not receive treatment or not in 
context of this study.
bdue to ASAT and ALAT > 2 upper limit of normal without liver metastases there was a time of two months between 
randomization and start of cabazitaxel therapy.
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ABSTRACT
Background: The interpretation of the presence of AR-V7 in circulating tumor cells 
(CTCs) in men with metastatic castration-resistant prostate cancer (mCRPC) remains to be 
elucidated. AR-V7 may hold promise as a predictive biomarker, but there may be prognostic 
impact of AR-V7 positivity as well. To investigate the clinical value of AR-V7, we determined 
whether AR-V7 detection in CTCs in mCRPC patients is associated with CTC counts and 
survival.
Methods: Between December 2011 and January 2019 three prospective clinical trials 
collected clinical data of mCRPC patients, who progressed after docetaxel and/or 
enzalutamide or abiraterone. Baseline (and follow-up) blood samples were withdrawn 
determining CTC count and AR-V7 expression. The majority of patients started cabazitaxel 
as next line of treatment following AR-V7 characterization.
Results: A total of 127 samples were evaluable for the analysis of CTC count versus AR-V7 
status. Although an association was observed between AR-V7 and CTC count in all mCRPC 
patients (p=0.017), no such association was found in the prognostic unfavorable subgroup 
of patients with ≥5 CTCs. After adjusting for clinical prognostic factors, AR-V7 expression in 
CTCs was not associated with overall survival (HR=1.33, 95%CI 0.81-2.15, p=0.25).
Conclusion: We found that AR-V7 expression in CTCs had no additional prognostic value 
in mCRPC patients, mostly treated with cabazitaxel. In mCRPC patients with a predefined 
worse prognosis of higher CTC count (≥5), a predictive biomarker is an important unmet 
medical need. Prospective trials should investigate whether AR-V7 detection in CTCs may 
guide treatment selection for these adverse prognosis patients.
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INTRODUCTION
AR-V7 is a mRNA splice variant of the androgen receptor (AR) translating to a constitutively 
active receptor that lacks the ligand binding domain.1 Several studies investigating the 
correlation between the presence of AR-V7 in circulating tumor cells (CTCs) of metastatic 
castration-resistant prostate cancer (mCRPC) patients and treatment response found 
that AR-V7 positive patients had decreased sensitivity to AR targeted therapy (ART), like 
enzalutamide and abiraterone, but not to taxanes.2,3 Therefore, AR-V7 expression is being 
explored as a potential predictive biomarker for ART. However, AR-V7 positivity has also 
been related to unfavorable baseline characteristics, therefore it may merely reflect a 
higher tumor burden.4-6 This could be of influence on how to interpreted the presence of 
AR-V7 in circulating tumor cells, as it suggests a prognostic value of AR-V7. To improve our 
understanding of the clinical value of AR-V7, we performed a post-hoc analysis evaluating 
the relationship between AR-V7 status in CTCs, CTC count and overall survival (OS).
METHODS
Patients and trials
Patients with mCRPC post-docetaxel included in one of three different trials performed in 
The Netherlands between December 2011 and January 2019: The PRELUDE trial (MEC-2015-
353), the CABARESC trial7 or the CABA-V7 trial (EudraCT number 2016-002993-11). The 
PRELUDE and CABA-V7 trial communicated the AR-V7 test results to the treating physician 
before new treatment was started. All patients in the CABARESC trial received cabazitaxel. 
The design of each study is described in the Supplementary Methods/Supplementary 
Table 1. These trials were performed according to the Declaration of Helsinki and all 
participants gave written informed consent.
Outcomes
The primary objective was to investigate associations between AR-V7 status in CTCs and 
CTC count in all mCRPC patients and in patients with an unfavorable prognosis based 
on CTC count ≥5. Additionally, OS was compared between AR-V7 positive and negative 
patients in all mCRPC patients and the patients with ≥5 CTCs to investigate its potential 
prognostic value. OS was calculated from the date when blood samples were withdrawn till 
date of death from any cause or end of the study, whichever came first.
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Sample processing and quality control
Two blood samples (one CellSave tube for CTC count and one EDTA tube for mRNA 
profiling) were withdrawn from mCRPC patients and processed within 96 hours (CTC 
count) or 24 hours (for RNA profile) at the laboratory of Translational Cancer Genomics 
and Proteomics of the Department of Medical Oncology, Erasmus MC Cancer Institute. 
CTC enrichment occurred from 7,5 mL of peripheral blood using the CellSearch System. 
After CTC enrichment from the EDTA tube, cells were lysed and RNA isolation followed 
by RT-qPCR. Processing of the samples occurred via standard operation procedures in 
a pre-PCR environment and was approved by an independent external audit. The steps 
of our quality control are described by Sieuwerts et al.8 In short, the first checkpoint 
was blood collection of at least 7,5 mL. To ensure we could compare the experiments of 
different trials and different processing sessions with each other, a calibrator of cultured 
VCaP RNA with known expression of our gene expression markers had to be included in 
all RT-qPCR sessions for evaluation of these samples. If samples were analyzed without a 
VCaP calibrator, these samples were excluded from analysis. By the usage of the average 
Cq value of three references genes (GUSB, HMBS, HPRT1), the quantity and quality of 
RNA was checked. Only samples with an average reference gene Cq value <26.5 were 
considered to be of sufficient quality and quantity for a meaningful AR-V7 analysis. The 
Cq values measured for AR-V7 were normalized by the mean Cq value of two epithelial 
genes (EPCAM, KRT19) to correct for the number of epithelial CTCs present in the sample. 
Only samples with Cq value <26.0 for the average of the epithelial genes were considered 
to have enough epithelial load for a meaningful AR-V7 analysis. If a sample had sufficient 
Cq values for the reference and epithelial targets, but did not produce a quantitative PCR 
signal for AR-V7 within 8.5 cycles after the average Cq of the epithelial markers, the sample 
was considered AR-V7 negative. The rationale for this cut-off has been explained in detail 
before.8
Statistical analysis
AR-V7 status was tested for associations with CTC count, using a Mann-Whitney U test. 
Log-ranktesting was applied to perform OS analysis and Kaplan-Meier curves were drafted 
to visualize OS differences. Prognostic factors for survival (OS) were identified by univariate 
and multivariate Cox regression analysis. All factors with a P-value <0.05 detected in 
univariate analyses were included in multivariate analyses together with AR-V7 as variable 
of main interest. A backward selection method was used for the multivariate model where 
a threshold of P <0.05 was applied. All tests were two-sided and a p-value of <0.05 was 
considered statistically significant. Statistical analyses were performed using STATA, SPSS 
version 24 or Graphpad Prism 5.
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RESULTS
In this post-hoc analysis 212 patient samples of three trials were included; the CABARESC 
trial (n=109), the PRELUDE trial (n=31) and the CABA-v7 trial (n=72). Eighty-five samples 
had insufficient epithelial signal to reliably give a result on AR-V7 status. A total of 127 
samples were evaluable and included in the current analysis. For the survival analysis, data 
of 94 patients were available (Figure 1). Baseline characteristics, prior and subsequent life 
prolonging therapies are shown in Table 1.
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Figure 1. Flowchart
AR-V7 status and CTC count
Of the 127 evaluable samples, presence of AR-V7 was detected in 45 patients (35%). 
Despite the correction for epithelial signal a significantly higher median CTC count of 25 
CTCs/7.5 mL blood was detected in AR-V7 positive patients compared to a median CTC 
count of 10 CTCs/7.5 mL blood in AR-V7 negative patients (p=0.017, Figure 2a). In patients 
with ≥5 CTCs no significant difference in median CTC count could be detected between 
AR-V7 positive (n=36) and negative (n=50) patients (34 and 33, p=0.24, Figure 2b). In 
the 0-4 CTC group, no association between AR-V7 positivity and CTC count was detected 
(Supplementary Figure 1).
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Table 1. Baseline characteristics
Total (n=94)
(median, IQR)
AR-V7 pos (n=34)
(median, IQR)
AR-V7 neg (n=60)
(median, IQR)
Age (years) 69 (65 – 75) 68 (64 – 73) 73 (66 – 76)
WHO PS, n (%)
- 0 34 (36%) 13 (38%) 21 (35%)
- 1 43 (46%) 15 (44%) 28 (47%)
- 2 1 (1%) 0 (0%) 1 (2%)
- Missing 16 (17%) 6 (18%) 10 (17%)
Prior therapies, n(%)
- Docetaxel 94 (100%) 34 (100%) 60 (100%)
- Enzalutamide 27 (29%) 14 (41%) 13 (22%)
- Abiraterone 13 (14%) 5 (15%) 8 (13%)
Hb, mmol/L 7.7 (6.9 – 8.2) 7.3 (6.8 – 8.2) 7.8 (7.1 – 8.2)
- Missing n=15 (16%) n=4 (12%) n=12 (20%)
PSA, µg/L 186 (67 – 356) 171 (68 – 358) 198 (61- 373)
- Missing n=39 (41%) n=9 (26%) n=30 (50%)
Subsequent Treatment after AR-V7 determination
- Cabazitaxel 73 (78%) 32 (94%) 41 (68%)
- Enzalutamide 11 (12%) 2 (6%) 9 (15%)
- Abiraterone 4 (4%) 4 (7%)
- Apalutamide 1 (1%) 1 (1.5%)
- Radium-223 1 (1%) 1 (1.5%)
- None 4 (4%) 4 (7%)
Abbreviations: pos = positive, neg = negative, IQR = inter quartile range, WHO PS = World Health
Organization Performance Score, Hb = Hemoglobin, PSA = prostate specific antigen
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Figure 2. Relation between AR-V7 status and CTC count. 
All samples are quality controlled checked. Blue dots are AR-V7 negative and red dots are AR-V7 positive.  
a samples with all CTC counts are included, p=0.017. b Samples with at least 5 CTCs are included, p=0.24
Figure 2. Relation between AR-V7 status and CTC count.
All samples are quality controlled checked. Blue dots are AR-V7 negative and red dots are AR-V7 positive.
a samples with ll CTC counts ar  included, p=0.017. b S mples with at least 5 CTCs are included, p=0.24
Chapter 7 – 115
7
AR-V7 status and OS
After adjusting for CTC count and clinical prognostic factors no difference in survival 
between AR-V7 positive and negative patients was observed (Figure 3a/Supplementary 
Table 2). As expected, patients with ≥5 CTCs had a significantly worse prognosis with a 
median survival of 6.9 months (IQR 4.3-13.8) compared to patients with <5 CTCs (median 
22.3 months, IQR 19.2-34.6, Figure 3b). In this subgroup also no difference in survival was 
observed between AR-V7 positive and AR-V7 negative patients (HR of 1.1, 95%CI 0.6-1.9, 
p=0.78, Figure 3c).
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Figure 3. Survival curves 
a. All patients stratified by AR-V7 status. b. All patients stratified by CTC count. c. Patients with ≥ 5 CTCs 
stratified by AR-V7 status. 
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a. All patients stratified by AR-V7 status. b. All patients stratified by CTC count. c. Patients with ≥ 5 CTCs stratified by 
AR-V7 status.
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DISCUSSION
In this post-hoc analysis of mCRPC patients enrolled in 3 clinical trials post-docetaxel, 
we evaluated associations between the AR-V7 expression in CTCs, CTC count and OS. A 
significantly higher median CTC count was observed in AR-V7 positive patients compared 
to AR-V7 negative patients. However, this association was not found in the unfavorable 
prognosis patient group with ≥5 CTCs. Moreover, AR-V7 positivity in CTCs was not 
associated with a worse prognosis in mCRPC men mostly treated with cabazitaxel.
We observed an association between AR-V7 status and median CTC count in all mCRPC 
patients, which was probably driven by a lack of AR-V7 positivity in patients with 4 or less 
CTCs. Lower incidence of AR-V7 positivity in patients with a low CTC count could potentially 
be explained by intra-patient heterogeneity of AR-V7 expression in CTCs and the lack of 
specificity of the test in samples with a low CTC count (or no CTCs at all).9,10 Other platforms 
for AR-V7 determination such as nuclear AR-V7 protein expression in tissue/CTCs, mRNA 
expression in extracellular vesicles like exosomes/peripheral blood mononuclear cells/
whole blood face the same issue of low specificity to a lesser or greater extent.10-13 The 
availability of all these different testing methods indicates that AR-V7 testing is far from 
standardized. Consensus on the analytical method of testing is needed before clinical 
implementation is possible.
AR-V7 may also be a biomarker that identifies a subgroup of patients with advanced 
disease and thus may be underrepresented in the good prognosis group. Therefore, AR-V7 
determination in the low (<5) CTC population may not be reliable nor relevant for clinical 
decision making. The ADNA test, often used to determine AR-V7 expression in CTCs, has 
no ability to count the CTCs. The CTC count could potentially be relevant to discriminate 
in which patients AR-V7 determination is clinically relevant, therefore it is suggested 
to incorporated the CTC count in the AR-V7 testing. The recent study of Sharp et al. did 
incorporate the CTC count by Cellsearch and combined this with the AR-V7 expression.14 We 
showed similar results (Figure 2 of both studies), as a significant difference in CTC count 
between AR-V7 positive and negative patients was found in both studies. In addition, 
similar to our results most patients with a low to zero CTCs are tested AR-V7 negative. 
It remains to be determined if these patients are truly AR-V7 negative, which seems 
debatable as some of the CTC based AR-V7 negative patients in the study of Sharp et 
al. have AR-V7 protein expression in the tumor biopsies and these patients had limited 
response to ART. In additional to their work, we investigated the association in the poor 
prognosis group of mCRPC patients with ≥5 CTCs.
Chapter 7 – 117
7
We confirmed the prognostic value of CTC count at the cut-off of 5 CTCs in this patient 
cohort.15 The sub-group with ≥5 CTCs had a median OS of 6.9 months, in which the 
presence of AR-V7 did not further impact survival. The short survival time of patients 
with ≥5 CTCs emphasizes the need to carefully select treatment as the ‘window of 
opportunity’ to administer an effective treatment is relatively small. Our CTC based AR-V7 
characterization test has a turnaround time of less than 2 weeks enabling early treatment 
advice in this specific sub-group.8 Therefore, we propose that the value of AR-V7 should 
be further assessed in patients with ≥5 CTCs, as they have the highest need for rapidly 
available accurate predictive biomarkers.
The predictive value of AR-V7 could not be further addressed in this study since no 
control group was available. However, AR-V7 positivity in CTCs of mCRPC patients, 
mostly treated with cabazitaxel was not associated with worse outcomes. Recently, the 
negative prognostic value of AR-V7 has been validated prospectively in abiraterone and 
enzalutamide treated patients, indicating that AR-V7 positivity was associated with worse 
outcomes with these novel ART.16 A limitation of the study by Armstrong et al. was the 
heterogeneity of the patient cohort and the treatment selection. In our study most patients 
started cabazitaxel, sometimes based on the AR-V7 result. This may confound the potential 
prognostic value of AR-V7, as it may correct for an otherwise poor prognosis and potentially 
influence our results. However, the majority - of AR-V7 negative patients - also received 
cabazitaxel.
CONCLUSION
In conclusion, detection of AR-V7 in CTCs has no additional prognostic value in mCRPC 
patients, who were mostly treated with cabazitaxel and prospective validation is needed to 
investigate if AR-V7 could fulfill the criteria for a useful predictive biomarker.
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SUPPLEMENTARY
Supplementary methods – Design of the studies
The CABARESC study was a multicenter, pharmacodynamic study investigating the effects 
of budesonide on cabazitaxel-induced diarrhea in which, as secondary objective, baseline 
CTC samples were collected.7 In the primary study clinical details and survival data of the 
patients had already been collected. All patients received cabazitaxel treatment.
The PRELUDE study was a feasibility study across six different hospitals in the Netherlands 
to determine the logistics of reporting the results of AR-V7 determination in CTCs to 
different hospitals around the nation. Since this feasibility study did not include clinical 
or survival data of the patients, these had to be retrospectively collected. The protocol of 
this post-hoc analysis was reviewed by the Ethical Committee of the Erasmus MC Cancer 
Institute and was assessed as no subject to Medical Research. After the positive report by 
the Ethical Committee, clinical and survival data were collected with consent of the patient 
if possible, e.g. if the patient was alive. The test results had been communicated to the 
treating physician before treatment start, therefore patients in the PRELUDE trial had been 
treated with hormonal therapy or cabazitaxel therapy.
The CABA-V7 study is still actively recruiting and prospectively investigates PSA response 
rates in AR-V7 positive patients treated with cabazitaxel. In this trial all clinical data needed 
for this post-hoc analysis had already been collected, including the data of AR-V7 negative 
patients. All AR-V7 negative patients were allowed treatment with hormonal therapies as 
well as cabazitaxel. The CABA-V7 trial communicated the AR-V7 test results to the treating 
physician before new treatment was started.
All patients had given written informed consent before participation to one of the studies, 
which included a paraphrase referring to the potential use of clinical and collected data 
for future research. Although all trials had slightly different primary objectives, they all 
included baseline CTC count and AR-V7 quantification by RT-qPCR in CellSearch enriched 
CTC fractions. The CABARESC and CABA-v7 trial also included CTC response with AR-V7 
characterization at cabazitaxel cycle 3 or 4, which we took into account for the association 
between AR-V7 and CTC count.
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Supplementary Table 1. Study details
Study Recruitment period
Survival data 
collection
Patients eligible for 
survival analysis (n)
Median survival  
(months, 95%CI)
CABARESC Dec 2011 – Oct 2016 Oct 2016 34 12.3 (7.5-15.8)
PRELUDE Sep 2015 – Mar 2016 Jan 2019 18 15.8 (7.6-21.7)
CABA-V7 Feb 2017 – Jan 2019 Jan 2019 42 8.0 (4.0-19.9)
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Supplementary Figure 1. Association between AR-V7 positivity and CTC count in the 0-4 CTC group.  
 
 
 
Supplementary Table 2. Univariate and Multivariate analyses of baseline prognostic factors 
 
Variable 
Univariate analysis Multivariate analysis 
HR 95% CI p-value HR 95% CI p-value 
AR-V7 1.33 0.81-2.18 0.253    
CTC ≥ 5 5.66 2.92-10.95 < 0.001 7.36 2.71-20.05 < 0.001 
WHO PS  
0 vs 1/2 
 
2.27 
 
1.26-4.07 
 
0.006 
 
2.66 
 
1.39-5.09 
 
0.003 
Hb (mmol/L) 0.67 0.49-0.93 0.016    
AP (U/L) 1.002 1.001-1.003 < 0.001 1.001 1.000-1.002 0.013 
LDH (U/L) 1.001 1.001-1.002 0.001 1.002 1.001-1.002 0.001 
Abbreviations: HR = hazard ratio, CI = confidence interval, AR-V7 = androgen-receptor splice variant 7, CTC = 
circulating tumor cells, WHO = world health organization performance status, Hb = hemoglobin, AP = alkaline 
phosphatase, LDH = lactate dehydrogenase  
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Variable
Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
AR-V7 1.33 0.81-2.18 0.253
CTC ≥ 5 5.66 2.92-10.95 < 0.001 7.36 2.71-20.05 < 0.001
WHO PS
0 vs 1/2 2.27 1.26-4.07 0.006 2.66 1.39-5.09 0.003 
Hb (mmol/L) 0.67 0.49-0.93 0.016
AP (U/L) 1.002 1.001-1.003 < 0.001 1.001 1.000-1.002 0.013
LDH (U/L) 1.001 1.001-1.002 0.001 1.002 1.001-1.002 0.001
Abbreviations: HR = hazard ratio, CI = confidence interval, AR-V7 = androgen-receptor splice variant 7, CTC = 
circulating tumor cells, WHO = world health organization performance status, Hb = hemoglobin, AP = alkaline 
phosphatase, LDH = lactate dehydrogenase
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ABSTRACT
Androgen-deprivation therapy (ADT) has been the mainstay of treatment for metastatic 
prostate cancer since the first report of its hormonal dependence in the 1940s. Since 2015, 
the addition of docetaxel and the addition of abiraterone to ADT have demonstrated 
to confer significant overall survival benefit in men with metastatic castration-naïve 
prostate cancer (mCNPC). The shift of these treatment options for metastatic prostate 
cancer from the castration-resistant setting to the castration-naïve setting has led to 
new challenges in the management of this disease. It remains to be determined which 
patient may benefit most from either early concomitant docetaxel, or from abiraterone, 
since biomarkers for early therapy response and risk stratification are currently lacking. 
Therefore, the ability to generate personalized medicine is hampered. Furthermore, the 
earlier detection of metastatic prostate cancer by using new imaging modalities makes the 
application of clinical trial results in daily practice increasingly challenging. Recently, both 
local radiotherapy to the primary tumor combined with ADT, and abiraterone combined 
with ADT showed a survival benefit in low-volume disease patients. The latest data also 
demonstrated a survival benefit with the addition of apalutamide or enzalutamide to 
ADT. The extent of metastatic disease may become one of the most important factors 
to determine treatment choice. In this review article we summarize trial data to provide 
guidance for treatment selection in metastatic castration-naïve prostate cancer.
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INTRODUCTION
In the past 15 years, several new treatment options for metastatic castration-resistant 
prostate cancer (mCRPC) have been approved including docetaxel, cabazitaxel, abiraterone, 
enzalutamide and radium-223.1-8 Recently, major shifts in the treatment of metastatic 
prostate cancer have occurred, since significant survival benefit has been obtained with 
docetaxel and abiraterone in addition to the standard of ADT in metastatic castration-naïve 
prostate cancer (mCNPC).9-12 The challenge is now to identify the mCNPC patients who 
will benefit most from combination strategies (ADT+docetaxel or ADT+abiraterone/
prednisone). The trials were conducted with slightly different patient populations. 
Unfortunately, no biomarkers are available, leaving the treatment choice based on clinical 
symptoms, patients’ preference, experience, toxicity, and costs. However, stratification of 
patients by disease burden seems to be a possible factor for treatment selection, since the 
recently published post-hoc analysis of the STAMPEDE abiraterone trial showed a survival 
benefit in low-volume (LV) mCNPC patients, which has not been significantly established 
by the addition of docetaxel.13 The latest insights include the benefit of local radiotherapy 
to the prostate in LV disease patients, and the OS benefit obtained by the addition of 
apalutamide or enzalutamide to ADT in mCNPC patients.14-16 In this review article we aim to 
provide guidance for treatment selection of the approved drugs in mCNPC patients.
METHODS
The methods are described in online-only Supplementary Data.
ADT + DOCETAXEL
The addition of docetaxel to ADT has been investigated in three large phase III trials; the 
GETUG-AFU15, the CHAARTED and the STAMPEDE trial (docetaxel comparison).9,10,17 All 
trials compared overall survival (OS) in mCNPC patients, who were treated with ADT alone 
versus the combination of ADT plus docetaxel. The study design, included patients and 
primary outcomes are shown in Tables 1, 2 and 3. The first trial, GETUG-AFU15 (N=385), 
showed significant longer biochemical and clinical progression-free survival in the 
combination group, but failed to show an OS benefit (OS 58.9 months (95%CI 50.8-69.1) 
versus 54.2 months (95%CI 42.2-not reached,P=0.95).17 Based on these results, the authors 
did not recommend the addition of docetaxel to standard ADT in the castration-naïve 
setting. However, the sample size of the GETUG-AFU15 was relatively small and the larger 
CHAARTED and STAMPEDE trials shed a new light on this conclusion. The mature analysis of 
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the CHAARTED trial (N=790) showed an OS benefit of 10.4 months for patients treated with 
ADT plus docetaxel compared to ADT alone (57.6 months versus 47.2 months, HR=0.72, 
95%CI 0.59-0.89,P=0.0018).10.18 In addition, this trial conducted a preplanned subgroup 
analysis based on disease burden. The majority of patients (65%) had high-volume (HV) 
disease, which involved presence of visceral metastases or ≥4 bone metastases of which 
at least 1 was beyond pelvis and vertebrae (Tables 2 and 3). In the HV disease group 
(N=513) an even larger survival benefit of almost 17 months was observed in the patients 
treated with ADT plus docetaxel (51.2 months versus 34.4 months, HR=0.63, 95%CI 0.50-
0.79,P<0.001). A survival benefit was absent in the LV disease group (N=277) (HR=1.04, 
95%CI 0.70-1.55,P=0.86).18 Thereby, the mature results of CHAARTED have demonstrated 
the survival benefit of docetaxel was only obtained in patients with HV metastatic disease. 
A post-hoc analysis of the CHAARTED and GETUG-AFU15 trials, confirmed the results 
of the mature analysis of CHAARTED.19 The pooled risk of death was 32% lower with 
the combination of ADT plus docetaxel in the HV disease group (HR=0.68, 95%CI 0.56-
0.82,P<0.001).
The STAMPEDE trial has a unique multi-arm, multi-stage design to evaluate survival benefit 
in patients commencing ADT for prostate cancer including patients with both metastatic 
and high-risk locally advanced disease with the addition of several treatments [e.g. 
docetaxel, bisphosphonates, zoledronic acid, abiraterone, prostate radiotherapy] to ADT.9 
For this review we only included the study details of metastatic patients (Tables 1 and 2). 
The STAMPEDE docetaxel comparison included 1086 patients with mCNPC, and showed 
a survival benefit of 15 months in favor of the combination group (60 months versus 45 
months, HR=0.76, 95%CI 0.62-0.92,P=0.005). The investigators did not stratify for LV or HV 
disease in the docetaxel comparison of the STAMPEDE trial.
Both STAMPEDE and CHAARTED studies showed a longer survival with the addition of 
docetaxel to ADT compared to ADT alone in the total patient cohort including both HV 
and LV disease. Only in CHAARTED, stratification based on disease volume was conducted 
suggesting the survival benefit is mainly driven by metastatic HV disease patients. 
Following the results of these trials, the addition of chemotherapy became the new 
standard of care in HV mCNPC patients, while the benefit in LV disease patients had not 
firmly been established.
ADT + CYP17 INHIBITION (ABIRATERONE)
The addition of abiraterone and prednisone to ADT in CNPC patients has been investigated 
in two large trials: LATITUDE and STAMPEDE abiraterone comparison.11,12 The design and 
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patients included in these trials are shown in Tables 1 to 3. Briefly, LATITUDE only included 
patients with metastatic HV disease (involving two or more of the following risk factors; 
Gleason≥8, bone lesions≥3, visceral metastases), whereas STAMPEDE also included LV 
disease patients and patients with locally advanced disease. The final analysis of the 
LATITUDE trial (N=1199) showed a 34% reduction in the risk of death in the abiraterone 
group (HR=0.66, 95%CI 0.56-0.78,P<0.001).20 Although the benefit of the addition of 
abiraterone to ADT in the trial was evident, the lack of cross-over to abiraterone in the 
placebo group at the time of disease progression to mCRPC was a serious confounder 
of this study. Due to the double-blinding nature of the study, the treating physician was 
unaware of the received treatment. As a result, only 11% of the placebo treated patients 
received abiraterone at the time of mCRPC. Other subsequent life-prolonging therapies 
at disease progression were docetaxel (40%), enzalutamide (16%), radium-223 (6%) and 
cabazitaxel (6%). Interestingly, 21% of the placebo treated patients did not receive any 
subsequent life-prolonging therapy. Consequently, one could argue that the LATITUDE 
trial tested early abiraterone versus no abiraterone, rather than early abiraterone versus 
abiraterone at the time of mCRPC.4,21 Therefore, the design of the trial evokes concern, since 
the use of abiraterone in the mCRPC setting has demonstrated survival benefit and should 
have been available as a standard treatment option.4,21 However, based on the results of the 
LATITUDE trial, EMA and FDA have licensed abiraterone for HV mCNPC.
In STAMPEDE, abiraterone was added in the multi-arm trial design of the study to 
investigate its addition to ADT in CNPC (N=1002).12 The median OS was not reached in 
the combination group, but there was survival benefit in the combination group with 150 
deaths compared to 218 deaths in the ADT alone group (HR=0.61, 95%CI 0.49-0.75). Toxicity 
occurred more frequent in the abiraterone group (grade 3-5, 47% versus 33%, Table 6), 
but was similar to toxicity rates observed in the COU-AA-301 and COU-AA-302 studies.4,5,21 
In this study, 6% of patients did not receive any subsequent life-prolonging treatment 
at the time of progression, while others received docetaxel (37%), enzalutamide (26%), 
abiraterone (22%), cabazitaxel (5%) or radium-223 (4%).
Table 3. Definition of metastatic burden 
CHAARTED LATITUDE HORRAD
High-
volume/
high-risk
presence of visceral metastases 
or ≥ 4 bone metastases of 
which at least 1 was beyond 
pelvis and vertebrae
Metastatic disease with at least 
two of the following risk factors; 
Gleason score ≥ 8, and/or ≥3 bone 
lesions, and/or presence of visceral 
metastases
≥ 5 metastases
Low-volume/
low-risk
No visceral metastases and no 
bone metastases outside the 
pelvis and vertebrae or less 
than 4 bone metastases
All patients with less than two of the 
above mentioned risk factors
< 5 metastases
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The STAMPEDE investigators recently conducted a post-hoc analysis of all metastatic 
patients enrolled into the abiraterone comparison, classifying patients by metastatic 
extent according LATITUDE and CHAARTED criteria (Table 3).13 The post-hoc analysis 
demonstrated that, according to the LATITUDE criteria, 428 patients (48%) were identified 
as having LV disease, of whom 220 received ADT and 208 received ADT plus abiraterone. 
Patients treated with ADT plus abiraterone in this LV disease group showed a 34% reduced 
risk of death compared to the ADT alone group (HR=0.66, 95%CI 0.44-0.98, P=0.041), 
resulting in a difference of 4% in 3-year OS rates. However, the median OS in this LV patient 
group had not yet been reached during this follow-up period. More events are needed to 
show the real magnitude of the survival benefit. At the time of this post-hoc analysis the 
median OS was reached in the HV disease group, confirming the benefit in HV patients 
(HR=0.54, 95%CI 0.41-0.70,P<0.001).
ADT + RADIOTHERAPY TO THE PRIMARY TUMOR
In 2018 two large trials, HORRAD and STAMPEDE radiotherapy comparison, reported a 
potential survival benefit by prostate radiotherapy (RT) in addition to ADT in patients 
with newly diagnosed LV metastatic disease.14,22 The STAMPEDE investigators investigated 
the effect of prostate radiotherapy by adding an extra comparison in their multi-arm, 
multi-stage trial design, enrolling newly diagnosed metastatic prostate cancer patients 
(N=2061,Tables 1 and 2). Patients were randomized in a 1:1 ratio to receive either ADT+/-
docetaxel (during the trial the addition of docetaxel became the new standard of care) or 
ADT+/-docetaxel plus prostate radiotherapy (RT). Radiotherapy was commenced as soon as 
possible after randomization, or within 3-4 weeks after the last docetaxel cycle. The results 
showed no significant OS benefit from the addition of local RT in the complete patient 
group (HR=0.92, 95%CI 0.80-1.06,P=0.27). However, there was a robust improvement in 
FFS (HR=0.76, 95%CI 0.68-0.84,P<0.001). A directionally hypothesized and pre-specified 
subgroup analysis based on disease burden was conducted prior to study analysis, but not 
prior to accrual. The results revealed that LV patients defined by CHAARTED, obtained OS 
benefit when local RT was added to ADT+/-docetaxel (HR=0.68, 95%CI 0.52-0.90,P=0.009). 
This study was the first to show a survival benefit by treatment of the primary tumor in 
metastatic prostate cancer and is truly practice changing.
The HORRAD trial included 432 patients with newly diagnosed metastatic disease 
confirmed by bone-scintigraphy and randomized patients (1:1) to receive either ADT 
plus prostate RT (N=216) or ADT alone (N=216).22 The study showed no OS benefit of the 
addition of prostate radiotherapy. Although not statistically significant, a trend towards 
survival benefit was seen in LV disease patients with a HR of 0.68 (95%CI 0.42-1.10), 
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concordant with the HR of the STAMPEDE study. In the HORRAD trial the majority of 
included patients had HV disease (63%) and the trial was not powered to detect a difference 
in the subgroup of LV patients. Therefore, the trend in LV patients observed in this trial 
supports the benefit of radiotherapy in LV patients obtained in the STAMPEDE study.
In an ongoing 4-arm trial, PEACE-1, the question of the addition of prostate radiotherapy to ADT 
plus docetaxel in mCNPC will again be explored (NCT01957436). In this study, mCNPC patients 
are randomized to either standard of care (SOC = ADT+Docetaxel), SOC plus abiraterone, SOC 
plus prostate radiotherapy, or SOC plus abiraterone and prostate radiotherapy. This study will 
conclude on the extent of the benefit of prostate radiotherapy in LV disease patients, as well as 
whether combining treatments may lead to additional survival benefit.
ADT + NOVEL AR TARGETED THERAPIES
Recently, the addition of novel AR targeted therapies enzalutamide and apalutamide to 
ADT have also shown survival benefit in the castration-naïve setting. The ENZAMET trial 
showed additional benefit of enzalutamide plus ADT compared to ADT plus standard 
antiandrogen therapy (bicalutamide/flutamide/nilutamide) in mCNPC.15 Patients 
(N=1125) were stratified according to disease volume by CHAARTED definition. The 
study was amended to allow patients to receive early docetaxel (up to two cycles before 
randomization), as this was established as the new standard of care. A 33% reduced risk 
of death in the combination group of ADT plus enzalutamide compared to the standard 
antiandrogen group was shown (HR=0.67, 95%CI 0.52-0.86, p=0.002).15 Early docetaxel 
was planned in 45% of patients. All six cycles were delivered in 65% of patients in the 
enzalutamide group and 76% in the standard antiandrogen group. A small majority (52%) 
of patients had HV-disease. Although the trial was not powered for subgroup analysis, it 
showed smaller effects on OS in patients who received early docetaxel (HR=0.90, 95%CI 
0.62-1.31), and in HV disease patients (HR=0.80, 95%CI 0.59-1.07). The overall benefit of 
the addition of enzalutamide to ADT was supported by the interim results of the ARCHES 
trial presented at the ASCO GU 2019.23 In ARCHES, 1150 patients were randomized to 
receive enzalutamide versus placebo combined with standard ADT in men with mCNPC. 
The primary endpoint radiographic PFS (rPFS) was significantly longer in the enzalutamide 
group compared to placebo (HR=0.39, 95%CI 0.30-0.50, p<0.0001). The publication of final 
data of the ARCHES needs to be awaited.
In addition, the TITAN study showed OS benefit of ADT combined with apalutamide, a 
new AR targeted agent with a similar working mechanism as enzalutamide, compared to 
ADT plus placebo.16 The TITAN trial (N=1052) investigated ADT plus apalutamide versus 
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ADT plus placebo in men with mCNPC. Prior docetaxel (6 cycles) was allowed and patients 
were stratified according to disease volume by CHAARTED, resulting in a total of 113 
patients (11%) who had received prior docetaxel, and 660 patients (63%) with HV disease. 
The results showed that patients treated with apalutamide plus ADT had a 52% lower risk 
of radiographic progression compared to ADT plus placebo (HR=0.48, 95%CI0.39-0.60, 
p<0.001). Preliminary analysis of OS showed a 32% decreased risk of death among patients 
treated with apalutamide (HR=0.68, 95%CI 0.51-0.90, p=0.005). The favorable effect of 
apalutamide on rPFS and OS was consistent across all subgroups.
CONSIDERATIONS BASED ON THE TRIAL DATA OF CURRENT AGENTS 
INCLUDED IN THE GUIDELINES
Comparisons of treatment options
Thus far, no direct prospective trials have been conducted between the available therapy 
options for mCNPC, in part because some therapy options were introduced only recently. 
Hereunder, we will discuss treatment comparisons and considerations based on the agents 
included in the current guidelines (docetaxel and abiraterone).
Although STAMPEDE was not designed to directly compare the docetaxel arm and the 
abiraterone arm, the investigators performed a retrospective analysis of those patients who 
had been accrued and treated in the overlapping period from November 2011 to March 
2013.24 A total of 566 patients had been allocated to receive either docetaxel (N=189) or 
abiraterone (N=377). With a median follow-up of 4 years, no difference was found in OS 
(HR=1.16, 95%CI 0.82-1.65,P=0.4) or prostate cancer-specific survival (HR=1.02, 95%CI 
0.7-1.49). Also, metastasis-free survival and symptomatic skeletal-related events were 
similar. A advantage of abiraterone was seen on failure-free survival (HR=0.51, 95%CI 
0.39-0.67,P<0.001) and progression-free survival (HR=0.65, 95%CI 0.48-0.88,P=005). In 
contrast, OS was in favor of patients treated with docetaxel, likely due to the larger number 
of non-prostate cancer related deaths in the abiraterone arm (19% in abiraterone arm 
versus 9% in docetaxel arm).24 Considering similar efficacy, but larger non-prostate cancer 
related deaths in the abiraterone comparison, docetaxel might be the preferred treatment 
in these patients.
Additionally, several meta-analyses have made some cautious, indirect comparisons on 
the best treatment for mCNPC patients in terms of OS and other endpoints.25-32 A 23-27% 
reduction in the risk of death was observed when ADT was combined with docetaxel 
compared to ADT alone with pooled HRs of 0.73-0.77 and the addition of abiraterone to ADT 
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resulted in a 37-40% reduction in risk of death with pooled HRs of 0.60-0.63 (Table 4). Pooled 
results of ADT + prostate radiotherapy showed no OS improvements in the total patient 
population, although patients with low tumor burden (<5) had improved OS (HR=1.47, 95%CI 
1.11-1.94,P=0.007). Nonetheless, across trial comparisons remain difficult due to different 
inclusion criteria and patient populations. Even when only the HV patients of CHAARTED and 
LATITUDE were compared, still 18% of patients had been risk-stratified differently based on 
disease volume, using both studies inclusion criteria (Table 3).13 While this field is pending 
the results of the direct comparison of the ongoing trials, considerations extracted from 
the subgroup/post-hoc analyses of the CHAARTED/STAMPEDE/LATITUDE trials is the best 
available evidence but should be interpreted with caution. In Table 5 recommendations from 
current international guidelines and consensus conferences are described.
Table 4. Overview of included meta-analyses and pooled results of overall survival
Meta-analysis/
Review Year Trials included
Pooled HR 
(95%CI) 
ADT+Doce
Pooled HR 
(95%CI) 
ADT+Abi
Pooled HR 
(95%CI)
ADT+prostate 
Rtx
Vale et al. [25] 2016 GETUG-AFU15 - CHAARTED - 
STAMPEDE (doce)
0.77 (0.68-087)
Tucci et al. [26] 2016 GETUG-AFU15 – CHAARTED - 
STAMPEDE (doce)
0.73 (0.60-0.90)
Gravis et al. [27] 2017 GETUG-AFU15 – CHAARTED - 
STAMPEDE (doce)
0.77 (0.68-0.87)
McNamara et 
al. [28]
2017 GETUG-AFU15 – CHAARTED - 
STAMPEDE (doce)
LATITUDE - STAMPEDE (abi)
0.73 (0.60-0.90)
Wallis et al. [29] 2017 GETUG-AFU15 – CHAARTED - 
STAMPEDE (doce)
LATITUDE - STAMPEDE (abi)
0.75 (0.63-0.91) 0.63 (0.55-0.72)
Vale et al. [30] 2018 GETUG-AFU15 – CHAARTED - 
STAMPEDE (all armsa)
LATITUDE – CALGB - ZAPCA
0.77 (0.68-0.87) 0.61 (0.53-0.71)
Tan et al. [31] 2018 GETUG-AFU15 – CHAARTED - 
STAMPEDE (all armsa)
LATITUDE – CALGB – ZAPCA - 
MRC PR05
0.74 (0.63-0.86) 0.60 (0.50-0.70)
Burdett et al. 
[32]
2019 HORRAD – STAMPEDE (Rtx) 0.92 (0.81-1.04)
Abbreviations: HR = Hazard ratios, CI = Confidence Interval, ADT = androgen-deprivation therapy, Doce = docetaxel, 
Abi = abiraterone, Rtx = radiotherapy
a without Rtx comparison, as this comparison had not yet been added to the multi-arm, multi-stage design of 
STAMPEDE trial.
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Disease burden
As mentioned GETUG-AFU15, CHAARTED, LATITUDE, STAMPEDE and HORRAD applied 
different definitions of disease burden and different criteria for inclusion, resulting in a 
different patient selection (Table 2). It is important to be aware of these differences when 
translating the study results into clinical practice. Based on the CHAARTED and GETUG-
AFU15 studies, only patients with HV disease benefited from the addition of docetaxel. 
In the analysis of the mature datasets of both studies, the initial trend towards benefit in 
the LV group was lost with a HR of 1.04.10,19 Unfortunately, there had been no post-hoc 
collection of information on the extent of disease in the STAMPEDE (docetaxel comparison) 
trial. The STAMPEDE investigators did however conduct a post-hoc analysis of disease 
extent in patients enrolled into the abiraterone comparison, classifying patients according 
to LATITUDE and CHAARTED criteria.13 As expected these data showed a benefit by the 
Table 5. Recommendations from international guidelines concerning therapy of mCNPC patients, assessed June 2019
Guidelines Docetaxel in mCNPC Abiraterone in mCNPC
Local radiotherapy in 
mCNPC
NICE -
Prostate 
cancer 
guideline
Offer 6 cycles of 75mg/m2 
docetaxel in newly diagnosed 
metastatic prostate cancer 
patients who do not have 
significant co-morbidities
ESMO  In newly diagnosed metastatic 
CNPC patients, who are fit 
enough for chemotherapy, ADT 
plus docetaxel is recommended 
as first-line treatment
 In patients with metastatic CNPC 
ADT plus abiraterone/prednisone 
may be considered as first-line 
treatment
 In patients with newly 
diagnosed low-volume 
metastatic prostate cancer, 
local prostate radiotherapy 
is recommended in addition 
to ADT
EAU  Offer ADT plus docetaxel in all 
patients with newly diagnosed 
metastatic CNPC, who are fit 
enough for chemotherapy
 Offer ADT plus abiraterone/
prednisone to all patients with 
newly diagnosed metastatic CNPC 
and who are fit enough for the 
regimen
 Offer ADT plus prostate 
radiotherapy to patients with 
newly diagnosed metastatic 
CNPC and who have low-
volume disease according to 
CHAARTED
NCCN  Offer ADT plus docetaxel in high-
volume patients with metastatic 
CNPC, who are fit enough for 
chemotherapy
 Offer ADT plus abiraterone/
prednisone in all patients with 
metastatic CNPC
 Offer ADT plus prostate 
radiotherapy for low-volume 
metastatic disease
APCCC 
2017
 Offer ADT plus docetaxel in 
high-volume (according to 
CHAARTED) patients with newly 
diagnosed metastatic CNPC or 
relapsing disease after prior local 
therapy, who are fit enough for 
chemotherapy
 Data not yet published. But 
a rather large percentage 
of panel would consider 
treatment of the primary 
tumor in some patients with 
metastatic disease.
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addition of abiraterone in the HV group, but also LV patients benefit the addition.13 The 
STAMPEDE (radiotherapy comparison) had demonstrated that metastatic burden is also a 
discriminating factor for additional radiotherapy to the prostate since survival benefit was 
only obtained in LV disease patients. These STAMPEDE comparisons were the first to show 
survival benefit in LV patients with newly diagnosed metastatic disease.
Taken together, based on disease burden, patients with HV metastatic disease should 
receive either ADT plus 6 cycles docetaxel or long-term abiraterone/prednisone. The extent 
of the benefit by the addition of docetaxel or abiraterone in HV patients is similar based on 
the indirect comparison in STAMPEDE.24 Patients with LV metastatic disease can be treated 
with either ADT plus abiraterone or ADT plus prostate radiotherapy.
Time of metastatic presentation
Some mCNPC patients have newly diagnosed metastatic disease, while others may present 
with recurrent disease after previous local therapy. Both patient groups were included 
in most above-mentioned trials, albeit patients with metastases after local therapy in 
smaller numbers (Table 2). In general, patients with previous local treatment had longer 
OS compared to those with newly diagnosed metastatic disease.33 In CHAARTED a 
preplanned subgroup analysis was conducted, showing no statistically significant benefit 
by the addition of docetaxel to ADT in the patient group with recurrent disease after prior 
local therapy (HR=0.55, 95%CI 0.23-1.31,P>0.05).10,19 However, the trial was not sufficiently 
powered for a subset analysis of this much smaller subgroup (27%).10,27 Since patients 
recurring after local therapy are not well represented, the benefit of early docetaxel in this 
patient group is not known. Therefore, treatment decisions might be preferably based 
on disease volume instead of prior local therapy. As a result of close follow-up, patients 
who underwent prior local therapy have a tendency to develop LV metastatic disease 
at recurrence, and thus are not likely to benefit from docetaxel. However, if a patient 
might develop HV metastatic disease after prior local therapy, chemotherapy might still 
be considered. Similarly, numbers of patients with previous local therapy treated with 
abiraterone were very small (5%, Table 2). The additional benefit of abiraterone to ADT in 
this patient group is therefore unknown.
Patients with high-risk locally advanced or lymph node positive disease without previous 
local treatment may sometimes rapidly progress (3 to 6 months) to metastatic disease, or 
disease may become apparent as a result of clinical or radiological flare effects. Although 
these patients are not strictly newly diagnosed metastatic patients, it is conceivable that 
they might also benefit from early combined therapy.
152 – Chapter 9
9
Imaging modalities
In the herewith presented phase III trials, conventional imaging (bone-, CT-scan) was used 
for the diagnosis, the extent of metastatic disease, and the inclusion in studies. Despite 
being standard modalities for years, CT and bone scans lack the ability to accurately 
detect small volume metastases, recurrent disease (especially with low PSA values) and 
differentiate high- from low-grade disease.34 New imaging techniques have become 
available representing more sensitive methods for staging at first diagnosis and at 
biochemical recurrence.35 Upcoming modalities are whole body diffusion weighted MRI 
(WB-MRI) and PET CT-scan with various potential tracers, e.g. 18F-Choline, 68Ga-PSMA.36 
WB-MRI has a pooled sensitivity of 95% and specificity of 92% to detect bone and lymph 
node metastases at primary diagnosis.37 Although WB-MRI can detect metastases at very 
low PSA values, there was no consensus by international experts for its use at biochemical 
recurrence.38,39 The most promising imaging modality to replace conventional imaging 
at biochemical recurrence is 68Ga-PSMA PET/CT, with a sensitivity of 64% and specificity 
95%.38,40 Prostate-specific membrane antigen (PSMA) is a cell transmembrane protein 
which is overexpressed in prostate cancer cells and 68Ga-PSMA has a remarkable affinity to 
the extracellular domain of this peptide. The 68Ga-PSMA tracer excels by having a higher 
detection rate even with low PSA values; a pooled analysis showed 42% sensitivity in PSA 
values <0.2 ng/mL compared to a detection rate of 30-40% in PSA values <3 ng/mL for 
other PET-CT tracers.40,41 The sensitivity for CT/MRI to detect lymph node (LN) metastases, 
based on the morphological changes of the LN, ranges from 30-80% as compared to 
63-86% for PSMA-PET.41,42
To date, the use of 68Ga-PSMA PET/CT is recommended in the EAU-guidelines only for the 
purpose of detecting recurrent disease after local treatment.43 But with the expanded 
sensitivity of 68Ga-PSMA PET/CT and WB-MRI compared to conventional imaging, it will 
be increasingly utilized as an imaging tool in the initial diagnosis and staging of prostate 
cancer, although it is not approved by regulatory authorities yet.39,40 The early detection of 
(oligo-)metastatic disease may allow for early and metastasis-directed therapy. However, 
the randomized clinical trials (RCTs) concerning early therapy in mCNPC patients were 
based on diagnosis by conventional imaging and the majority of the included patients 
have overtly newly diagnosed metastatic disease. Therefore, to date it remains unclear how 
the detection of more extensive metastatic disease in newly diagnosed metastatic patients 
by PSMA PET/CT scan imaging should be interpreted, and hence treated.
In conclusion, for the purpose of risk stratifying patients for treatment decisions based 
on disease volume, bone and CT scan remain the gold standard. In the STAMPEDE 
(radiotherapy comparison) study bone scans demonstrated to be predictive for the benefit 
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of local RT combined with ADT.14 Therefore, the majority of patients diagnosed with LV 
disease on bone scan, should not be denied prostate radiotherapy, even when PSMA scan 
shows HV disease. Yet, personalized exceptions are possible, together with a well-informed 
patient shared decision making could provide decisive guidance.
Toxicity and Quality of Life
When comparing the early addition of AR-targeted therapy or docetaxel to ADT for 
mCNPC patients, it is important to be aware of the incidence and severity of toxicities of 
these regimens. In addition, the quality of life (QoL) of these patients during and after 
their treatment should be taken into account. The highest-grade toxicities observed per 
treatment and per phase III trial are shown in Table 6. It has been suggested that the risk of 
febrile neutropenia is higher in the mCNPC setting as compared to the mCRPC setting.2
An additional analysis of the STAMPEDE trial compared toxicity of treatment with docetaxel 
and abiraterone during the overlapping inclusion period in the STAMPEDE trial.24 In this 
analysis the incidence of adverse events was similar with 50% grade 3-5 adverse events 
in the docetaxel comparison and 48% in the abiraterone comparison. However, the types 
of adverse events differed with more (febrile) neutropenia occurring in docetaxel treated 
patients (13% versus 1%), and more cardiovascular disorders occurring with abiraterone 
treatment (9% versus 3%). After 2 years, the prevalence of grade 3-4 toxicity in patients 
without a prior FFS event was 11% for docetaxel as well as for abiraterone. However, it 
is likely that after 14 months docetaxel treatment will have benefits over abiraterone 
treatment in terms of toxicity, since at this time point, docetaxel therapy is completed 
(5 months) and the patients have regained their QoL (6-9 months after treatment 
completion). Docetaxel is generally followed by a certain period of time without any 
treatment (except for ADT), which regains and restores QoL. In contrast, abiraterone has 
to be administered for about 2-3 years or until disease progression, in which patients are 
constantly exposed to therapy and thus more prone to toxicity, which may affect QoL.
Because of the increased cardiovascular risk observed in patients treated with abiraterone, 
patients should be carefully selected. In view of the modest survival gain of abiraterone 
in LV disease patients, those patients who are at risk for cardiovascular morbidity or 
mortality, especially those who have a history of cardiovascular disease, should not be 
treated with abiraterone. Such patients would appear excellent candidates for the addition 
of radiotherapy to the prostate. In HV disease patients with a cardiovascular risk profile, 
docetaxel is the preferred treatment.
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FUTURE PERSPECTIVES
The field of mCNPC treatment is rapidly evolving and there is an ongoing effort to establish 
the efficacy of other treatment options in the same disease phase. After the positive 
results of the addition of enzalutamide to ADT in the ENZAMET and the ARCHES trial, the 
Table 6. Frequent adverse events per treatment and phase III trial of the agents included in the guidelines
Grade 3/4 adverse events
Docetaxel TAX327 GETUG-AFU15 CHAARTED STAMPEDE Docetaxela
Any grade 3/4 event NR NR 114 (29%) 288 (49%)
Neutropenia 32% 61 (32%) 47 (12%) 66 (11%)
Febrile neutropenia 3% 14 (7%) 24 (6%) 84 (14%)
Anemia 5% 4 (2%) 5 (1%) NR
Peripheral Neuropathy 30% 3 (2%) 2 (<1%) 19 (3%)
Endocrine disorders
(hot flushes, 
impotence)
NR 24 (13%) NR 57 (10%)
Grade 5 events 0.3% 2 (1%) 1 (<1%) 4 (<1%)
Abiraterone COU-AA-302 LATITUDE STAMPEDE Abirateronea
Any grade 3/4 event NR 374 (63%) 443 (47%)
Hypertension 10 (1%) 131 (22%) 44 (5%)
Hypokaliemia 30 (4%) 70 (12%) 12 (1%)
Increased ALAT/ASAT NR 61 (10%) 63 (6%)
Any cardiac disorder 33 (4%) 23 (4%) 92 (10%)
Edema 63 (19%) 5 (1%) 5 (1%)
Grade 5 events 38 (6%) 9 (1%)
Radiotherapy STAMPEDE Radiotherapyb
Any grade 3/4 event 
(bladder/bowel)
51 (6%)
Diarrhea 12 (1%)
Proctitis 11 (1%)
Cystitis 7 (1%)
Haematuria 6 (1%)
Bowel obstruction 1 (<1%)
Grade 5 events 0 (0%)
Abbreviations: NR= Not Reported. Horrad study did not present any adverse events. Quality of Life evaluation 
concerning these patients will follow.
a STAMPEDE docetaxel and abiraterone comparisons present the worst grade events, while other studies present all 
grade 3/4 events.
b STAMPEDE Radiotherapy only presents adverse events related to radiotherapy and no adverse events related to docetaxel 
treatment in patients who also had additive docetaxel. Adverse events of both radiotherapy schedules are merged.
Chapter 9 – 155
9
STAMPEDE enza comparison (NCT00268476), will soon report their results which also 
involve the efficacy of enzalutamide with or without abiraterone in mCNPC. Besides the 
forthcoming results of the PEACE-1 trial, other trials will report results in the near future.44 
Other systemic therapies currently under investigation are ADT+docetaxel+darolutamide 
(ARASENS, NCT02799602) and ADT+TAK-700 (SWOG1216, NCT01809691). For 
oligometastatic disease the benefit of metastatic directed therapy is investigated in STOMP 
(NCT01558427), ORIOLE (NCT02680587) and PLATON (NCT03784755). Finally, effects 
of radiotherapy or surgery of the prostate is investigated in PEACE-1 (NCT01957436), 
g-RAMPP (NCT02454543), TRoMbone (ISRCTN15704862) and SWOG1802 (NCT03678025).
CONCLUSION
In patients with mCNPC, the addition of docetaxel or abiraterone to ADT significantly 
improved survival as compared to ADT alone. Survival benefits obtained are much 
larger compared with these drugs given at later disease stages, i.e. CRPC. Most recent 
data showed longer survival with prostate radiotherapy, enzalutamide, or apalutamide 
in combination with ADT, of which the last two await official approval. Prostate cancer 
remains a very heterogeneous disease, and while pending molecular biomarkers to 
individualize treatment choice, clinical factors may provide guidance to risk stratify 
patients; such as metastatic extent and comorbidities. LV mCNPC patients appear to obtain 
survival benefit from novel AR targeted therapies or prostate radiotherapy. The role of 
docetaxel is currently uncertain in LV disease. However, this might be soon addressed by a 
metastatic burden analysis of the STAMPEDE docetaxel comparison. In HV disease patients 
no apparent difference in OS benefit was observed between the addition of docetaxel or 
abiraterone to ADT. However, patients with a history of cardiovascular disease or those 
with increased risk of cardiovascular morbidity may not be served best by the addition of 
abiraterone, but should receive radiotherapy or docetaxel depending on the metastatic 
extent of the disease. Moreover, the benefit of shorter treatment periods with docetaxel/
radiotherapy could outweigh the longer treatment period of abiraterone and its adverse 
events affecting QoL of these patients. Further research is needed to determine the impact 
of recurrent disease, the role of new imaging techniques, the effect of the combination of 
agents, and development of predictive molecular biomarkers.
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SUPPLEMENTARY METHODS
We performed a non-systematic review of literature from January 2013 to June 2019 by 
searching Medline and Embase with the keywords: metastatic castration-naïve prostate 
cancer, metastatic hormone-naïve prostate cancer, metastatic castration-sensitive 
prostate cancer, metastatic hormone-sensitive prostate cancer, docetaxel, abiraterone, 
local radiotherapy. All clinical trials and review articles written in English were reviewed. 
Conference abstracts were also included and cross-matching references were used to find 
additional articles. Only articles that clearly defined the mCNPC study population, clinical 
endpoints, and methods were included in this review. In total, we included 12 articles that 
investigated the treatment of mCNPC.

Chapter 10
General discussion and summary
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In this thesis two main issues regarding the treatment of metastatic prostate cancer are 
addressed. At first, we raise the importance of pharmacological changes in drug treatment 
in patients with metastatic castration-resistant prostate cancer (mCRPC). Next, the thesis 
continues on identifying factors determining treatment selection or treatment response 
in the wide landscape of therapies in mCRPC as well as in metastatic hormone-sensitive 
prostate cancer (mHSPC).
PERSPECTIVE ON PHARMACOLOGY
Clinical pharmacology aims to improve efficacy and safety of drug treatment by increasing 
knowledge on pharmacokinetics and pharmacodynamics. Pharmacokinetics describe how 
drugs are metabolized in the body, based on administration, distribution, metabolism and 
elimination of the medication. Interference of these processes can potentially result in 
clinical relevant changes in concentrations of the drugs. Simple patient-related factors, like 
ageing, organ failure, pregnancy or malnutrition can alter the pharmacokinetic processes. 
Moreover, food, herbal supplements (e.g. grapefruit, St. John’s Wort, curcumin) and co-
medication can also distort this process.1 For instance, NSAIDs may lower kidney function 
and affect the excretion of lithium, resulting in higher levels of lithium. Especially in agents 
with a small therapeutic window, like most oncological agents, slight changes may already 
result in sub-optimal or toxic levels of medication, which should be avoided.
Since nearly two decades the treatment possibilities for metastatic prostate cancer have 
evolved rapidly. With the introduction of docetaxel, cabazitaxel, abiraterone, enzalutamide 
and radium-223 in the mCRPC setting, the challenge on treatment choice and sequencing 
treatment has augmented.2-8 Moreover, metastatic prostate cancer is a heterogeneous 
disease. Thus, combining therapies with different complementary mechanisms of 
action has the potential for additional survival benefit and is therefore increasingly 
investigated.9,10 In the pre-clinical setting the enhanced efficacy of taxanes in combination 
with androgen-suppressing agents has been shown.11 This confirms the active role of 
the androgen receptor (AR) pathway in mCRPC and enhances a rationale for combining 
taxanes with novel AR-targeted therapies (ART). Combining anti-cancer agents also means 
an increased risk for clinical relevant pharmacokinetic drug-drug interactions. Taxanes 
of interest, docetaxel and cabazitaxel, are extensively metabolized by the cytochrome 
P450 iso-enzyme CYP3A4 in the liver, which is prone for inhibition/induction from other 
drugs. Therefore, combinations involving taxanes warrant thorough pharmacokinetic 
evaluation to ensure safety of the combination. For instance, enzalutamide, an orally 
available AR-targeted agent, is a strong inducer of the CYP3A4 enzyme. When combining 
enzalutamide with cabazitaxel, we observed a decline in geometric mean exposure of 22% 
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(95%CI 9-34%, p=0.005) in cabazitaxel concentration (Chapter 2). The clinical relevance of 
this interaction lies in the magnitude of the interaction in combination with a recent study 
showing non-inferiority in terms of overall survival (OS) between the registered 3-weekly 
dose of cabazitaxel (25 mg/m2) and a 20% lower dose (20 mg/m2).12 As the lower dose has 
led to less toxicity, while maintaining its efficacy, it is currently widely used. However, when 
the promising combination with enzalutamide is further investigated, it is not desirable 
to lower the cabazitaxel dose to 20 mg/m2 on forehand as this might lead to sub-optimal 
concentrations of cabazitaxel, due to the found drug-drug interaction. In previous research, 
the effect of enzalutamide has also been investigated in combination with the other taxane 
used in prostate cancer; docetaxel. In that study, only a modest interaction with 12% 
decrease in docetaxel concentration was observed.13 The variety of the interaction of both 
combinations might lie in the different taxanes that were used. Moreover, the observation 
period in the study investigating the combination of enzalutamide with docetaxel was 
shorter. Although the drug-drug interaction is larger in combination with cabazitaxel, 
this combination has a greater potential to be used in the mCRPC setting, as nowadays 
docetaxel is often used in the hormone-sensitive setting of prostate cancer. In this setting, 
docetaxel has been investigated in two large trials; one used docetaxel in combination 
with prednisone, while the other used docetaxel without prednisone.14,15 Prednisone is a 
moderate CYP3A4 inducer, so could potentially also influence docetaxel concentrations. 
Since the registration of docetaxel in 2004 it has been combined with prednisone. 
Prednisone’s impact on prostate cancer itself remains to be elucidated. It has been 
suggested that prednisone lowers the testosterone production via the adrenal glands, 
affects PSA, and reduces taxane-induced toxicity.16-18 However, no effect of prednisone on 
OS has been observed and in a recent phase III trial (CHAARTED) docetaxel-induced toxicity 
did not increase without prednisone.14 On the contrary, long-term use of corticosteroids 
is accompanied by negative adverse events like osteoporosis, which especially in prostate 
cancer patients with bone-metastases is an adverse event to avoid. Therefore, the omission 
of prednisone from standard docetaxel regimens would be beneficial, particularly in 
mHSPC patients who have not yet been introduced to prednisone therapy. In a randomized 
pharmacokinetic cross-over trial we investigated the effect of prednisone on docetaxel 
concentrations. We observed no substantial differences in docetaxel concentration when 
combined with prednisone compared to docetaxel monotherapy (Chapter 3). From a 
pharmacokinetic perspective prednisone could be eliminated from the regimen, although 
the benefits of the omission should outweigh the positive effects of prednisone therapy 
before definite exclusion of prednisone can be suggested. Therefore, the individual 
impact of prednisone on metastatic prostate cancer needs to be clarified and it should be 
confirmed that non-inferiority in terms of incidence of docetaxel-induced toxicities holds 
with or without prednisone.
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Pharmacodynamics describe how drugs have an effect on organ function (and the tumor 
of the patient). Most extensively investigated (prior to clinical implementation of new 
drugs) is the influence of a drug on cardiac repolarization. Measurement of the QT-interval 
in electrocardiography (ECG) indicates ventricular repolarization, and it is corrected for 
the heart rate (QTc). Prolongation of ventricular repolarization can potentially result 
in arrhythmias, or even cardiac arrest. Therefore, caution is needed and development 
of new drugs always includes QTc-prolongation studies. One of the new developed 
AR-targeted agents for metastatic prostate cancer is apalutamide (240 mg). Apalutamide 
is a new anti-androgen, directly binding to the ligand binding domain of AR, inhibiting 
AR nuclear translocation and DNA binding and impedes AR-mediated transcription.19 
In an international, multicenter trial we found a moderate, clinically irrelevant effect of 
apalutamide on ventricular repolarization in mCRPC and non-metastatic CRPC patients 
(Chapter 4). Extensive ECG measurements at cycle 1 and cycle 3, when steady state of 
apalutamide was reached, showed QTc intervals and their associated 90% confidence 
interval (CI) changed ≤20 ms from baseline. These results may be considered mild for an 
anti-cancer agent and an extensive QTc study like this is therefore considered negative 
when showing these results.20 Patients treated in this pharmacodynamic study were 
allowed to continue treatment when effective, resulting in remarkable long responses to 
apalutamide indicating its potential as additional therapy option, or in combination with 
other treatment options. Apalutamide has been approved in the USA for non-metastatic 
CRPC, and recent results have suggested survival benefit in mHSPC patients.21,22
PERSPECTIVE ON TREATMENT SELECTION - mCRPC
A major challenge for physicians treating metastatic prostate cancer patients remains the 
choice of treatment and sequence of treatments. Both abiraterone and enzalutamide have 
shown to be effective before or after docetaxel.4,5,7,8 Efficacy of cabazitaxel treatment was 
not different in patients who had received prior ART.23 In addition, cabazitaxel has shown 
similar efficacy to docetaxel as first-line chemotherapy for mCRPC patients; yet cabazitaxel 
is also an effective agent in the post-docetaxel mCRPC setting.3,24 Therefore, it is preferably 
used as second-line chemotherapy. Since no predictive biomarkers are currently available 
in clinical practice, it is challenging to determine which patient would benefit from which 
treatment. Over the past couple of years, the predictive value of the presence of androgen 
receptor splice variant 7 (AR-V7) has increasingly been investigated and was recently 
validated, showing a decreased response to ART, enzalutamide and abiraterone. However, 
consensus needs to be achieved on outstanding issues regarding the right assay and 
criteria to allocate a patient AR-V7 positive before clinical implementation is accessible. 
Meanwhile, research on AR-V7 continues to improve the knowledge on this potential 
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predictive biomarker. Apart from that, cohort studies and post-hoc analyses of large 
phase III trials (to determine response biomarkers) provide the best available evidence 
for treatment choice. Here we discuss some considerations to guide treatment choice in 
mCRPC patients based on this thesis and other literature.
Prognostic factors
Currently, treatment choice is often based on patients’ preferences, co-morbidities and 
toxicity profile. Prognostic factors might help to determine treatment choice as well 
as treatment start. In mCRPC patients scheduled to start chemotherapy, prognostic 
factors identified include the WHO performance status, presence of visceral metastases, 
pain, duration of androgen-deprivation therapy (ADT), Gleason score, circulating tumor 
cells (CTCs) and laboratory results: hemoglobin (Hb), alkaline phosphatase (AP), lactate 
dehydrogenase (LDH), prostate specific antigen (PSA) and derived neutrophil/lymphocyte 
ratio (dNLR).25-30 In a large prospectively collected dataset of mCRPC patients treated 
with cabazitaxel (the CABARESC trial),31 we confirmed some of these prognostic factors 
including WHO performance status, Hb, AP and complemented these by albumin as 
additional prognostic factor for overall survival (OS). Moreover, we found Hb and AP 
predictive of PSA response in this patient cohort. With these prognostic factors we 
designed a nomogram for OS and PSA response, which could be easily implemented in 
clinical practice. A clear overview on prognosis might help the physician to determine 
when treatment start could be extended or when intervention is needed, before a patients’ 
condition deteriorates (Chapter 5). In our cohort, we were not able to analyze pain, 
Gleason score, visceral metastases and duration of ADT as potential prognostic factor since 
these data were not collected in the CABARESC trial. The parameter for an inflammatory 
response rate of the host, dNLR, was collected, however it was not correlated with OS in 
our cohort. Nevertheless, its relevance as prognostic factor in prostate cancer patients has 
been established based on other post-hoc analyses and it is advised to be incorporated in 
prospective randomized controlled trials as stratification factor.29,32
In addition to these baseline clinical and laboratory factors, genetic variation appears to 
be of prognostic value. Besides being able to estimate the probability for survival, genetic 
alterations (single-nucleotide polymorphisms; SNPs) can help identifying patients with 
an increased risk of developing adverse events. Taxanes’ main dose limiting toxicity is the 
development of neutropenia, which could potentially result in life-threatening febrile 
neutropenia. In consequence to neutropenia the dose is reduced, treatment is interrupted, 
or may even be discontinued. Identification of factors predicting for occurrence of toxicity, 
especially neutropenia, in taxane treated patients would therefore be of great value. For 
cabazitaxel therapy SNPs have been identified which were related to toxicity and activity 
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in 45 patients with advanced urothelial cell carcinoma. Polymorphisms in CYP3A5 and 
ABCB1 were identified as potentially related to altered adverse events profile and efficacy 
of cabazitaxel.33 In this thesis we aimed to identify genetic variations associated with 
toxicity, survival or pharmacokinetics in mCRPC patients in an explorative analysis (Chapter 
6). A large, prospectively collected, dataset of mCRPC patients treated with cabazitaxel 
was used for this analysis, complemented by data of two smaller pharmacokinetic trials 
(n=24) investigating cabazitaxel concentrations in mCRPC patients. We genotyped 128 
bloodsamples of men with mCRPC treated with cabazitaxel for 7 SNPs in 6 genes (CYP3A4, 
CYP3A5, SLCO1B1, SLCO1B3, ABCB1 and TUBB1), which are involved in the metabolism 
and working mechanism of cabazitaxel. The haplotype of SLCO1B1*15 was significantly 
associated with a lower incidence of leukopenia and neutropenia. The isolated hepatic 
expression of OATP1B1, the influx transporter encoded by SLCO1B1, strongly suggests a 
pharmacokinetic rationale for the influence of these SNPs on toxicity. However, none of the 
SNPs were associated with pharmacokinetic changes. Moreover, the observed associations 
were opposite to the expected working mechanism of the genetic variated influx 
transporter.34,35 Therefore, the observed associations of SLCO1B SNPs to lower incidence of 
neutropenia and leukopenia in cabazitaxel treated mCRPC are likely to be false-positive 
and imply that studying SLCO1B1 SNPs does not seem indicated in future cabazitaxel 
research.
Additionally, an extensively investigated prognostic factor in patients with several solid 
tumor types is the enumeration of circulating tumor cells (CTCs). Men with a baseline 
‘favorable’ CTC count of <5 CTCs/7.5mL blood have a better survival compared to patients 
with an ‘unfavorable’ CTC count of ≥5 CTCs/7.5mL blood at baseline.28 CTCs after treatment/
at progression have also been shown to be prognostic for survival. Post-treatment CTC 
count was even more informative for prognosis than a ≥50% change in PSA.27,36 In addition, 
CTC responses defined as the decline of an unfavorable CTC count (≥5) to a favorable CTC 
count (<5), during treatment have been associated with OS.27 The use of CTC enumeration 
as prognostic factor at the start of a new treatment should be incorporated in daily practice 
and the presence of CTCs offers opportunities for additional analysis to unravel tumor 
information (Chapter 7-8).
Predictive markers
Besides CTC enumeration, molecular characterization of CTCs harvests great interest. The 
presence of AR-V7 is associated with decreased response to ART, but not to taxanes, as 
shortly mentioned above.37-40 AR-V7 is a mRNA splice variant of the androgen receptor 
(AR) that translates into a constitutively active AR in absence of ligands.41 Its expression 
is increased in patients with more advanced disease, who have been treated before with 
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abiraterone or enzalutamide. Therefore, it has been suggested that AR-V7 represents a 
greater disease burden, rather than its predictive value to ART.42 This was supported by 
data showing decreased responses to taxanes and showing PSA responses to ART in 
AR-V7 positive patients.43,44 To improve our understanding of the clinical value of AR-V7 we 
have conducted a post-hoc analysis of three clinical trials to investigate the association 
of AR-V7 in CTCs with CTC count and OS (Chapter 7). An association was observed 
between CTC count and AR-V7 status. However, this association was not found in patients 
with an unfavorable prognosis due to a baseline CTC count ≥5 CTCs. In addition, in our 
cohort of mCRPC patients who were mostly treated with cabazitaxel, AR-V7 positivity 
was not associated with a worse prognosis. In an ongoing prospective clinical trial (the 
CABA-V7 study) the PSA response and OS in AR-V7 positive men with mCRPC treated with 
cabazitaxel will be investigated. Moreover, another recent prospective trial validated AR-V7 
as predictive factor in patients treated with abiraterone and enzalutamide.45 Therefore, it 
seems that AR-V7 expression will keep its predictive value in mCRPC patients treated with 
ART.
Treatment response markers
Optimal guidance of metastatic prostate cancer patients during treatment requires early 
response markers. Nowadays PSA and radiographic responses are primarily used to 
determine treatment response, albeit with some limitations. CTC enumeration and CTC 
responses are extensively incorporated in prospective phase III trials in combination with 
PSA and radiology to improve our knowledge on its role as potential response indicators. 
Yet it is unclear if a failure to show CTC response would imply to directly change treatment 
for an individual patient. As an example; a patients’ CTC count can decline from 100 to 10 
during treatment, without having formally achieved a CTC response, while a decrease in 
CTC count from 7 to 4 CTCs is referred to as a CTC response. This indicates the difficulty in 
CTC responses as a treatment response marker. Therefore, in my opinion, individual disease 
monitoring by CTC enumeration/response should be in combination with the absence of 
other signs of progression to generally indicate a treatment response and to determine if 
treatment can be continued.
In this thesis we describe the results of the interim analysis of the CABA-V7 study, focusing 
on CTC response rates in AR-V7 positive men with mCRPC who are treated with cabazitaxel 
(Chapter 8). We found a moderate 15% CTC response rate after 3 cabazitaxel cycles (9 
weeks). Additionally, we observed 45% of patients converted from AR-V7 positive CTCs 
to AR-V7 negative during these 3 cycles of cabazitaxel. While the preliminary results of 
CTC response in this cohort were disappointing and less informative, the conversion of 
AR-V7 is an interesting observation, since it was also associated with survival. In this study, 
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AR-V7 expression was determined at baseline and already after 3 cycles (9 weeks after 
start of treatment), suggesting the potential of characterization of CTCs as early treatment 
biomarker in AR-V7 positive patients treated with cabazitaxel. Without prejudice to the final 
results of the CABA-V7 trials, I think it would be interesting to investigate if AR-V7 converted 
patients would again be sensitive to ART.
PERSPECTIVE ON TREATMENT SELECTION – mHSPC
For years, the only treatment of mHSPC (equally referred to as metastatic castration-naïve 
prostate cancer; mCNPC) has been androgen-deprivation therapy (ADT). Recently, major 
shifts in the treatment of mHSPC have occurred. Several trials, CHAARTED, STAMPEDE, 
LATITUDE and HORRAD, have shown survival benefit in mHSPC patients treated more 
aggressively, with additional therapy combined with ADT.14,15,46-50 The additional therapy 
options in mHSPC have expanded with docetaxel, abiraterone, prostate radiotherapy, 
enzalutamide and apalutamide, of which the last two await official approval and 
incorporation into the international guidelines.21,51 With the introduction of these additional 
therapies to the hormone sensitive setting, the challenge of individualizing therapies 
has also been introduced in this setting, as it is in the castration-resistant phase. Pending 
molecular biomarkers to individualize treatment choice, clinical factors may provide 
guidance to risk stratify patients; such as metastatic extent and comorbidities. Low-volume 
patients, according to the definition by CHAARTED, appear to obtain survival benefit with 
novel ART or local radiotherapy to the prostate.50,52 At this moment, there is no role for 
docetaxel in low-volume patients. In high-volume patients, both docetaxel and abiraterone 
has shown large survival benefit.14,52 In this patient group, the comorbidities can be decisive 
for treatment choice. As abiraterone showed increased cardiovascular toxicity, patients 
with cardiovascular risk or morbidity might not be served best with abiraterone. Moreover, 
the treatment period of docetaxel, or radiotherapy in low-volume patients, is substantially 
shorter compared to abiraterone treatment, which could potentially affect quality of life 
and can be taken into account to determine treatment choice. In Chapter 9 we provide a 
comprehensive overview of the current available treatment options for mHSPC and aim to 
provide some tools to guide treatment selection in this patient group.
FUTURE PERSPECTIVES
In the near future, new therapy options will be explored and the timing of treatment will 
require additional awareness.53-56 Moreover, interesting treatment strategies of novel 
ARTs/local prostate treatment in combination with taxanes/other ARTs will supervene 
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to show potential additive or synergistic effect of both treatment options in mCRPC/
mHSPC patients. By doing so, pharmacokinetic studies will continue to be important to 
ensure a safe administration of combination of agents. In both disease phases, mCRPC 
and mHSPC, increasing effort will be made to individualize treatment by determination of 
molecular biomarkers. While pending results on predictive biomarkers, clinical factors of 
post-hoc analyses and cohort studies are the best we have to select the right treatment 
for an individual patient. The treatment landscape of metastatic prostate cancer continues 
to evolve and new perceptions on treatment selection and sequence of treatment will 
continue to be shared. Therefore, it is important to be up to date and to continue to treat 
metastatic prostate cancer patient in a multidisciplinary team, to merge the latest insights 
of each medical specialization.
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Prostaatkanker heeft een hoge incidentie met meer dan 12.000 nieuwe gevallen per jaar in 
Nederland. De vijfjaarsoverleving van patiënten met prostaatkanker (prostaatcarcinoom) 
bedraagt circa 90%.1 Prostaatkanker, welke nog niet uitgezaaid is, kan in het overgrote 
deel genezen worden door het chirurgisch verwijderen van de prostaat (en eventuele 
lymfklieren), of door lokale bestraling van de prostaatloge. Indien de ziekte terugkeert 
met uitzaaiingen (metastasen) of wanneer ten tijde van de diagnose de ziekte al 
gemetastaseerd is, wordt systemische behandeling ingezet om de prostaatkanker te 
onderdrukken en de overleving te verlengen. Systemische behandeling is een behandeling 
die alle cellen in het hele lichaam bereikt, zoals bijvoorbeeld chemotherapie. Sinds 1941 is 
bekend dat het onderdrukken van de testosteron productie in de testis door chirurgische 
castratie de prostaatkanker gemiddeld 20 maanden onder controle kan houden, daarna 
wordt de ziekte castratieresistent.2 Later werd anti-hormonale medicatie ontdekt, die de 
hypofyse-hypothalamus-gonaden as verstoort, wat chemische castratie of androgeen-
deprivatie therapie (ADT) wordt genoemd.3 Jarenlang is castratie de enige behandeloptie 
voor gemetastaseerde prostaatkanker geweest.
Vanaf 2004 is de eerste additionele systemische therapie, het chemotherapeuticum 
docetaxel geïntroduceerd.4 In de daaropvolgende jaren zijn er meer 
antikankerbehandelingen voor gemetastaseerd prostaatkanker ontwikkeld, zoals 
het nieuwe chemotherapeuticum cabazitaxel, de nieuwe anti-hormonale middelen 
enzalutamide en abiraterone en verder radioactief radium-223.4-9 Taxanen (docetaxel en 
cabazitaxel) stabiliseren de celdeling door in te grijpen op de structuur binnen de cel, 
wat leidt tot natuurlijke celdood (apoptose). Daarnaast remmen ze het transport van 
de androgeenreceptor naar de celkern.10 Anti-hormonale middelen zijn voornamelijk 
effectief door het verstoren van de werking van de AR. Zo bindt enzalutamide aan de AR 
en deactiveert hierdoor de werking van de AR. Abiraterone vermindert de productie van 
testosteron uit de bijnier en in de tumor zelf door het remmen van het CYP17-enzym, 
dat essentieel is voor de omzetting van progesteron naar testosteron. De anti-hormonale 
middelen richten zich voornamelijk op de androgeenreceptor (AR), omdat deze een 
belangrijke rol speelt bij progressie van ziekte ondanks het castratieniveau van testosteron 
(<50 ng/dL). Radium-223 wordt alleen ingezet bij patiënten met botmetastasen. 
Radioactief radium-223 werkt door afgifte van lokale straling nadat het door het lichaam 
is ingebouwd in de botten, voornamelijk op plekken waar uitzaaiingen zitten. Deze 
behandelopties kunnen in de castratieresistente fase van de ziekte worden ingezet en laten 
in toenemende mate additionele effectiviteit zien in de hormoonsensitieve fase (wanneer 
de ziekte nog gevoelig is voor castratie) van de ziekte.
Momenteel wordt onderzocht of verschillende combinaties van deze therapieën, met 
verschillende werkingsmechanismen, een mogelijk toegevoegd effect hebben op 
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overleving of progressievrije overleving in patiënten met gemetastaseerd castratieresistent 
prostaatcarcinoom (mCRPC).11 Echter, bij combinatietherapieën is het van essentieel belang 
om te weten of er geneesmiddeleninteracties met klinische relevante gevolgen optreden. 
Zo kan er sprake zijn van toxische (te hoge) of subtherapeutische (te lage) levels van 
medicatie, indien het metabolisme (omzetting/verwerking) van het desbetreffende middel 
geremd of gestimuleerd wordt. Taxanen worden in de lever grotendeels gemetaboliseerd 
door het cytochroom-P450 iso-enzym CYP3A4.12,13 Enzalutamide is bekend als een sterke 
CYP3A4-inductor (activator). Daarom hebben wij in hoofdstuk 2 van dit proefschrift 
onderzocht of de preklinisch veelbelovende combinatie van enzalutamide en cabazitaxel 
invloed heeft op de concentratie van cabazitaxel in het bloed van de patiënt. Daaruit bleek 
dat bij gelijktijdige behandeling de concentratie van cabazitaxel met 22% daalt. Recent is 
gebleken dat een lagere dosering (20 mg/m2) van cabazitaxel niet minder effectief is dan 
een hogere dosering (25 mg/m2), maar wel minder bijwerkingen oplevert.14 Daarom wordt 
momenteel de lagere dosering wereldwijd veelvuldig toegepast. Indien de combinatie 
verder onderzocht gaat worden in klinische trials, dient rekening gehouden te worden met 
de interactie en lijkt het niet gewenst om de concentratie van cabazitaxel bij voorbaat te 
verlagen door een lagere dosering.
Uitgaande van hetzelfde mechanisme hebben we in hoofdstuk 3 onderzocht of de 
standaardcombinatie van docetaxel met prednison een interactie geeft. Prednison is 
een milde inductor van het CYP3A4 enzym, waardoor docetaxel gemetaboliseerd wordt. 
Zowel bij patiënten met gemetastaseerd hormoonsensitief prostaatcarcinoom (mHSPC) 
als mCRPC wordt vanaf de registratie van docetaxel, prednison aan de behandelstrategie 
toegevoegd. Prednison zelf heeft een effect op de PSA (prostate-specific antigen) respons, 
beinvloedt de productie van bijniertestosteron en vermindert mogelijk de bijwerkingen 
van docetaxel.15,16 Echter brengt langdurig prednison gebruik ook nadelige effecten met 
zich mee, zoals osteoporose (botontkalking) en bijnierschorsinsufficiëntie. In een recent 
onderzoek met mHSPC patiënten is daarom docetaxel ook zonder prednison is gegeven, 
zonder duidelijke toename van docetaxel-geïduceerde bijwerkingen.17 De resultaten van 
onze interactiestudie lieten geen significant effect van prednison op de concentratie 
van docetaxel zien. Vanuit farmacotherapeutisch oogpunt is er dus geen argument voor 
het weglaten dan wel toevoegen van prednison aan de chemotherapie. De mogelijk 
beschermende werking van prednison tegen docetaxel-geïnduceerde bijwerkingen en de 
individuele impact van prednison als therapie dient verder onderzocht te worden. Bij het 
ontbreken van een significant toegevoegde waarde van prednison dient dit afgewogen 
te worden tegen de nadelige bijwerkingen van langdurig prednison gebruik. Zeker voor 
mHSPC patiënten, die over het algemeen nog geen prednison gebruiken, kan het weglaten 
van prednison en daarmee het verkorten van de behandelperiode met prednison voordelig 
zijn.
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Naast combinaties van bestaande middelen worden ook nieuwe middelen ontwikkeld. 
Apalutamide, een nieuw anti-hormonaal middel, heeft een vergelijkbare werking als 
enzalutamide.18 Voor de veilige ontwikkeling van een nieuw middel dient men op de 
hoogte te zijn van de farmacodynamische effecten van het middel op het lichaam. In 
hoofdstuk 4 hebben we in een internationale multi-centerstudie onderzocht wat het 
effect van apalutamide was op de geleidingstijden van het hart. Daaruit bleek een milde, 
niet klinisch relevant effect op de duur van het elektrisch herstel van het hart bij steady-
stateconcentraties van apalutamide. Er werden geen andere essentiële veranderingen 
op het hartfilmpje (electrocardiogram; ECG) geconstateerd, waarna het middel verder 
ontwikkeld kon worden. Momenteel is apalutamide in de VS goedgekeurd als therapie 
in niet-gemetastaseerd CRPC. In Nederland heeft apalutamide op dit moment nog geen 
plek binnen de behandeling van gemetastaseerd prostaatkanker gekregen vanwege 
gebrek aan bewijs voor een daadwerkelijke overlevingswinst ten opzichte van andere 
behandelingen.19 In de registratietrial van apalutamide is alleen aangetoond dat de 
metastase-vrije overleving verlengd wordt bij gebruik van apalutamide ten opzichte 
van placebo in patiënten met niet-gemetastaseerd CRPC.20 Deze fase van de ziekte komt 
in Nederland bijna niet voor omdat patiënten die een PSA stijging hebben maar geen 
tekenen van gemetastaseerde ziekte, in Nederland niet gecastreerd worden. In Amerika 
wordt dat al wel gedaan waardoor patiënten dus castratieresistent kunnen raken alvorens 
zij radiologisch gemetastaseerd zijn. In mei 2019 is vanuit een klinische fase III trial 
gebleken dat apalutamide wel overlevingswinst geeft bij patiënten met mHSPC.21 Hiermee 
bestaat de mogelijkheid dat apalutamide binnenkort toch op de Nederlandse markt 
beschikbaar wordt.
Om uit de vele middelen die beschikbaar zijn voor prostaatkanker de juiste keuze voor een 
individuele patiënt te kunnen maken wordt gezocht naar ‘prognostische’ en ‘predictieve’ 
factoren die respectievelijk de prognose en de respons op een bepaalde therapie kunnen 
voorspellen. In een grote dataset (van de eerdere CABARESC-studie22) met mCRPC 
patiënten die behandeld waren met cabazitaxel, hebben we gekeken of we prognostische 
factoren konden identificeren en eerder beschreven prognostische factoren konden 
bevestigen (hoofdstuk 5). Daaruit bleken baselinefactoren zoals WHO performance 
status (WHO PS; conditie van de patiënt), hemoglobine (Hb), alkalisch fosfatase (AF) en 
albumine voorspellend voor overleving. Daarnaast gaven Hb en AF ook een inzicht in de 
kans op PSA respons. Dit komt overeen met voorgaande publicaties, maar parameters als 
PSA, neutrofielen/lymfocyten ratio en tijd sinds vorige chemotherapie konden we in onze 
dataset niet valideren als voorspellers voor overleving.23-25 Desalniettemin kan de situatie 
van een individuele patiënt aan de hand van de geïdentificeerde baselinefactoren op 
dat moment worden ingeschat, hierdoor kan de prognose maar vooral de timing van de 
behandeling bepaald worden. Als voorbeeld; wanneer de geïdentificeerde prognostische 
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factoren een ongunstige verandering laten zien, kan dit de behandelend arts helpen om 
tijdig te starten met de cabazitaxel behandeling waardoor de kans op deze behandeling 
niet gemist wordt door een te snel verslechterde conditie van de patiënt.
Naast voorspellers voor overleving kunnen patiëntfactoren ook voorspellend zijn voor de 
ontwikkeling van bijwerkingen. Binnen de oncologie is bijvoorbeeld bekend dat dragers 
van genetische variaties in het DPYD-gen een verhoogde kans op toxiciteit hebben 
wanneer ze met fluoropyrimidines worden behandeld.26 Voor prostaatkanker patiënten 
zijn dergelijke genetische factoren helaas nog niet bekend, maar het belang ervan is 
des te groter gezien de verscheidenheid aan behandelmogelijkheden. In hoofdstuk 6 
hebben we daarom gekeken naar de associatie tussen veel voorkomende genetische 
variaties (‘single-nucleotide polymorphisms’; SNPs) en de hoogte van de concentratie 
van cabazitaxel in het bloed, het ontstaan van bijwerkingen en de overleving bij mCRPC 
patiënten die behandeld worden met cabazitaxel. Geen van de onderzochte SNPs was 
geassocieerd met de farmacokinetiek van cabazitaxel of overleving. Voor het ontstaan 
van bijwerkingen was er in ons cohort een associatie met genetische variaties in genen 
coderend voor transporteiwitten (het SLCO-gen). Echter konden we deze associatie 
niet ondersteunen met farmacologische veranderingen of verklaren op basis van het 
veranderde werkingsmechanisme van het eiwit. Op basis hiervan lijken de gevonden 
resultaten vals-positief en impliceren dat er in de toekomst geen plaats is voor SLCO1B1 
bepaling ter voorspelling van therapierespons of bijwerkingen bij mCRPC patiënten die 
behandeld worden met cabazitaxel.27,28
Een veelvuldig onderzochte prognostische factor bij patiënten met kanker is de 
hoeveelheid circulerende tumorcellen. Circulerende tumor cellen (CTCs) zijn kankercellen 
die losgekomen zijn van de primaire tumor of uitzaaiingen en via het bloed in andere 
organen in het lichaam terecht komen, waar ze nieuwe uitzaaiingen kunnen vormen. 
Via een simpele bloedafname (liquid biopsy) kunnen in ongeveer 60% van de patiënten 
met uitgezaaide epitheliale kanker CTCs geïdentificeerd worden. Bij bepaalde tumoren, 
waaronder prostaatkanker, is aangetoond dat het aantal CTCs voorspellend is voor 
overleving zowel voor als na een nieuwe behandeling.29 Een ‘unfavorable’ CTC aantal van 
5 of meer (per 7.5mL bloed) geeft een slechtere prognose dan een CTC aantal van minder 
dan 5/7.5 mL bloed.
Naast de voorspellende waarde van het aantal CTCs, bezitten de CTCs ook 
genetische informatie van de tumor. Deze kan over de tijd en onder invloed van anti-
kankermedicatie veranderen. Momenteel gaat veel aandacht uit naar het identificeren 
van genetische tumoreigenschappen die voorspellend zijn voor de respons op 
bepaalde therapie, waardoor een geïndividualiseerde therapiekeuze gemaakt kan 
Chapter 11 – 183
11
worden. Zoals eerder benoemd is de AR van belang voor progressie van ziekte en 
zijn de meeste behandelmethodes erop gericht de functie van de AR te remmen. Een 
resistentiemechanisme tegen anti-kankermiddelen is het vormen van genetische variaties 
van de AR, zoals de androgeen-receptor splice variant 7 (AR-V7). Deze variant van de AR 
blijft ook in de afwezigheid van androgenen actief. Anti-hormonale behandeling met 
enzalutamide en abiraterone blijkt minder effectief bij patiënten met AR-V7, terwijl die niet 
geldt voor behandeling met taxanen.30-32 Daarom wordt bij prostaatkanker AR-V7 status 
als mogelijk predictieve factor gezien. Echter blijft de klinische waarde van AR-V7 onzeker. 
Er zijn namelijk aanwijzingen dat AR-V7 meer gerelateerd is aan de mate van ziekte-
uitbreiding en dat suggereert dat AR-V7 positieve patiënten überhaupt een slechtere 
prognose hebben, ongeacht de behandeling.33-35 Om de waarde van AR-V7 beter te kunnen 
begrijpen hebben we in hoofdstuk 7 de associatie tussen AR-V7 status, het aantal CTCs en 
overleving uiteengezet bij patiënten die voornamelijk behandeld zijn met cabazitaxel. AR-
V7 blijkt in deze groep geen additionele prognostische waarde te hebben ten opzichte van 
bekende prognostische factoren. En hoewel er in het gehele cohort een associatie tussen 
AR-V7 en het aantal CTCs werd gevonden, was de associatie niet aanwezig bij patiënten 
met ≥5 CTCs/7.5 mL bloed. Deze groep heeft bij voorbaat een slechtere prognose, met een 
gemiddelde overleving van circa 7 maanden. Zij zullen daarom extra gebaat zijn bij een 
marker die therapierespons kan voorspellen, zodat direct de juiste therapie gestart kan 
worden. Aanvullend onderzoek in de toekomst zal moeten uitwijzen of AR-V7 deze rol in 
deze patiëntengroep daadwerkelijk kan vervullen.
Buiten de zoektocht naar factoren die overleving of therapierespons bij voorbaat kunnen 
voorspellen, zijn er ook indicatoren nodig die tijdens een behandeling eenvoudig kunnen 
weergeven of een patiënt op de behandeling reageert. Wanneer tijdens een behandeling 
het CTC aantal daalt van ≥5 CTCs naar <5 CTCs wordt dat CTC-respons genoemd. Echter 
is nog onduidelijk wat de waarde van CTC-respons tijdens de behandeling is, en of dit 
beleidsconsequenties heeft. Om meer inzicht te krijgen in de waarde van CTC-respons 
hebben we in hoofdstuk 8 in een kleine groep van 20 mCRPC patiënten met zeer 
uitgebreide voorgeschiedenis die destijds met cabazitaxel behandeld werden, de 
CTC-respons geobserveerd. Er bleek na 9 weken behandeling in 15% van de patiënten 
sprake van een CTC-respons. Er waren te weinig patiënten met een CTC-respons om dit te 
correleren aan overleving. Daarnaast hebben we de AR-V7 status bepaald voor en tijdens 
de behandeling en zagen we in 45% van de patiënten een conversie van AR-V7 positief 
naar AR-V7 negatief na 9 weken behandeling met cabazitaxel. Dit wekt de suggestie dat 
cabazitaxel de tumor mogelijk weer gevoelig kan maken voor anti-hormonale behandeling.
In hoofdstuk 9 richten we ons tenslotte in een uitgebreid overzichtsartikel (review) op 
de recente ontwikkelingen in de behandeling van hormoonsensitief prostaatkanker. 
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In grote gerandomiseerde studies (CHAARTED, STAMPEDE, LATIDUDE) is een langere 
overlevingswinst gebleken wanneer docetaxel en abiraterone in combinatie met ADT 
gebruikt worden in de hormoonsensitieve fase ten opzichte van de castratieresistente 
fase.17,36-38 Daarnaast blijkt lokale radiotherapie op de prostaat ook overlevingswinst 
te geven in patiënten met mHSPC en onlangs zijn daar apalutamide en enzalutamide 
aan toegevoegd.21,39,40 Ondanks de duidelijke overlevingswinst bij het vervroegen van 
additionele therapie naast ADT, blijft onduidelijk welke patiënt het meeste gebaat is bij 
welke therapie. Vooralsnog is de mate van uitzaaiing de meest relevante factor voor het 
bepalen van de behandeling. In nagenoeg alle trials werd onderscheid gemaakt tussen 
hoog- en laag-volume ziekte. Hoewel de definitie hiervan per trial verschillend was, wordt 
over het algemeen de CHAARTED definitie aangehouden waarbij de aanwezigheid van 
uitzaaiingen in andere organen of de aanwezigheid van 4 of meer uitzaaiingen in het bot 
(waarvan tenminste 1 buiten het bekken) als hoog-volume ziekte wordt gezien. Patiënten 
met hoog-volume ziekte bleken voornamelijk baat te hebben bij behandeling met ADT 
+ docetaxel/abiraterone, terwijl lokale radiotherapie/abiraterone in combinatie met ADT 
ingezet kan worden bij laag-volume patiënten. Daarnaast kan de co-morbiditeit van de 
patiënt een aanvullende bepalende factor zijn. Aangezien meer cardiale events voorkwamen 
bij behandeling met abiraterone, heeft het de voorkeur om patiënten met een cardiale 
voorgeschiedenis of verhoogd risico op cardiale events te behandelen met docetaxel.
In de nabije toekomst zullen nieuwe behandelingen en behandelcombinaties hun intrede 
doen, waardoor de behandeling van patiënten met gemetastaseerd prostaatkanker zich 
blijft ontwikkelen en een multidisciplinaire aanpak vergt voor het beste advies. Onderzoek 
naar farmacologische effecten van de (combinaties van) medicatie is daarbij belangrijk 
om de effectiviteit en veiligheid te kunnen waarborgen. Daarnaast zal wereldwijd veel 
aandacht uitgaan naar identificeren van biomarkers via translationeel onderzoek. Hoewel 
er nog een hoop openstaande issues zijn, blijft het vermoeden dat AR-V7 van predicitieve 
waarde zal zijn voor mannen met mCRPC. Er zal daarbij een internationale consensus 
bereikt moeten worden over de manier waarop AR-V7 wordt bepaald, en wat de strikte 
criteria worden om een patient AR-V7 positief of negatief te noemen. Daarnaast heeft 
CTC-respons met het bepalen van de genetische informatie van de CTC, potentie om 
als early biomarker voor treatment respons in klinische trials gebruikt te gaan worden, 
maar daarvoor zal eerst meer bekend moeten worden over de kinetiek (natuurlijk 
beloop) van CTCs en blijft de discussie of surrogaateindpunten ooit overall survival 
kunnen vervangen. Voor de hand ligt dat aanvullend onderzoek naar de waarde van 
liquid biopsies in de komende jaren zoveel informatie gaat opleveren dat het standaard 
behandelbeleid van gemetastaseerde prostaatkanker-patiënten omgezet kan worden naar 
een geïndividualiseerd behandeladvies, dat in samenspraak met een goed geïnformeerde 
patiënt kan leiden tot een weloverwogen behandelplan.
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‘Winnen doe je met zijn allen’ (Johan Cruijff ), oftewel het dankwoord. 
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Mijn wetenschappelijke kennis reikte op dat moment niet verder dan wat retrospectief 
statusonderzoek op de Intensive Care in het kinderziekenhuis van Melbourne, waarbij ik 
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werden de strubbelingen van een promotie mij ook al snel duidelijk. Het lijkt of geen 
promovendus zich kan onttrekken aan langzaam verlopende inclusies (die bij voorbaat 
altijd positiever worden ingeschat dan uiteindelijk blijken), duizelingwekkende databases 
(waar je met 4 weken statistiek van de opleiding geneeskunde echt niks van kan maken) 
en eindeloze submissies (die je subtiel doch duidelijk de impact van jouw onderzoek in de 
wetenschappelijke wereld laten zien). Des te belangrijker waren in deze tijd de mensen om 
me heen.
Als eerst wil ik alle patiënten bedanken die hebben deelgenomen aan de verschillende 
studies beschreven in dit boekje. Uw inzet voor de wetenschap, in een moeilijk periode 
van uw eigen leven is bewonderenswaardig. Zonder uw bijdrage, valt geen onderzoek te 
voltooien. 
Mijn beide promotoren wil ik bedanken. Prof. dr. de Wit, Beste Ronald, hoewel ik nooit aan 
jouw wetenschappelijke standaard heb kunnen tippen, heb ik de afgelopen jaren een hele 
hoop geleerd, zowel op professioneel als op persoonlijk vlak. Dankzij jouw expertise en 
internationale aanzien heb ik de kans gekregen aan mooie studies mee te werken. Bedankt 
dat je mij de mogelijkheid hebt gegeven kennis te nemen van de wetenschappelijke 
wereld. 
Prof. dr. Mathijssen, Beste Ron, de manier waarop jij je promovendi begeleidt is 
bewonderenswaardig. Binnen een paar jaar is de onderzoeksgroep translationele 
farmacologie uitgegroeid van een paar promovendi tot één groot team. De lat ligt daarbij 
hoog, maar de drempel is laag. Bedankt dat ik afgelopen paar jaar deel heb mogen 
uitmaken van dat team.
Dr. Lolkema, Beste Martijn, het enthousiasme waarmee je je vak uitoefent en je kennis 
overbrengt is aanstekelijk. Jouw didactische vaardigheden en geduld, maakten dat zelfs ik 
begreep wat je bedoelde. Bedankt voor de wijze lessen, ik zal ze missen.
Dr. Van Soest, Beste Robert, je telefoontje om te peilen of ik interesse had voor een 
promotietraject kan ik me nog goed herinneren. Dank voor je vertrouwen om deze stap te 
maken en je geduldige begeleiding waar ik op elk moment in de afgelopen jaren op terug 
kon vallen. Ik heb veel gehad aan je kritische blik en de manier waarop je het overbrengt, 
en ik hoop dat ik op een later moment in mijn opleiding nog meer van je mag leren. Succes 
om je ambities waar te maken, daar heb ík alle vertrouwen in.   
Dr. Bins, Beste Sander, jij hebt me wegwijs gemaakt in de eerste stappen van mijn 
promotieonderzoek. Het was bijna irritant om te zien met welk gemak je analyses 
uitvoerde, figuren maakte en argumenten formuleerde in een pittige discussie, maar dat 
natuurlijk vooral uit bewondering. Ik heb genoten van onze relativerende gesprekken op 
de momenten dat het even moeilijk was. Ik vind het heel leuk dat je vandaag in de grote 
commissie wilde plaatsnemen.
De leden van de leescommissie wil ik bedanken voor het lezen van het manuscript en de 
bereidheid om van gedachte te wisselen.  
Voor de patiënte inclusie, dataverzameling en logistieke zaken rondom de verschillende 
studies heb ik veel hulp gehad vanuit alle hoeken. 
Allereerst wil ik de oncologen en arts-assistenten van het Erasmus MC bedanken voor hun 
bijdrage aan de inclusies en follow-up van studie patiënten. De artsen en onderzoekers  
van het maandelijkse prostaatkanker PhD overleg, dank voor jullie kritische vragen en 
opmerkingen die mijn studies ten goede kwamen. De verpleegkundigen van de afdeling 
B0-zuid in het oude Daniel den Hoed en de huidige oncologie afdeling in het nieuwe 
Erasmus MC, dank voor jullie lieve zorg voor studie patiënten en tijdige bloedafnames. 
Collega’s van back&frontoffice, dank voor de verwerking van deze bloedsamples.
Dr. Hamberg, Beste Paul, en Suzan Ras, de goedlopende logistiek en samenwerking op 
uw afdeling/poli maakten het SFVG een van de best includerende ziekenhuizen voor de 
CABARESC, CABENZA, Doce-Pred en CABA-v7 studie. Dank daarvoor.
Alle medewerkers van het Clinical Trial Center die hebben bijgedragen aan de uitdagende, 
logistieke zaken rondom de CABARESC, Doce-Pred, CABA-v7 studie, wat hebben jullie mij 
veel werk uit handen genomen, dank voor jullie hulp!
Dank aan de medewerkers van de verschillende secretariaten voor het organiseren van 
afspraken met patiënten en (co-)promotoren.
Lieve collega’s van het farmacolab,  bedankt voor jullie advies wanneer ik even vastliep, 
voor jullie hulp wanneer ik het niet wist, maar vooral voor het lachen! Ik heb genoten van 
de maandagochtend koffietjes en de lunches in het park, de vrijdagmiddagborrels vanaf 
half 4 en de gezellige uitjes de afgelopen jaren. 
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Lieve uro-collega’s, ook al kwam ik maar sporadisch boven, het was er altijd erg gezellig. 
Misschien maar goed dat ik daar niet zat, want anders was er niks van dit proefschrift 
terecht gekomen. Dank voor de introductie bij Dennis en de gezellig RUAG borrels, die we 
natuurlijk gewoon zullen blijven voortzetten!
Lieve Bruno, wat ben ik blij dat ik jou heb leren kennen tijdens mijn promotietijd. In een 
wereld waar iedereen maar door raast en meer wilt, is het heerlijk om thuis te komen bij 
iemand die je een andere kant van het leven laat zien. We hebben genoten van de vrijheid, 
en jij maakte deze periode voor mij echt een heel stuk leuker. Bedankt voor al je begrip en 
lieve zorgen de laatste hectische tijd voor het afronden van dit boekje en het starten van 
de opleiding. Ik kan altijd op je terugvallen. 
Lieve Tim en Bob, dank dat jullie vandaag mijn paranimfen willen zijn. Het onaantastbare 
gevoel wat jullie mij geven wanneer we samen zijn, kan ik vandaag extra goed gebruiken. 
Wie doet me wat als ik jullie heb? Jullie vertrouwen, liefde en humor heeft me al zo ver 
gebracht en brengt mij vandaag de dag wel door. Tim, mijn grote broer waar ik altijd 
tegenop kijk, die altijd alles net een beetje sneller en beter kan. Je bent daarmee voor 
mij een enorme drijfveer. Ik bewonder hoe je alle ballen zo ogenschijnlijk makkelijk hoog 
houdt, ik geniet van je lieve fantastische gezinnetje en ik luister graag naar je advies. 
Bobba, mijn kleine grote broer, streeft me inmiddels aan alle kanten voorbij. Je bijzondere 
verschijning, je wijsheid en je humor maken dat iedereen zich jouw na een eerste 
ontmoeting nog kan herinneren. Ik kan altijd bij je terecht, voor ontspanning en een goed 
gesprek. Ik heb fantastische herinneringen aan onze mooie reis samen, en geniet altijd van 
je aanwezigheid. 
Lieve pap en mam, bedankt voor de bijzonder liefdevolle thuishaven waar ik altijd steun 
kan vinden. In de vorm van een goed gesprek of een warme knuffel wijzen jullie mij de 
juiste richting. Wat jullie mij hebben gegeven zal ik nooit kunnen terug geven, maar ik zal 
proberen hetzelfde door te geven. 
Ik ben jullie voor altijd dankbaar.
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Name: Bodine P.S.I. Belderbos PhD period: January 2016 – June 2019
Department: Medical Oncology Promotors: Prof. R. de Wit; Prof. A.H.J Mathijssen
Research School: MolMed Co-promotors: Dr. M.P.J. Lolkema; Dr. R.J. van Soest
1. PhD training Year Workload (ECTS)
General Courses
- Basiscursus Regelgeving Klinisch Onderzoek (BROK) 2016 1.5
- Scientific Integrity 2017 0.3
- Biostatistical Methods I: Basic Principles 2016 5.7
Specific Courses
- CPO minicourse in methodology 2016 0.3
- Genetics for Dummies 2016 0.6
- MS Excel: Basic workshop 2016 0.3
- MS Excel: Advanced workshop 2016 0.4
- Basic introduction on SPSS 2017 1.0
- Biomedical English writing 2017 2.0
- Basic and Translation Oncology 2017 1.8
- English Biomedical Writing and Communication 2017 3.0
- Introduction in GraphPad Prism 2018 0.3
Seminars and Workshops
- Training Open Clinica 2017 0.5
- Vena Workshop ‘Pitch jezelf’ 2017 0.5
- Department of Urology Symposia (Refereeravonden) 2016-2019 1.0
- Department of Oncology Symposia (Jong Oncologen avonden) 2016-2019 1.0
Presentations
- Translational pharmacology meetings, Erasmus MC 2016-2019 1.5
- Medical oncology research meetings, Erasmus MC 2017-2019 1.5
- Annual meeting, Astellas ISR 2016-2017 1.0
- Annual meeting ASCO GU, Orlando 2017 0.5
- Expert meeting ASCO GU, Orlando 2017 0.5
- Scientific meeting, Erasmus MC 2017 0.5
- Annual meeting NFKVB, Utrecht 2018 0.5
- Annual meeting ESMO, Munchen 2018 0.5
- Annual meeting ICPAD, Amsterdam 2018 0.5
- Meeting Tour d’Europe, Rotterdam 2018 0.5
(Inter)national conferences
- Annual meeting ASCO GU 2016 2.0
- Annual meeting NFKVB 2016-2018 1.5
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- Annual meeting EAU 2018 2.0
- Annual meeting ESMO 2018 2.0
- Annual meeting ICPAD 2018 0.5
- Tour d’Europe 2018 1.0
Other
- Scientific meeting, Medical Oncology, Erasmus MC 2016-2018 1.0
2. Teaching Year Workload (ECTS)
Supervising Master’s Thesis
- Leonie van Harten 2017 1.0 
- Raji Singh 2019 1.0 
Lecturing
-  Clinical examination, Anatomy and General Urology for medical students/
interns and OR assistants 
2017 0.5 
Total 40.2




